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Zusammenfassung  
 
Die Oberfläche von Nanopartikeln (NP) spielt eine wichtige Rolle bei der Interaktion der 
Partikel mit ihrer Umgebung, definiert insbesondere ihr Schicksal in biologischen Medien 
und kann genutzt werden, um eine große Anzahl an funktionalen Gruppen aufzunehmen, die 
verschiedenste Anwendungsmöglichkeiten bieten. 
 
Das Hauptthema dieser Thesis ist die Synthese, die Oberflächenmodifikation sowie die 
Charakterisierung von Gold NP (GNP). Die Nanopartikel wurden in den gängigsten Größen 
(bis hin zu 100 nm Durchmesser) und Formen (sphärisch und stabförmig) synthetisiert. Die 
verwendeten NP wurden ursprünglich in wässriger Lösung vorbereitet, stabilisiert mittels 
Zitrat-Ionen im Falle der sphärischen GNP (SGNP) und mittels 
Cetyltrimethylammoniumbromid (CTAB) während der Synthese der stabförmigen GNP 
(GNR). Diese Ligandenmoleküle sind jedoch nur schwach an die Oberfläche gebunden und 
daher ungeeignet für biomedizinische Anwendungen der Partikel. Die Stabilisation der GNP 
war das Hauptziel dieser Arbeit welches durch den Austausch der vorhandenen Liganden 
durch andere Moleküle mit höherer Affinität zum Kern der GNP und der Anwendung eines 
das Partikel umgebenden, amphiphilen Polymers (poly(isobutylene-alt-maleic anhydride) 
dodecylamine grafted, (PMA)) erreicht wurde. Die Technik der Polymer-Beschichtung wird 
bereits seit Jahren erfolgreich für die Beschichtung verschiedenster NP-Systeme verwendet, 
welche ursprünglich in organischen Lösungsmitteln synthetisiert werden müssen und auch 
nur dort stabil sind. Die NP, die mittels dieser Herstellungsvariante erhalten wurden, sind 
höchst stabil, auch in physiologischen Medien. Um dieser Methode auch für wasserlösliche 
Systeme nutzen zu können, wurde ein neuartiger Ansatz mittels eines so genannten Wechsels  
eingeführt, welcher einen Phasentransfer vor dem eigentlichen Beschichten einführt. Zuerst 
wurden die NP mit Hilfe von -metoxi--thiol-poly-(ethyleneglycol)- (PEG) Ketten 
(mPEG-SH (Mw= 750 Da)) stabilisiert, um dann mittels Dodecylamin (DDA) von wässriger 
Lösung in Chloroform überführt werden zu können. Diese solcher Art DDA-beschichteten 
NP wurden anschließend mit einem amphiphilen Polymer vermischt und beschichtet, 
ermöglicht  durch die hydrophobe Interaktion der Liganden (Kohlenstoff Ketten) an der 
Oberfläche der NP sowie den hydrophoben Seitenketten des Polymers. Die resultierenden 
Polymer-beschichteten-NP wurden anschließend aufgereinigt mittels Gel-Elektrophorese, 
charakterisiert über UV-Vis Spektroskopie sowie Dynamische Licht Streuung (DLS), Laser 
Doppler Anemometrie (LDA) und Transmissions Elektronen Mikroskopie (TEM).
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Ferner wurde die Oberfläche der NP mit PEG verschiedenster Größen modifiziert um die 
Bildung einer so genannten Protein-Korona zu verhindern sowie die kolloidale Stabilität zu 
erhöhen. Diese Stabilität wurde daraufhin in unterschiedlichen biologischen Medien mittels 
UV_VisSpektroskopie und DLS getestet. Außerdem wurde die Toxizität der hergestellten NP 
sowohl in Krebszelllinien als auch in standard-Zelllinien überprüft und als nicht toxisch 
eingestuft unterhalb einer Konzentration von 1 mg/mL. 
Außerdemwurde der Einfluss von GrÖße, Geometrie sowie Oberflächenbeschaffenheit von 
Nanopartikeln auf deren Interaktion mit Proteinen und Blutzellen untersucht. 
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Abstract 
The nanoparticles (NPs) surface plays an important role in the interaction of the NPs with 
surrounding environments, defines their fate in the biological media and it can be engineered 
to provide a large number of functional groups for different applications. 
The main topic of this thesis is the synthesis, the surface modification and the 
characterization of gold NPs (GNPs). The NPs were prepared with different sizes (up to 100 
nm) and shapes (spherical and rods). The employed NPs were prepared originally in aqueous 
medium, stabilized by citric ions in case of spherical GNPs (SGNPs) and by 
hexadecyltrimethylammonium bromide (CTAB) in case of gold nanorods (GNRs). These 
ligand molecules are weakly bound to the NPs surface and thus, they are unsuitable for 
biomedical applications. Stabilizing of these NPs was the target of this work and then, it was 
achieved by exchange these ligands by other molecules with higher affinity and finally 
wrapping the NPs with an amphiphilic polymer (poly(isobutylene-alt-maleic anhydride) 
dodecylamine grafted, (PMA)). The polymer coating technique has been used over the past 
years for coating of NPs, which are synthesized originally, and only dispersible in organic 
media. The NPs obtained using this methodology are highly stable in physiological media. 
Aiming to use this technique in water-soluble NPs, a new round-trip process was developed 
using a phase transfer step before the polymer coating. The NPs were stabilized with -
metoxi--thiol-poly-(ethyleneglycol)- (PEG) chains (mPEG-SH (Mw= 750 Da)) and then 
transferred from water to chloroform using dodecylamine (DDA). The DDA-capped NPs 
were coated with a modified amphiphilic polymer due to the hydrophobic interaction 
between the hydrophobic ligands (carbon chains) on the surface of the NPs and the 
hydrophobic side chains of the used polymer. The resulted polymer coated NPs were cleaned 
and characterized using different techniques, such as agarose gel electrophoresis, UV-Vis 
spectroscopy, dynamic light scattering (DLS), laser Doppler anemometry (LDA) and 
transmission electron microscopy (TEM). 
Furthermore, the surface of the polymer-coated NPs was modified using different molecular 
weight of PEG to provide them with higher colloidal stability and prevent the formation of 
the so-called protein corona. The colloidal stability of all particles was assayed against 
different biological media via UV-Vis spectroscopy and DLS. The toxicity of these NPs was 
tested in cancer and non-cancer cells lines showing no-toxicity up to 1 mg/mL concentration 
levels. 
 
Additionally, the effect of NPs size, shape, and surface coating on their interaction with 
plasma proteins and blood cells was studied. 
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1. Introduction 
 
 
Nanotechnology is one of the most important fields of science, which includes physics, 
chemistry, engineering, biology, and medicine[1,2,3,4,5]. There are different perspectives 
between the researchers from different area of science about the definition of the 
nanotechnology but the most common definition as provided by the U.S. National 
Nanotechnology Initiative (NNI) is the formation and control of the matter on nanometer 
scale, which is commonly in the range of 1-100 nm[6,7]. However, in some cases, the 
nanomaterials have dimensions of hundreds of nanometers as in case of nanowires[8].   
 
The manipulation of the materials at nanometer scale will face new different properties[9,10] 
compared with those for the same materials when they are in the bulk form. For instance, the 
silver is nontoxic in bulk form but the silver NPs (AgNPs) is very toxic and can be used as 
antimicrobial agents[11,12]. Many properties like color, weight, and strength changed and also 
in some cases the same metal becomes semiconductor or insulator when the nanometer scale 
is reached[10]. 
 
Nanomaterials can be fabricated in two ways by using the process which is called “bottom-up” 
(was first discussed in 1959 by Richard Feynman)[13]. The first one: by self-assembly in 
which the nanomaterials can be fabricated “atom by atom” (“bottom-up” approach). This 
concept of self-assembly can be observed in natural biological process where the molecules 
are assembled together to form a complex system as in case of formation of DNA double 
helix. By following this approach, the scientist can create nanomaterials with specific 
properties, controlled size and shape and designed to correspond specific function. The other 
way to produce nanomaterials is called “top-down” approach, which essentially depends on 
breaking down the system into its compositional sub-units (finer components)[14]. The work 
presented in this thesis falls within the approach of “bottom-up” and therefore aims to control 
the matter from the atomic to the nanometer scale. 
 
NPs, have a huge number of applications in diagnosis, imaging, drug delivery and therapy 
(i.e. photothermal therapy (PTT)), due to the special physical and chemical properties of NPs 
in comparison with their bulk material counterpart. These applications and properties depend 
on the size and shape of the NPs. GNPs is the most common example of such NPs. For 
instance, SGNPs are not the best choice for PTT because they absorb light in the range 515-
580 nm depending on the size; and the light in this range can be also absorbed by the body 
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constituents (water, hemoglobin, fat, etc.). On the other hand, the anisotropic NPs such as 
GNRs are more effective in the PTT because they can absorb the light in the range of 650-
1100 nm and the body constituents have transmission window in this range[15,16]. 
 
Colloidal metallic NPs have a long history dated back to millennia. Colloidal gold was used 
in Chinese medicine for more than 5000 years as purported curative for a wide variety of 
diseases and also, it was used by Egyptian Pharaohs for health and beauty[17]. GNPs and 
AgNPs are known, or at least used since ancient in the Roman times for coloring the glass. 
They added the gold salt during glass preparation which was reduced to colloidal gold during 
annealing of the glass producing a transparent strong red-colored glass. This color was due to 
the nucleation and growth of small GNPs which have size in range of 4-60 nm[17, 18]. One of 
the common examples of colloidal metallic NPs is the famous Lycurgus Cup which is 
presented in British Museum as shown in Figure 1a. The presence of the GNPs and AgNPs in 
a glass matrix of this Cup is responsible for its color where the color of the glass is changed 
depending on the position of the light source. If litted from outside, it appears green and if 
litted form inside, it appears red. Another example is using the colloidal GNPs for staining 
the glass widows in old European cathedrals as shown in Figure 1b, due to the pretty red 
color of the GNPs[10,19]. The red color of the glass is due to the absorption of the light around 
515 nm where small SGNPs usually appear red but with increasing the size and changing the 
shape, the color is changed. This phenomenon is due to optical properties of the noble metals 
(e.g. GNPs), which originate from the ability of the free conduction electrons to oscillate at 
the NPs surface, that called localized surface plasmon resonance (SPR), when they are 
excited by light of a certain wavelength.  
 
 
Figure 1. a) Lycurgus cup is presented in the British Museum and its color is due to the 
presence of GNPs inside the glass[17, 18]. b) Stained glass by GNPs used in medieval in 
churches [10,19]. 
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1.1. Surface Plasmon Resonance (SPR) in NPs.   
 
SPR was first described by Otto in 1968[20] and introduced commercially to bimolecular 
applications by Biacorin in 1990[21]. SPR is a unique characteristic optical phenomenon of 
metallic NPs. The incident photons can induce surface plasmon oscillations of the free 
conduction electrons of the NPs surface when they have the appropriate energy. The resonant 
energy will depend on the particle size, shape, material and environment[16]. The oscillation 
of these electrons induces an electric field inside the nanoparticle (NP) that can be much 
larger than and opposite to the incident light[22]. 
 
 
Figure 2. a) Scheme illustrating the interaction of polarized light with a metallic NP to form 
SPR. The electric field of the incident light induces collective oscillation of the conduction 
electrons moving them towards the NP surface with respect to the positively charged metallic 
core. b) Absorption spectrum for SGNPs, which have one SPR band in the visible region and 
its maximum absorption wavelength is around 520 nm depending on the size of NPs. 
 
 
For the better understanding, let’s imagine metallic NP is irradiated by light as shown in 
Figure 2a. The electromagnetic waves of the incident light (in resonance with the SPR) 
induce a collective coherent oscillation of the free conduction electrons moving them towards 
the NP surface. This oscillation will cause charge separation between the free electrons and 
the ionic metal core forming an electric dipole inside the NP[22,23]. This dipole will produce 
an electric field within the NP, which works to return the electrons to the equilibrium position 
once the electric filed of light is removed. These free conduction electrons oscillate alongside 
the NP surface with a specific frequency called SPR, since it is located at the surface. The 
SPR induce strong absorption of light, which is responsible for the observed color of metallic 
NPs[24,25,26]. The SPR band is much stronger, especially, for noble metallic NPs (Au and Ag) 
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than other metals and it is measuring for absorption of light by metallic NPs,!as done by UV-
Vis spectroscopy. The SPR band parameters (intensity and wavelength) depend on some 
factors such as metal type, capping material, particle size, shape and dielectric constant of 
surrounding medium, which affect on the electron charge density on the particle 
surface[25,27,28]. 
 
 Figure 3. UV spectrum for GNRs showing two SPR bands; one of them is located in the 
visible region corresponding to electron oscillations along the short axis (transversal) and the 
second located is in the infrared region corresponding to electron oscillations along the long 
axis (longitudinal). 
 
 
In case of SGNPs, the free conduction electrons can oscillate in just one symmetric mode 
showing strong SPR band in visible region around 520 nm (Figure 2b). The position of SPR 
band shifted to high wavelength and also the color of the colloidal solution changed from 
intense red to purple or blue with increasing the size of the NPs[29]. Usually, the SPR 
wavelength is located in visible region for SGNPs (and also for AgNPs) but when the shape 
of the nanospheres changed to nanorods, which have an anisotropic structure, two SPR bands 
will be resulted as shown in Figure 3[30]. First: Longitudinal SPR which is a strong band 
corresponding to the oscillation of the conduction electrons along the long axis and located in 
the near infarred region (NIR). Second: Transversal SPR which is a weaker band, 
corresponding to the oscillation of the conduction electrons along the short axis and located 
in the visible region similar to that of the SGNPs band but it is not sensitive to size of 
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spherical or rods. Increasing the aspect ratio (length/width) of rods will shift the position of 
the NIR band to a higher wavelengths and also the color of the solution will be changed from 
blue to red[10,23,25]. On the other hand, the transversal SPR does not depend on the aspect ratio. 
The aspect ratio of the rods can be controlled by optimizing the experimental parameters in 
the growth solution such as pH, seed solution volume or concentration, surfactant, silver ions 
and the strength of the reducing agent; typically weak redactants are producing anisotropic 
NPs (i.e. ascorbic acid (AA))[26,31,32]. 
 
Due to manipulating the light at nanometer scale, SPR technology can be used in different 
fields, including biomedical, energy, and sensing. Nowadays, the application of SPR 
increases quickly with the development of new nanomaterials fabrication techniques and 
manipulation.  
 
1.2. Novel methods for preparation of NPs. 
 
In general, several methods have been developed and reported in the literature for the 
synthesis of metallic NPs such as sol-gel method, chemical reduction of metallic salts, 
thermal decomposition of metallic compounds, etc.[33,34]. The metallic NPs are often prepared 
by either decomposition or reduction of the metal precursor to produce Zero-valent metal 
atoms [33], which are the main component of the metallic NPs. Preparation of colloidal 
metallic NPs in aqueous and/or organic solvent, which termed “wet chemical method”, 
depends on the chemical reduction of metal salts in the presence of appropriate stabilizing 
agents to prevent the aggregation of NPs and improves their chemical stability[35,36]. In many 
cases, these stabilizing agents work as stabilizers and shape directing agents such as CTAB in 
synthesis of GNRs[37,38]. 
 
Significant efforts have been exerted during the last decade to fabricate monodisperse GNPs 
with controlled size and shape using chemical reduction method. In this part of the thesis I 
am going to talk only about the reduction method for preparation of the SGNPs and GNRs. 
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1.2.1. SGNPs. 
 
Generally, SGNPs can be prepared in aqueous and organic media according to the following 
methods:  
 
- Turkevich method 
 
In 1857, for first time, Michael Faraday prepared a ruby fluid of colloidal GNPs by reducing 
in aqueous solution chloroauric acid with phosphors in presence of carbon disulphide[39] as 
shown in Figure 4. In the period of 1906-1917, many attempts have performed by Richard 
Zsigmondy for preparing of GNPs and finally, obtained gold hydrosols by reducing 
chloroauric acid with formaldehyde in a weakly alkaline solution[40]. In 1951, Turkevich 
modified the Zsigmondy method by using the sodium citrate as reducing agent instead of 
formaldehyde[41]. The sodium citrate was used not only as reducing agent but also as a 
capping agent to keep the NPs separated by electrostatic repulsion. In 1973, G. Frens refined 
this work, by studying the effect of concentration ratio of sodium citrate to gold salt on the 
resulting particle diameter[42].  
 
 
 
Figure 4. Colloidal gold NPs by Michael Faraday, which are reproduced by courtesy of the 
Royal Institution of Great Britain[43] . 
 
Turkevich method still is the most common way for preparation of aqueous SGNPs with 
changing the stoichiometry of the reagents (precursor salt and reduction agent)[44,45,46], 
sequence of the reagents addition (inverse and direct)[47] and reaction conditions (temperature, 
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pH, stirring, etc.) to control the size distribution, particle shape and diameter[48,49]. The 
preparation of GNPs in aqueous solution involves consecutive steps. Once the gold salt is 
reduced, the gold atoms are formed and undergo for a fast nucleation process from the 
homogeneous solution which is followed by slow growth process leading to formation of 
NPs[17,33]. The initial formation of GNPs can be observed by a change the color to brown, 
since the particles at the beginning are very small (>3 nm) and do not present plasmon 
band[50]. Then, a characteristic red color appears (that is, the plasmon band) which spectral 
position depends on the size of NPs. Depending on this mechanism, monodisperse GNPs can 
be synthesized up to 200 nm by separating the nucleation and growth stages and addition of 
some restrictions to prevent a secondary nucleation during the subsequent growth steps as 
reported by Bastus et al.[51]. They used the formed NPs (8 nm in diameter) as seed nuclei and 
by using hot-injection technique[33], i.e. injecting the gold salt solution to the hot reaction 
mixture, they can grow these NPs to 180 nm in diameter with a better size distribution than 
using the classical method. 
 
- Brust Method 
 
Brust prepared GNPs in organic solvent in 1990[52]. The gold salt (in water) is transferred to 
the organic phase (toluene) using tetraoctylammonium bromide (TOAB) and reduced to 
GNPs using sodium borohydride (NaHB4). Due to TOAB is a weak surfactant; additional 
ligand molecules such as dodecanethiol (DDT) are added to increase the stability of these 
NPs. The average particle diameter can be controlled between 3-6 nm changing the 
stoichiometry of the reagents, reaction condition and also by using different hydrophobic 
ligands. 
 
- Martin Method 
 
In 2010[53], Martin prepared naked GNPs in water by reducing the gold salt using sodium 
borohydride in the presence of sodium hydroxide (NaOH) and hydrochloric acid (HCl). 
These particles are colloidally stable even without using other stabilizer like citrate due to 
their high charge from the excess ions in solution. The average particle diameter can be 
controlled between 3-6 nm. These particles can be transferred to non-polar solvents using 
hydrophobic ligands such as DDT. 
 
! 8! 
1.2.2. GNRs. 
 
- Seeded growth method 
 
It is the simplest method to synthesize GNRs[54]. The first seeded growth synthesis for GNRs 
was done by Jana in 2001[55] and developed by the groups of Murphy and El-Sayed[32,56,57]. 
This method depends on three steps as shown in Figure 5. i) using a strong reducing agent 
such as NaBH4 to reduce the gold sat (Au+3) to seed NPs (4 nm) in the presence of CTAB; ii) 
using a weak reducing agent such as AA to reduce more Au+3 to Au+1 in presence of silver 
nitrate (AgNO3) and CTAB, and iii) using the seed particles to reduce the Au+1 to Au0 
forming the GNRs[37,58,59]. CTAB is the most popular molecule for this synthesis which is 
used to direct the reaction for formation of the GNRs[38]. However, the mechanism of GNRs 
growth is still poorly understood. Recent modifications introduced to the GNRs synthesis 
method to control the dimensions of Au nanorods. These modifications include changing the 
synthesis conditions, such as the concentration of CTAB, seeds particles, ascorbic acid and 
silver nitrate and also, changing the pH of the growth solution[32,60,61,62]. In addition to, the 
effect of surfactants on the gold nanorods yield and aspect ratio using binary surfactant 
mixtures composed of CTAB and aromatic additives (e.g. 5-bromosalicylic acid or 
benzyldimethylhexadecylammonium chloride, etc.)[63] or composed of CTAB and sodium 
oleate (NaOL)[64] also were reported.  
 
Although, it is easy to prepare GNPs with different sizes and shapes, there are still some 
impedimenta related to their colloidal stability and toxicity, especially in the case of GNRs. 
The ionic stabilization, which is produced from coating of the particles with molecules such 
as citrate or CTAB, is generally insufficient to prevent the aggregation of particles in 
biological media and then, the particles are unsuitable for biomedical applications. Therefore, 
many strategies have been developed to improve the colloidal stability and to decrease the 
toxicity of particles, as I will explain in section 1.3. 
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Figure 5. Scheme illustrates the mechanism of preparation of GNRs using seed mediated-
growth method. 
 
Figure 6. Spherical core NPs with different kinds of ligands which can be used to stabilize 
the NPs in both aqueous and organic solvent. The schematic molecule structures above are 
not to drawn to nano-scale. Left to right: Oligomeric phosphines, silica shell, monothiol 
terminated-alkyl carboxilic acids (e.g. MAA, MUA, etc.), PEG derivatives, dendrons, and 
peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+" NaBH4"
+" AA"
+" Seeds"
Au+3" Au0"(4"nm)"
Au+3" Au+1"
Au+1" Au0"(Rods)"
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1.3. Stabilization of NPs against aggregation 
 
Colloidal stability plays a very important role and determines the fate of the NPs in different 
applications. The capping molecules present in the synthesis of the NPs are not only used to 
control the growth of the NPs during the synthesis but also to prevent the aggregation by 
repulsion forces between the particles. These ligands are selected depending on the NPs core 
materials and the dispersion medium. As soon as their stability decreased (by changing the 
dispersion medium, the pH, the ionic strength, etc.), they will start to agglomerate and big 
aggregates of NPs will be formed. The agglomeration is the result of an attractive interaction 
between the surfaces of individual NPs and it can be prevented by surface modifications. 
These modifications can be done using different kinds of ligands (Figure 6), which bind to 
the NPs surface preventing the aggregation of the NPs by inducing repulsion forces among 
the individual NPs. These repulsion forces are either electrostatic repulsion (Figure 7a), 
which are originated due to the NPs are surrounded by a double layer of electric charges and 
the interaction between these charges is described by Van der Waals forces (equally “charged” 
particles repel each other); or steric repulsion (Figure 7b), which is originated between the 
molecules adsorbed on the surface of neighboring NPs. The size and the chemical nature of 
these molecules determine the stabilility degree. Also, it is worthy to mention that the 
surfactants can be attached to the particle surface by electrostatic attraction and/or 
hydrophobic interaction and/or covalent binding depending on their functional groups. There 
are chemical functional groups with higher affinity to metallic materials such as thiols which 
bind strongly to Au and Ag[65,66]. In many cases, thiolated ligands are added during the NPs 
synthesis and bound to the NPs core to provide colloidal stability[52,67]. Some of these ligands 
are only soluble in non-polar solvents (i.e. chloroform or hexane) such as DDT meanwhile 
others can be soluble in both of polar and non-polar solvents such as PEG and 
Mercaptohexanoic acid (MHA)[68] 
 
Figure 7. Shows NPs stabilized by a) electrostatic repulsion and b) steric repulsion. 
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As I mentioned in section 1.2.1, GNPs can be prepared in both organic and aqueous solvents. 
Again, GNPs in organic solvent are prepared in the presence of TOAB and stabilized with 
DDT. 
 
As described above, GNPs in aqueous solution can be prepared in the presence of citrate 
(nanospheres) or in the presence of CTAB (nanorods). The resulting nanospheres are capped 
with citrate anions which are negatively charged (-COOH-). On the other hand, the nanorods 
are capped with CTAB bilayers that are highly positive charges due to the ammonium groups. 
In both cases, the particles are stabilized by electrostatic repulsion. However, once the ionic 
strength is changed and the resulting charge screening is large enough, the capped ligand 
molecules will ride out and the NPs will aggregate and subsequently, precipitate. Therefore, 
these synthesized-GNPs are not suitable for biomedical applications and they need for 
modifying their surface by exchange these capped ligand molecules to improve their colloidal 
stability and and also to decrease their toxicity, especially in case of GNRs due to the toxicity 
of CTAB itself[69]. There are many ligand molecules that can be used to exchange these 
original ligands from the particles synthesis and the incoming ligands bind more strongly to 
the NPs surface. The new ligand molecules should have high affinity to the inorganic core 
NPs to quickly replace the original (or old) ligands. For instance, mercaptoacids and 
thiolated-PEG are the most common ligands due to the high affinity of thiol/GNPs[65,66]. The 
mercaptoacids will provide electrostatic stabilization and the particles will be stable at higher 
salt concentrations. On the other hand, PEG molecules provide steric stabilization and if they 
have a pH reactive group in the other end (e.g. amine or carboxylic group) the particles will 
be charge stabilized as well. Therefore, PEGylated NPs are stable at longer times and at 
higher salt concentrations than electrostatically stabilized NPs[67].  
 
In addition to, the GNPs in aqueous media can be stabilized using layer-by-layer (LBL) 
approach forming dense alternating shells of positive poly-allylamine hydrochloride (PAH) 
and negative polystyrene sulfonate (PSS) around the NPs[70,71]. The formed new shell can be 
modified with different molecules for different applications. Poly(vinylpyrrolidone) (PVP) 
can be used for preparation and stabilizing of SGNPs in aqueous media[17,72,73]. Citrate can be 
replaced in few hours by PVP providing high colloidal stability[74]. But in the case of GNRs, 
it is harder to exchange CTAB by PVP due to the strong binding of CTAB to the GNRs 
surface. However, an indirect way to stabilize the GNRs by PVP was reported[75]. Firstly, 
GNRs are wrapped by PSS and PAH layers using the LBL technique described above. Then, 
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the PVP is adsorbed to PAH coated NPs by electrostatic interaction. The PVP can slightly 
screen the surface charge from ca. +36 mV to +16 mV as described by Pastoriza-Santos et 
al.[75]. Remarkably, Wei and coworkers reported that GNRs could be stabilized by citrate. 
The GNRs were subjected to PSS and after three cycles of centrifugation and redispersion for 
removing the excess of unreacted CTAB. Then, the PSS capping the GNRs was replaced by 
citrate providing of citrate-capped GNRs with the typical colloidal stability of the citrate-
capped NPs[76]. 
 
Another way to preform a ligand-exchange is transferring the particles from water to organic 
solvent by using phase-transfer reagents, such as surfactants (e.g. alkanethiol, alkylamine or 
other ligands), to improve the solubility of nanoparticles in organic solvent. For instance, 
GNPs can be transferred from water to organic solvent using cationic surfactants (e.g. 1-
butyl-3-methylimidazolium hexafluorophosphate) in ionic liquids[77], C11-resorcinarene[78], 
DDT[79] and thiolated-PEG[80] as reported in the literature. Also, S. Emory and co-workers 
transferred the GNPs to chloroform using dicyclohexylamine (DCHA) in two steps: first, 
GNPs were functionalized with mercaptoacetic acid (MAA) and second, the DCHA was 
attached covalently to MAA immobilized on the NPs surface after activation of the carbonyl 
carbon of MAA by using dicyclohexylcarbodiimide (DCC)[81]. However, Transferring 
aqueous NPs, with different sizes (up to 100 nm) and different shapes to organic solvent still 
faces a big challenge because the stability of synthesized-GNPs is not enough to prevent the 
NPs aggregation when they are in contact with organic solvents.! In 2015[82], W. Parak and 
co-workers solved this problem by using the PEG as mediator for stabilizing the particles at 
the phase transfer point. Then, the original ligands (citrate or CTAB) capped GNPs can be 
replaced by DDA to transfer these NPs from aqueous media to organic solvent. During this 
process, the amine group (-NH2), which terminated the DDA at one side, binds strongly to 
the NPs surface in order to replace the original ligands and the other side (hydrophobic 
chains) have hydrophobic character to dissolve the particles in the organic phase. Also, 
additional components can be added, e.g. methanol or NaCl that decreases the surface tension 
at the interface to facilitate the contact of the NPs with the phase boundary.!
 
In both cases, whether GNPs were prepared originally in organic solvent or prepared in 
aqueous media and transferred to organic solvent, they usually can’t be used in biomedical 
applications because the biological process takes place only at aqueous environment. 
Therefore, it is necessary to transfer them to aqueous solution (water) before using them in 
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biomedicine. There are different methodologies for transferring the NPs from organic solvent 
to aqueous solution[68]. These methodologies should offer certain criteria: 1) They must offer 
good water solubility for the NPs, 2) they should provide with a colloidal stability to the NPs, 
3) they should decrease the toxicity of NPs in some cases, 4) they should not affect the 
physic-chemical properties of the NPs, and 5) they can offer further functionalization options 
for the NPs modification with different purposes. Therefore, the most common methodology 
which can satify all these criteria is coating of particles with amphiphilic polymer (PMA) 
which consist of an anhydride rings backbone[83]. This polymer is synthesized by modifying 
its anhydride rings with aminated hydrocarbon chains (e.g. DDA) creating two domains in 
the polymer: one hydrophilic domain, which will bear a charge after the transference to water 
and a second hydrophobic domain consisted of the side aliphatic chains which will interact 
(hydrophobic multivalent interaction) with the hydrophobic surfactants of the NP surface. If 
the hydrophilic domains, unreacted anhydride rings, are exposed to basic aqueous buffer such 
as sodium borate (SBB pH 12), these anhydride rings will open providing carboxylates (-
CO2-) and the polymer will forms a dense shell around the NP core providing colloidal 
stability by electrostatic repulsion of the charged groups. Typically, this polymer coating 
technique has been applied for the coating of small hydrophobic NPs (usually <20 nm), to 
transfer them from an organic solvent to aqueous solution as reported the first time by 
Pellegrino et al.[84]. Until 2015, the biggest size of polymer coated NPs was 35 nm in lenght 
(semiconductor CdSe/CdS nanorods) by Malvindi et al.[85].     
           
In the work presented in this thesis, I used this methodology to coat GNPs with different 
sizes (up to 100 nm) and different shapes (spheres, rods and triangular nanoprisms) providing 
high colloidal stability in high ionic strength media. This strategy allow to the NPs to have a 
universal surface and then easily to functionalize them with different kinds of biomolecules. 
Figure 8 summarizes some kinds of molecules which used in the present work for stabilizing 
and functionalizing the surface of the NPs. 
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Figure 8. Scheme showing the different surfactants which can be used for NPs surface 
modification during the work presented in this thesis. OA is the abbreviation of oleylamine 
surfactant. 
 
In the literature the stability of NPs using other ligand molecules has been extensively 
explored. These molecules include dimethylamino pyridine (DMAP)[86], peptides[87], 
Dithiocarbamate[88], dendrons[89] and dendrimers[90] among others. Also, the use of polymers 
such as poly(ethylene imine) (PEI)[91], and poly(acrylic acid) (PAA)[92] or silica 
encapsulation[93] have been  reported. 
 
1.4. Functionalization of NPs toward biomedical applications.  
 
GNPs have suffered a significant increment in their biomedical applications, including 
diagnostic, optical imaging of cells and tissues[23], immunoassays and photothermolysis of 
cancer cells[15], as well as drug[22] and gene delivery[26]. For biomedical applications, surface 
functionalization of GNPs is very important to apply them to specific area of disease and 
allow them to selectively interact with cells[94,95]. The ligand molecules, which stabilize the 
NPs, often give functional groups for such a functionalization, i.e. NPs stabilized with the 
electrostatic repulsion of –CO2-. These functional groups are either part of individual 
surfactant molecules (like in PEG, MUA, etc.) or part of an amphiphilic polymer backbone 
and can be used to anchor biomolecules on the NPs. For this purpose, the water-soluble 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) is commonly used as shown in Figure 
9. EDC react with the carboxylic groups activating them to form an unstable intermediate 
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compound that easily reacts with primary amines. This primary amine will form an amide 
bond with the original –COOH and by this way, we can introduce to the NPs surface 
different kinds of biomolecules such as PEG, organic fluorophores, antibodies, DNA, etc. for 
different purposes[68,96].  
 
 
Figure 9. Scheme illustrating the conjugation reaction of –COOH groups from the NP 
surface with EDC. The water-soluble EDC activates the -COOH forming an unstable o-
acylisourea intermediate. This can either be hydrolyzed or react with a primary amine group 
forming an stable amide bond. 
 
Another possibility was reported[83] to introduce the biofunctional molecules (such as PEGs, 
dyes, sugars, etc.) to the NPs surface by embedding additional monomer in the amphiphilic 
polymer backbone after synthesis. The only limitation of this approach is that only molecules 
either soluble or stable in organic solvents are suitable for their insertion into the polymer. 
 
A quick reaction to introduce the biomolecules to the surface of nanomaterial and to deliver 
an active pharmaceutical agent to specific organelles was developed through click chemistry, 
which defined and described by Sharpless in 2001 (Nobel Prize in Chemistry)[97]. The idea of 
click chemistry is based on the coupling of two reactive partners (covalently) that will react 
easily providing a very high yield. Typically, these click chemistry reactions can be 
performed in a variety of solvents and under mild conditions. The click processess are used 
for labeling of biomolecules such as proteins, nucleic acids, DNA, peptides and also can be 
used for introducing multiple functionalities onto NPs surface using different kinds of click 
reactions[98]. Such reactions involve certain functional groups presented on the NPs surface 
which will bind, in one step, to the functional group of the added molecules. The most 
common reaction within the click chemistry is Cu(I)-catalyzed azide alkyne cycloaddition 
(CuAAC). This reaction basically involves coupling of alkyneto an azide forming a 1,2,3-
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Triazole ring under catalyst of Cu (I) at room temperature[99,100]. For example, using this 
reaction lipase was conjugated to SGNPs[101] (Figure 10a) and peptides were conjugated to 
GNRs[102]. Also, thiolated PEG chains have been linked to magnetic NPs through another 
click reaction called thiol–yne reaction under catalyst of UV light[103] (Figure 10b).  
 
 
 
 
Figure 10. Scheme illustrating the conjugation mechanism of lipase and thiol-PEG to the 
gold and iron oxide NPs by using a) CuAAC reaction and b) Thiol-yne reaction respectively. 
 
 
1.5. PEGylation 
 
PEG is the common abbreviation for poly(ethylene glycol), which consist of repeated 
ethylene glycol units (-CH2-CH2-O-). Polyethylene glycols (PEGs) having different 
molecular weight are soluble in water and in many organic solvents forming random coils 
with diameters relatively larger than proteins of comparable molecular weight[68]. The 
attachment of the PEG chains to other molecules, normally a drug or a protein, called 
PEGylation, is one of the most successful techniques to enhance the therapeutic and 
biotechnological applications of these molecules[104]. The various applications of the PEG in 
chemistry and biological applications are explained by its simple structure, chemical stability, 
as well as its inert behaviour, non-toxicity, non-immunogenicity and highly solubility in 
water[68]. 
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mPEG-SH as surfactants has the ability to interact directly with NPs core by place-exchange 
reactions providing the colloidal stability and to transfer the NPs from organic solvent to 
aqueous media or vice versa[68,80]. Also, bifunctional thiolated-PEG containing reactive 
groups such as -COOH or NH2 can be used to introduce new functional groups to the NPs 
surface through conjugation chemistry as described above. In addition to, PEG can be either 
embedded in amphiphilic polymer before NPs coating or interact with NPs surface by 
covalent coupling (carboxylic-amine coupling or thiol-amine coupling) depending on the 
functional group on the NP surface[83]. In all cases, PEGs tend to form a dense shell around 
the NP that increases the NP hydrodynamic diameter (dh) in order of a few to tens of 
nanometers depending on their molecular weights[105] and their graft desity as well[106], which 
provide the colloidal stability of the NPs by steric repulsion[107,108]. 
 
NPs are often functionalized with PEG to reduce the non-specific adsorption of proteins and 
to shield them from being recognized by immune system[109]. In addition to, the density of the 
PEG on the NPs surface can be controlled to increase the circulation time of NPs in vivo. 
However, the cell uptake PEGylated NPs[110,111] is reduced in vitro. 
 
To fully understand the NPs behavior in physiological environments, we need to know in 
detail the protein corona formation, composition, topology and the particular conformation of 
the individual proteins inside the corona, which produced due to the interaction of NPs with 
the cells. 
 
1.6. Interaction of the NPs with the cells 
 
NPs-cells interaction is very critical in many applications such imaging, PTT and drug 
delivery. These applications require a steady control over this interaction, which are mainly 
depend on the surface properties of NPs. In the biological environment, there are more than 
1000 different proteins, which are the main components of blood plasma[112].  Also, the lipids 
and nucleic acids are presented in the blood plasma. Once the NPs are injected to the 
biological media, they are going to interact with the different blood plasma components and a 
competition will happen between them to adsorb on the NPs surface. The non-specific 
adsorption of proteins on the NPs surface leads to the formation of a protein corona around 
the NP, as shown in Figure 11, conferring a new biological identity[113,114,115]. This corona 
changes the size and the composition of the NPs and determines the physiological responses 
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including cellular uptake, accumulation, toxicity, agglomeration and circulation lifetime[116]. 
Blood proteins are polypeptides with a particular structure and carry surface charge 
depending on the pH of the surrounding medium. The adsorption of the proteins on the 
surface of the NPs depends on the NPs surface and it is affected by its size, shape, surface 
charge, core material and surface functional groups. Also, it depends on the nature of the 
physiological environment (blood, tissue fluid, etc.) and the duration of interaction with 
NPs[117,118,119,120]. Therefore, there is no one “universal” plasma protein corona for all NPs 
and the composition of the adsorbed proteins does not depend on their relative abundances in 
plasma but with their affinity constant for the NPs surface [113]. As well, it is known that the 
protein corona is a dynamic entity which can be modified along the time.  
 
 
Figure 11. Scheme showing the desorption and adsorption of proteins on the NPs surface 
forming a protein corona. This corona is formed from hard and/or soft corona which are not 
formed only from a single protein. In this scheme, two types of proteins are drawn for the 
protein corona due to the difficulty drawing of different proteins. 
 
 
At the initial stage of protein corona formation, most abundant proteins are adsorbed on the 
NPs surface and with time they will be replaced by higher affinity proteins (hard corona). 
The proteins which loosely bonded to the NPs or to the hard corona lead to the formation of 
“soft corona” which undergoes intensive exchange with the surrounding media. The 
formation of "hard corona" is due to the direct interaction of proteins with the surface of the 
nanoparticles (strongly attached) while the formation of "soft corona" is due to the protein-
protein interaction (soft with hard corona)[115]. However, in some case of NPs like PEGylated 
NPs, there is no hard corona can be formed but only a weak corona adsorbed on the NPs 
surface[121].  
 
! 19! 
Colloidal NPs often tend to agglomerate in the protein-free media in the presence of salts 
and/or big pH changes but when they are immersed in a biological media, the adsorption of 
proteins on the NPs surface improves their stability when they act as a spacer between the 
individual NPs and cause entropic or steric stabilization[122,123]. However, they are still having 
the tendency to agglomerate in the biological media when the proteins reduce the NPs surface 
charge[124] or directly bind to two NP and bridge them[125]; leading to changing the surface 
properties of NPs and the surface area for protein binding. However, the agglomeration of 
NPs induced by proteins in biologicl media is requried in some applications (e.g. 
immunoassays), where NP specifically binds antibodies[126]. The agglomeration of GNPs can 
be easily detected due to a strong shift in the SPR of the particles[127]. On the other hand, in 
many applications, the agglomeration of the particles is undesirable[128] and therefore, many 
studies have used different kinds of surfactants[82, 87,90] and polymer coating[83,91,92] to control 
the agglomeration of NPs in the biological medium.  
 
1.7. Applications of GNPs 
 
NPs have wide variety of applications in many areas including electronic and biomedical 
fields. One of these different kinds of NPs is the GNPs. The easy preparation, low toxicity, 
higher stability and unique optical properties make the GNPs widely studied and used in 
many applications[121]. For instance, GNPs can be used in electronics to connect the 
conductors, resistors and other elements of an electronic chip[129]. In biomedical fields, GNPs 
can be used in (i) PTT: Near-infrared absorbing GNPs (e.g. nanorods) can produce heat when 
excited with light leading to killing the tumors cells in treatment[23,130]; (ii) Drug delivery[131]: 
GNPs surface can be coated with different biomolecules (theraptic and target agents) and 
handle them to the desired place (e.g. cells, tissue, etc.); (iii) Diagnosis[132]: GNPs can be 
used to detect several diseases including cancer, heart disease, Alzheimer, etc. and (iv) 
Biomedical imaging: GNPs can scatter the light producing number of interesting color under 
the microscope which can be used in biological imaging[16,23,133]. 
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2. Synthesis and characterization of GNPs  
 
This chapter is assigned to the author’s experimental work and presents the preparation and 
surface modification of GNPs with different sizes and shapes. All theses particles were 
characterized with different techniques including UV-Vis spectroscopy, TEM, gel 
electrophoresis, DLS and LDA. Furthermore, the stability of the particles with different 
surface coating of was studied in different media and also, the toxicity of these particles was 
tested in cancer and non-cancer cells. Additionally, the biodistribution of the different types 
of NPs in various organs was studied by inductively coupled plasma mass spectrometry (ICP-
MS). 
 
2.1. Synthesis of NPs 
 
The GNPs with different sizes and shapes were prepared by using the seed-mediated growth 
method[51]. SGNPs with core diameter of 25 nm, 50 nm, and 60 nm were prepared and 
presented as 25-GNPs, 50-GNPs and 60-GNPs respectively. GNRs with SPR located at 850 
and 1100 nm were prepared and presented as 850-GNRs and 1100-GNRs respectively.  
 
2.1.1. Synthesis of SGNPs 
 
Preparation of Au seeds (AuNPs): were prepared by following a modified protocol of Bastús 
et al.[51] . This protocol depends on the reduction of gold salt using sodium citrate. To prepare 
AuNPs, 1.5 mL of tetrachloroauric acid (25 mM) was added to the boiling solution of sodium 
citrate (150 mL, 1.32 mM) in 250-flask connected to the condenser to prevent water 
evaporation. A color was immediately changed from yellow to blue and finally to soft red. 
After 10 min of boiling, the solution was cooled to room temperature. The resulted AuNPs 
have core diameter of 17.6 ± 3.4 nm, as shown in Figure 12.  
 
Figure 12. TEM picture of citrate capped AuNPs. b) Size distribution graph of the Au cores 
with diameter dc = 17.6 ± 3.4 nm. N (dc) refers to the total counts and the scale bar 
corresponds to 50 nm. 
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Growing of AuNPs to 25-GNPs, 50-GNPs and 60-GNPs: After the seeds synthesis, the 
AuNPs solution was cooled down to 90 ºC to prevent the secondary nucleation during the 
growth period. Then, 1 mL of HAuCl4 (25 mM) was injected to solution in the same vessel 
and stirred for 30 min. The last step was repeated twice and after that, the sample was diluted 
by extracting 55 mL of sample and adding 53 mL of MilliQ water and 2 mL of sodium citrate 
(60 mM). This process was repeated consecutively until we get particles with core diameters 
of 25, 50 and 60 nm. After each generation (i.e. g!, x from 0 to 5), the UV spectrum was 
recorded using UV-Vis spectroscopy as shown in Figure 13. 
 
 
Figure 13. Shows normalized UV spectra for SGNPs after different growth steps. The SPR 
peaked at 524, 526, 528, 532 and 537 nm after 5 growth steps (g0-g5). 
 
2.1.2. Synthesis of GNRs 
 
GNRs were prepared by using seed-mediated growth method based on two steps (seed and 
growth solution) as described below: 
 
Seed solution preparation: This step was done using strong reducing agent, NaBH4 to reduce 
(Au+3) to (Au0) in in the presence of CTAB. To produce seed solution of 4 nm Au NPs, in 
glass tube (40 mL), 5 mL of HAuCl4 (0.5 mM) were mixed with 5 mL of CTAB (0.2 M). 
After that, 0.6 mL of freshly prepared NaBH4 (0.01 M)) was diluted with 1 mL of cooled 
MilliQ water and injected to solution in the same tube with stirring. The solution color was 
changed immediately to brownish-yellow. The seed solution was strongly stirred for 2 min at 
1200 rpm and kept at room temperature for 30 min before using[64].  
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Growth solution preparation: This step was done using a weak reducing agent, AA to reduce 
Au+3 to Au+1 in the presence of CTAB and AgNO3. By following the protocol of Murray[64], 
the growth solution was prepared by dissolving, 7 g of CTAB and 1.234 g of NaOL in 250 
mL of hot MilliQ water at 50 ºC. After dissolving, the solution was cooled down to 30 °C and 
then, a specific volume of AgNO3 (4 mM) was added. The solution was kept at 30 °C for 15 
min without any shaking. After that, 250 mL of HAuCl4 (1 mM) was added to the solution 
with stirring at 700 rpm for 90 min. During this time, the solution color was changed from 
intense yellow to colorless. To control the aspect ratio of GNRs, a certain volume of HCl (37 
wt.% in water, 12.1 M) was added to adjust the pH (Table 1) and stirred again at 400 rpm for 
15 min. After that, 1.25 mL of AA (0.064 M) was added and the solution was vigorously 
stirred for 30 s. To reduce Au+1 to Au0, a small amount of seed solution (freshly prepared as 
described above) was injected into the growth solution (Table 1), stirred for 30 s and kept at 
30 °C without stirring overnight for GNRs growth. The CTAB concentration in GNRs is      
37 mM and the final products were isolated by centrifugation. 
 
 
 Table 1. Growth conditions for GNRs. VHCl refers to the volume of HCl which used to 
optimize the pH of growth solution, VAgNO3 refers to the volume of AgNO3 and Vseed refers to 
the volume of seed solution 
 
2.2. Stabilizing and phase transfer of GNPs 
 
Citrate-caped SGNPs and CTAB-caped GNRs are weak ligands and then, the particles are 
not stable for long time and further applications. So, I tried to exchange these ligands by 
transferring the particles from aqueous media to organic solution using different kinds of 
ligands such as DDA, DDT and OA. As shown in Table 2 but unfortunately, the particles 
were aggregated. Then, I tried to stabilize the particles at the critical point of phase transfer, 
which causes the particles to aggregate using mPEG-SH (750 Da). I used PEG because of its 
amphipatic nature it can be dissolved in both aqueous and organic solvent and then, expected 
to work as stabilizer and phase transfer helpers. The selected PEG contains a thiol group in 
one side, which has high affinity to the GNPs as it was mentioned in section 1.3, and a non-
charged methoxy group in the other side.  
Sample VHCl[mL] pH 
VAgNO3 
[mL] 
Vseed [mL] λLSPR [nm] 
1100-GNRs 5 1.2 24 0.8 1100 
850-GNRs 2.9 1.6 18 0.4 850 
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The particles were coated with PEG for few hours and using a basic pH to promote the thiol 
group reactivity and after that a 0.4 M solution of DDA in chloroform was mixed strongly 
with particles using stirring until the particles were transferred to the chloroform as shown in 
Figures 14-15. Remarkably, this transference process can be done as well in a separation 
funnel upon the methanol addition to enhance the two phases interaction. After that, the 
particles were cleaned twice by centrifugation to remove the unreacted DDA and PEG, 
dispersed in chloroform and their concentration was determined by UV-Vis spectroscopy 
(section 2.5.1).  
 
Two main advantages for the phase transfer approach have to be mentioned. First, the CTAB-
capping the GNRs is cytotoxic[69] and it is binded strongly to the GNRs compared with citrate 
and is hardly removed through the ligand exchange using the same synthesized-solution. But 
the CTAB exchange will be faster by transferring the GNRs to another phase (organic 
solvent)[79] as it was previously described. Then the toxicity of the remaining CTAB, in case 
there is still some, is prevented by wraping the NPs core with the amphiphilic polymer as 
shown in section 4. Secondly, this technique is very versatile. It can be applied to any 
aqueous NPs just adjusting the reactivity of the PEG chains. This PEGylation will increase 
their stability and will produce a common surface to study the cell-NPs interactions.  
 
 
Figure 14. Schematic illustration of the PEGylation and phase transfer strategies for a) 
SGNPs and b) GNRs. 1) Particles in water after their synthesis, 2) PEGylated particles before 
the phase transfer and 3) in chloroform after the phase transfer using DDA. 
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Figure 15. GNPs solutions. a) Left to right: 25-GNPs, 50-GNPs, 60- GNPs, 850-GNRs and 
1100-GNRs after PEGylation and before phase transfer. b) The same order for the GNPs but 
after their transference to the chloroform by using DDA. 
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Table 2: Different reactions conditions that were tested for transferring the particles 
conjugated with or without PEG (mPEG-SH, Mw=750 Da) from aqueous media (water) to 
organic media. CPEG/CNP refers to the ratio of added PEG (with concentration CPEG) to NPs 
(with concentration CNP); CLigand refers to the concentration of the ligand molecules.  
 
2.3. Polymer coating 
 
Once the NPs were dissolved in chloroform, the polymer coating technique can be applied.         
The particles were coated with a modified amphiphilic polymer. This polymer was 
poly(isobutylene-alt-maleic) with molecular weight of 6 kDa and consist of anhydride rings 
backbone. The modification of the polymer was done according to Lin et al.,[83]. Briefly, 
75 % of the polymer anhydride rings were modified with DDA in tetrahydrofuran (THF) at 
70 0C with stirring overnight (Figure 16). During reaction time, this anhydride rings were 
opened by the amine group of the DDA forming an amide bond. The other unreacted 25 % of 
Sample CPEG/CNP Ligand Ligand [M] Solvent Results 
25-GNPs 
5 · 103 OA 0.25 Chloroform Didn’t work 
1 · 105 OA 0.25 Hexane Didn’t work 
1.5 · 105 OA 0.25 Chloroform Didn’t work 
2 · 105 DDA 0.25 - 0.4 Chloroform Didn’t work 
3 · 104 DDA 0.25 - 0.4 Chloroform Worked 
6 · 104 DDA 0.25 - 0.4 Chloroform Worked 
50-GNPs 
3 · 104 DDA 0.25 Chloroform Didn’t work 
6 · 104 DDA 0.25 Chloroform Didn’t work 
1 · 104 DDA 0.4 Chloroform Didn’t work 
1.5 · 105 DDA 0.4 Chloroform Didn’t work 
3 · 105 DDA 0.4 Chloroform Worked 
60-GNPs 
3 · 104 DDA 0.4 Chloroform Didn’t work 
1 · 105 DDA 0.4 Chloroform Didn’t work 
2 · 105 DDA 0.4 Chloroform Didn’t work 
5 · 105 DDA 0.4 Chloroform Worked 
850-GNRs 
- OA 0.4 Chloroform Didn’t work 
- OA 0.1 Chloroform Didn’t work 
- DDT 0.75 Chloroform Didn’t work 
- DDT 0.75 Acetone Didn’t work 
1 · 105 DDT 0.75 Chloroform Didn’t work 
1 · 105 DDT 0.75 Acetone Didn’t work 
1 · 105 OA 0.4 Chloroform Worked 
6 · 104 DDA 0.4 Chloroform Worked 
1100-GNRs 
1 · 105 DDT 0.4 Chloroform Didn’t work 
6 · 104 DDT 0.4 Acetone Didn’t work 
8 · 104 DDA 0.4 Chloroform Worked 
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the polymer rings can be used for linking of other molecules like PEG, dye molecules, etc., 
through conjugation chemistry[83]. After modification process, the polymer was dried using a 
rotavapor under reduced pressure at 40 0C and dispersed in 30 mL of chloroform to produce a 
stock solution with final concentration 0.75 M.  
 
 
 
Figure 16. Schematic illustration of the the modification of poly(isobutylene-alt-maleicwith 
DDA in THF at 70 0C, to obtain the amphiphilic polymer with a hydrophilic and a 
hydrophobic domain. 
 
 
 
 
Figure 17. Scheme showing the polymer coating for both nanospheres and nanorods to 
transfer them from chloroform (1) to water (2). 
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The NPs were coated with a specific volume of polymer (PMA) as showns in Figure 17 
accordingly to the following equations 1-4[83]. Nanorods were considered as cylinders to 
simplify the calculations. The surface of one NP can be calculated employing formulas 1 and 
2 for SGNPs and GNRs, respectively. 
 
 
Where: A0 is the surface area of one NP; dc is the diameter of SNPs or GNRs; and Lc is the 
length of the GNRs as determined by TEM; dL corresponds with the thickness of the 
surfactant layer and deff is the effective diameter and equal to the NP core value determined 
by TEM (dc) plus two times the assumed thickness of the surfactant shell (dL = 1 nm). 
 
The total surface area (A) of the NPs can be calculated by Formula 3. 
 A = C×V×N!×A!                  (3) 
 
Where: C is corresponding to the NPs concentration [M]; V refers to the volume of solution 
[L] of NPs and NA is the Avogadro constant.  
 
Then, the amount of polymer needed to stabilize the NPs can be determined by formula 4. 
 
 
 
Where, VP is the volume of polymer needed to coat the NPs [L]; NP is the molar 
concentration of polymer [M]; CP, concentration of polymer in stock solution [M]; A is total 
surface area of all the colloidal NPs [cm2] in the solution and RP/Area is the ratio of monomer 
per nm2 needed to stabilize efficiently the particles and NA is the Avogadro constant.  
 
To increase the stability of the NPs the use of PEI (branched, Mw= 800 Da) as cross-linker 
was explored; and its volume can be calculated using the formula 5. 
 V! = !!∙! !!∙!!!/!!! !                (5)  
Where, VC is the volume of cross-linker solution added to the NPs solution [L]; VP is the 
volume of polymer needed to coat the NPs [L]; rC/P is the ratio of cross-linker added per 
polymer; CP, Cc are the concentration of polymer and cross-linker in stock solution, 
respectively. 
 
As an example, for coating of 1 mL of 50-GNPs with concentration equal to 5 nM, 2.748 mL 
A0 = 4π ∙ ( dc + !2dL /2)2 = π ∙ deff2  (1) A! = 2π ∙ d! + !2d!2 ∙ (L! + 2d!) (2) 
 
 
 
V! = N!C! = A! ∙ !R!/!"#$N! ! ∙ !C! !!!!!!!!!!!!!!!(4)    
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of polymer (Cp= 0.05 M, Rp/Area = 3000 monomers per nm2) was added. The volume of NPs 
and polymer were placed together in a round flask, and diluted with chloroform. After 20-30 
min, the chloroform was slowly evaporated[84] under reduced pressure using a rotavap at 
40 °C in the bath until the solvent was completely evaporated. This procedure was repeated 
twice. In case of using the crosslinker, it was added at this point; 0.75% of PEI (Cc= 0.05 M, 
Vc= 20.61 µL) was added to the NPs and diluted with chloroform. After 20-30 min, the 
chloroform was slowly evaporated and the resulting solids were quickly dissolved in basic 
buffer solution (0.1 M NaOH or SBB pH 12) to drive the NPs to the aqueous phase. To 
remove any big aggregate, the solution was filtrated through a syringe membrane filter (0.22 
m pore size). Then, the empty micelles generated by the excess of polymer were removed 
by precipitation of the NPs using centrifugation. The buffer was changed to water. See Table 
3 for the centrifugation conditions depending on the NPs size and shape. 
 
Three main advantages for polymer coating techniques have to be mentioned. First, the 
surface coating of inorganic NPs (semiconductor or metal oxide) by the polymer will not 
affect the physical properties of the core such as quantum yield, absorption, scattering or 
magnetism. Second, the NPs from different kinds of materials will be wrapped by a universal 
surface and then, the effect of the surface can be removed from the equation because they 
have the same surface coating. Third, this approach of NPs coating is not only used to 
transfer the NPs from an organic solvent to aqueous solution, but also serves as general 
platform which can be used for the attachment of biological molecules to the polymer surface 
through bioconjugation chemistry[83]. 
 
As reported by Murphy[64] , the CTAB in nanorods solution, directly after nanorods synthesis, 
has concentration of 37 mM. A specific volume of 850-GNRs, directly after synthesis, was 
diluted 15 times and the UV spectrum was recorded as shown Figure 19 (black spectra). In 
this sample, the concentration of CTAB is 3.3 mM due to the dilution of 15 times. Applying 
the round trip process of phase transfer and polymer coating will decrease the concentration 
of CTAB in the nanorods solution. This fact was tested recording the UV spectra for different 
CTAB concentrations in water in the region of the UV (Figure 18). Then, the absorbance in 
the same region of GNRs solutions after each step of surface modifications (from synthesis to 
PMA) was recorded (Figure 19). The results show that the concentration of CTAB in the 
GNRs solution decreased to less than 0.5 mM, which is the lowest concentration tested. 
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Figure 18. UV spectra for the different dilutions of CTAB dissolved in water. 
 
 
 
 
Figure 19. UV spectra for the 850-GNRs solution after each step of surface modification in 
the region of CTAB absorbance (200-270 nm range). 
 
2.4. PEGylation of NPs 
 
After polymer coating, the NPs surface is rich in –COOH groups. Therefore, using EDC 
chemistry[96] they can be activated and functionalized with different kind of molecules. In 
particular, NPs surfacewere modified with differnet mPEG-NH2 (Figure 20). The molecular 
weight of the PEG chains was varied between the different samples (from 0.75 to 10 kDa) as 
! 30! 
shown in Table 3. The interaction mechanism of the EDC with –COOH and -NH2 was 
reported in section 1.4. The reaction was left overnight and after that, the NPs were cleaned 
using dialysis for 1 h and concentrated by centrifugation.  
 
 
 
Figure 20. PEGylation of a) GNRs, b) SGNPs before (1) and after (2) PEGylation, using 
mPEG-NH2 by EDC chemistry. 
 
Table 3. Experimental conditions for all NPs. CNP, CDDA, CEDC and CPEG refers to 
concentration of NPs, DDA, EDC and PEG respectively. Rp/Area refers to the number of PMA 
monomer added nm2, rC/P refers to the ratio of crosslinker per polymer monomers, v refers to 
centrifugation speed and t refers to the centrifugation time. 
 
 
 
 
 
EDC$chemistry$to$
modify$the$
surface:$
PEGyla7on$
a) 1 
1 b) 
2 
2 
1 2 
1 2 
+$
+$
Sample 
Phase transfer Polymer coating PEGylation 
CPEG/ 
CNP 
CDDA [M] Rp/Area 
rC/P 
PEI 
Centrifugation 
CEDC/ CNP 
PEG 
[kDa] 
CPEG/ 
CNP v 
[rpm]  
t 
[min] 
25-GNPs 
5 · 105 0.75 3000 0.75 
9000  30 5 · 106 0.75 6 · 106 
50-GNPs 4000 35 30 · 106 5 3 · 106 
60-GNPs 3000  35 30 · 106 10 3 · 106 
850-GNRs 4000  35 8 · 106 5 1 · 106 
1100-GNRs 9000 30 8 · 106 10 1 · 106 
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2.5. Characterization of NPs 
 
The NPs were characterized after each step of surface modification by using the following 
techniques:  
 
2.5.1. Ultraviolet-visible spectroscopy 
 
UV-Vis spectroscopy was used to measure the absorbance and to check the stability of the 
particles. To measure the particles absorbance, the solvent was placed inside a 1 cm pathway 
polystyrene cuvette and used as blank. After that, the sample was immersed and diluted in the 
same cuvette. The UV spectra and SPR absorbance were recorded for all NPs as shown in 
Figure 21 and Table 4 respectively. 
  
As shown in Figure 21, the SPR position was shifted to higher wavelength for all NPs which 
were DDA-capped and dispersed in chloroform. The red-shifting is due the effect of the 
surrounding medium on the SPR wavelength, which the refractive index for chloroform 
(1.44) is higher than that to the water (1.33) and then, will led to shifting the SPR position to 
higher wavelength with considering the effect of surfactant on the SPR[17] as I mentioned in 
section 1.1. In case of GNRs (especially 1100-GNRs), the SPR position was shifted to lower 
wavelength after PMA and this might be due to some looses of the longer rods (higher aspect 
ratio) during the surface modification steps and cleaning stages of rods by centrifugation (see 
Table 4).   
 
Table 4. Summarizes the maximum of LSPR absorbance of all the GNPs in all the 
modification steps. 
  
(*) Highest wavelength that we can measure with our UV-Vis spectrophotometer 
 
 
Sample 
λSPR [nm] 
Citrate/CTA
B-capped 
mPEG-SH DDA-capped PMA-coated mPEG-
NH2 
25-GNPs 523 524 530 524 524 
50-GNPs 535 538 546 536 536 
60-GNPs 541 542 555 542 542 
850-GNRs 836 832 877 824 816 
1100-GNRs 1095 1055 ≥ 1100* 1075 1056 
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Figure 21. Normalized UV spectra for a) 25-GNPs, b) 50-GNPs, c) 60-GNPs, d) 850-GNRs, 
e) 1100-GNRs. Color codes stand for citrate/CTAB-capping (black), stabilization with 
mPEG-SH (red), after their phase transfer (DDA-capped) (blue), PMA coating (pink) and 
after PEGylation (green).  
 
Also, the yield (%Y) of the process was followed by UV-Vis spectroscopy. For each NP type, 
the concentration and the sample volume was controlled in each step. The concentration was 
measured using the extinction coefficients described in Table 5, and the NPs amount 
collected after each step was compared with the NPs obtained directly after the NPs synthesis 
(100%) as shown in Table 6. There are some problems with the adequation of the extinction 
coefficient especially for the 1100-GNRs in chloroform, but it is safe to say that the phase 
transfer is quantitative. Remarkably, the total yield after all the polymer coating procedure, 
including the cleaning steps is above the 73 % in all the cases (in some is as high as an 80 %). 
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Table 5. Shows the molar extinction coefficients values which were used for each NP for 
calculation their concentrations. λɛ refers to the wavelength number in which the ɛ was 
picked. λLSPR refers to the maximum of absorbance in the longitudinal LSPR of GNRs. 
 
 
 
 
 
 
 
Table 6. Yield of collected NPs after each step of surface modifications. C [nM] refers to 
concentration, V [mL] refers to the total volume and Y% refers to the yield. 
 
UV-Vis spectroscopy can be used to determine the concentration of the particles using the 
Beer-Lambert law[135] by Formula 6. The concentration of NPs depends on extinction 
coefficient of the particles and the absorbance values measured at the wavelengths indicated 
in the Table 5. 
 A = C××L                                                  (6) 
 
Where A is the absorbance of the NPs at wavelength of 450 nm, C is the concentration of NPs; L is 
the light path length in the cuvette (1 cm) and ɛ is the extinction coefficient of the particles. 
 
NPs ɛ [M-1 cm-1] λ ɛ[nm] 
25-GNPs 9.64 ·108 
450[134] 50-GNPs 9.92 · 109 
60-GNPs 1.73 · 1010 
1100-GNRs 8.5 · 109 
λLSPR
[133] 
850-GNRs 4.9 · 109 
Ligand 
25-GNPs 
%Y 
50-GNPs 
%Y 
60-GNPs 
%Y  
V [mL] C [nM] V [mL] C [nM] V [mL] C [nM] 
Citrate/CTAB 150 1.4 100 150 0.43 100 150 0.14 100 
mPEG-SH 152.5 1.37 99.5 153 0.41 97.3 152.1 0.13 94.1 
DDA 20.3 10.1 97.6 20 2.7 83.7 10 2 95.2 
PMA 2.15 82.4 84.6 8.55 5.8 76.9 4.2 3.8 76 
Ligand 
850-GNPs 
%Y 
1100-GNRs 
%Y 
V [mL] C [nM] V [mL] C [nM] 
Citrate/CTAB 52 6 100 103 0.8 100 
mPEG-SH 60 5.1 98.1 108 0.74 97.0 
DDA 19 15.2 92.6 90 0.5 54.6 
PMA 4.3 57.9 79.8 19 3.2 73.8 
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1.1.1. Dynamic light scattering (DLS) and laser Doppler anemometry (LDA) 
 
DLS was used to measure the hydrodynamic diameter (dh) of the NP that is used as a good 
indicator for the colloidal stability of the particles. Increasing dh with the time may be an 
indication for NP agglomeration. For measuring the dh, the sample was calibrated for 10 min 
at room temperature to be the measured movements only belong to Brownian motion. Then, 
1 mL of sample in a polystyrene cuvette is placed in the cuvette holder and the SOP 
(Standard Operating Procedure) setting is selected depend on the material, solvent and 
cuvette. The hydrodynamic diameter in number (N (dh)) and in intensity (I (dh)) was recorded 
3 times for all NPs as shown in Figures 24-29. As indicated by the DLS results, the particles 
are very stable during the steps of surface modifications and the dh for all nanospheres was in 
the same range (from synthesis to PMA). After PEGylation of NPs as shown in Figure 22 and 
Table 7, the dh is increased about 10 nm in case of 50-GNPs and about 18 nm in case of 60-
GNPs depending the length of the PEG molecule  
 
LDA can be used to measure the zeta () potentials. For this purpose, the Malvern Dip Cell 
Kit was used and the measurement conditions were the same as DLS with changing the SOP 
setting to be compatible with this measurement. The -potential was recorded 3 times for all 
NPs as shown in Figures 30-34.  
 
As shown in Figure 23, the surface net charge of the spherical particles changed from highly 
negative (citrate and PMA-coating), which is rich with negatively -COOH to less negative 
after PEG stabilization. After PEGylation, the surface net charge changed to be close to zero 
(neutral state) due to saturation of particles with PEG especially, in case of 50-GNPs and 60-
GNPs, which the number of -COOH are decreased and the particles surface is rich with non-
charged methoxy groups (-CH3) as confirmed also with gel electrophoresis (section 1.1.2). In 
case of GNRs, the surface net charge changed from positive (CTAB-capped), which is rich 
with positively ammonium groups (-NH3+) to less positivity (stabilized with PEG), to highly 
negative (PMA-coated) and finally changed to be close to Zero after PEGylation. 
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Figure 22. Shows the hydrodynamic diameter in intensity (I(dh)) for the SGNPs after each 
step of surface modifications 
 
 
 
 
Figure 23. ζ -potential values [mV] for all NPs in all the steps of the round phase transfer. 
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Table 7. dh [nm] in number (N (dh)) and intensity (I (dh)), Z-average (Zave), polydispersity 
index (PDI) and ζ -potential values (N (ζ)) for all NPs in all the steps. The size values for 
GNRs were used only as indicator to the colloidal stability in all the steps of the round phase 
transfer and have no physical meaning. 
 
Sample Modification N (dh)[nm] Zave[nm] PDI I (dh)[nm] 
N ( ) 
[mV] 
25-GNPs 
Citrate-capped 21.0 ± 0.5 29.3 ± 0.1 0.11 ±0.01 33.0 ± 0.4 - 31.1 ± 1.7 
mPEG-SH (750 Da) 26.4 ± 0.7 35.8 ± 0.3 0.11 ± 0.01 39.9 ± 0.3 - 14.8 ± 1.5 
DDA-capped 26.1 ± 0.8 36.5 ± 0.1 0.10 ± 0.01 40.7 ± 0.1 - 
PMA-coated 27.0 ±0.2 34.8 ± 0.1 0.08 ± 0.01 37.9 ± 0.1 - 25.7 ± 0.5 
mPEG-NH2 (750 Da) 28.6 ± 0.7 37.7 ± 0.2 0.09 ± 0.01 41.6 ± 0.2 - 13.4 ± 0.6 
50-GNPs 
Citrate-capped 35.4 ± 1.1 53.2 ± 0.2 0.21 ± 0.01 66.6 ± 0.2 - 35.8 ± 0.4 
mPEG-SH (750 Da) 38.6 ± 0.8 57.8 ± 0.1 0.19 ± 0.01 71.2 ± 1.0 - 23.3 ± 0.5 
DDA-capped 38.2 ±0.2 54.2 ± 0.4 0.18 ± 0.01 66.1 ± 0.5 - 
PMA-coated 43.4 ± 1.6 61.9 ± 0.1 0.19 ± 0.01 76.3 ± 0.4 - 34.3 ± 1.6 
mPEG-NH2 (5 kDa) 53.5 ±1.9 79.6 ± 0.3 0.15 ± 0.01 93.4 ± 0.7 - 8.8 ± 0.5 
60-GNPs 
Citrate-capped 49.5 ± 1.1 68.3 ± 0.8 0.15 ± 0.01 79.7 ± 0.5 - 31.0 ± 0.3 
mPEG-SH (750 Da) 43.2 ± 2.7 85.3 ± 1.0 0.23 ± 0.01 110.0 ± 2.1 - 21.7 ± 0.2 
DDA-capped 47.7 ± 1.1 60.0 ± 0.3 0.13 ± 0.01 80.0 ± 0.5 - 
PMA-coated 47.4 ± 1.1 74.3 ± 0.5 0.18 ± 0.01 89.2 ± 2.5 - 28.4 ± 0.3 
mPEG-NH2 (10kDa) 65.1 ± 2.0 95.4 ± 0.8 0.11 ± 0.01 108.7 ± 2.05 - 4.1 ± 0.5 
850-GNRs 
CTAB-capped - 10.4 ± 0.05 0.40 ± 0.01 8.24 ± 0.03 46.1 ± 0.9 
mPEG-SH (750 Da) - 8.23 ± 0.67 0.37 ± 0.02 7.17 ± 0.30 12 .0± 1.0 
DDA-capped - 27.27 ± 3.6 0.49 ± 0.11 11.23 ± 1.3 - 
PMA-coated - 14.38 ± 0.48 0.55 ± 0.07 8.99 ± 0.25 - 29.2 ± 0.4 
mPEG-NH2 (5 kDa) - 10.86 ± 0.1 0.27 ± 0.01 11.79 ± 0.33 9.5 ± 1.2 
1100-GNRs 
CTAB-capped - 27.84 ± 0.65 0.61 ± 0.04 58.91 ± 2.79 39.3 ± 0.5 
mPEG-SH (750 Da) - 33.32 ± 0.4 0.27 ± 0.01 48.24 ± 0.61 9.4 ± 1.2 
DDA-capped - 23.1 ± 0.8 0.52± 0.08 41.43 ± 1.92 - 
PMA-coated - 12.85 ± 0.11 0.57 ± 0.01 29.61 ± 0.48 - 33.5 ± 0.3 
mPEG-NH2 (10 kDa) - 22.38 ± 0.2 0.55± 0.03 49.68 ± 3.22 - 6.0 ± 0.4 
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Figure 24. Hydrodynamic diameter in number (N(dh)) for 25-GNPs after each step of surface 
modifications: a) citrate-capped b) after their stabilization with mPEG-SH; c) DDA-capped 
d) PMA-coated and e) after modification with mPEG-NH2 (Mw= 750 Da). 
Figure 25. Hydrodynamic diameter distribution in intensity (I(dh)) for 25-GNPs after each 
step of surface modifications:a) citrate-capped b) after their stabilization with mPEG-SH; c) 
DDA-capped d) PMA-coated and e) after modification with mPEG-NH2 (Mw= 750 Da). 
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Figure 26. Hydrodynamic diameter distribution in number (N(dh)) for 50-GNPs after each 
step of surface modifications: a) citrate-capped b) after their stabilization with mPEG-SH; c) 
DDA-capped d) PMA-coated and e) after modification with mPEG-NH2 (Mw= 5kDa). 
Figure 27. Hydrodynamic diameter distribution in intensity (I(dh)) for 50-GNPs after each 
step of surface modifications: a) citrate-capped b) after their stabilization with mPEG-SH; c) 
DDA-capped d) PMA-coated and e) after modification with mPEG-NH2 (Mw= 5kDa). 
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Figure 28. Hydrodynamic diameter distribution in number (N(dh)) for 60-GNPs after each 
step of surface modifications: a) citrate-capped b) after their stabilization with mPEG-SH; c) 
DDA-capped d) PMA-coated and e) after modification with mPEG-NH2 (Mw= 10kDa). 
 
Figure 29. Hydrodynamic diameter distribution in intensity (I(dh)) for 50-GNPs after each 
step of surface modifications: a) citrate-capped b) after their stabilization with mPEG-SH; c) 
DDA-capped d) PMA-coated and e) after modification with mPEG-NH2 (Mw= 10 kDa). 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! !
!
!
!
!
!
!
!
! !
1 10 100 1000
0
5
10
15
20
25
30
N
'(
d
h
)
!
!
!
!
!
!
!
!
!d
h
'[nm]
60-GNPs (Size by Number) 
1 10 100 1000
0
5
10
15
20
25
30
N
'(
d
h
)
!
!
!
!
!
!
!
!
!
!
!
!dh'[nm]
1 10 100 1000
0
5
10
15
20
25
30
N
'(
d
h
)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
d
h
'[nm]
1 10 100 1000
0
5
10
15
20
25
30
N
'(
d
h
)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
d
h
'[nm]
1 10 100 1000
0
5
10
15
20
25
30
N
'(
d
h
)
!
!
!
!
!!!
d
h
'[nm]
!
a)' b)'
e)'d)'
d)'
c)'
!
!
!
!
!
! !
!
!
!
!
!
!
!
!
! !
!
!
!
!
!
!
!
60-GNPs (Size by Intensity) 
1 10 100 1000
0
5
10
15
20
I&(
d
h
)
!
!
!
!
!
!
!
!
!
!
!dh&[nm]
1 10 100 1000
0
5
10
15
I&(
d
h
)
!
!
!
!
!
!
!
!
!
!
!
!dh&[nm]
1 10 100 1000
0
5
10
15
20
I&(
d
h
)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
d
h
&[nm]
1 10 100 1000
0
5
10
15
20
I&(
d
h
)
!
!
!
!
!!
!
!
!
!
!
!
!
!
!
!dh&[nm]
1 10 100 1000
0
5
10
15
20
I&(
d
h
)
!
!
!
!
!!!!
d
h
&[nm]
!
a)& b)&
e)&d)&
d)&
c)&
! 40! 
 
Figure 30. ζ-potential distribution (N(ζ)) for 25-GNPs along their surface modifications: a) 
citrate-capped; b) after their stabilization with mPEG-SH; c) DDA-capped; d) PMA-coated; 
e) after modification with mPEG-NH2 (Mw= 750 Da). 
 
Figure 31. ζ-potential distribution (N(ζ)) for 50-GNPs along their surface modifications: a) 
citrate-capped; b) after their stabilization with mPEG-SH; c) DDA-capped; d) PMA-coated; 
e) after modification with mPEG-NH2 (Mw= 5kDa). 
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Figure 32. ζ-potential distribution (N(ζ)) for 60-GNPs along their surface modifications: a) 
citrate-capped; b) after their stabilization with mPEG-SH; c) DDA-capped; d) PMA-coated; 
e) after modification with mPEG-NH2 (Mw= 10 kDa). 
 
Figure 33. ζ-potential distribution (N(ζ)) for 850-GNRs along their surface modifications: a) 
CTAB-capped; b) after their stabilization with mPEG-SH; c) DDA-capped; d) PMA-coated; 
e) after modification with mPEG-NH2 (Mw= 5 kDa). 
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Figure 34. ζ-potential distribution (N(ζ)) for 1100-GNRs along their surface modifications: 
a) CTAB-capped; b) after their stabilization with mPEG-SH; c) DDA-capped; d) PMA-
coated; e) after modification with mPEG-NH2 (Mw= 10 kDa). 
 
1.1.2. Gel electrophoresis  
 
Normally, gel electrophoresis is used for purification of the particles by the separation from 
other molecules depending on their size, shape and charge. Also, it can be used to check the 
colloidal stability of the NPs. The particles which have a stable surface coating, can run 
through the gel without precipitation or aggregation. For using gel electrophoresis, 1 % of gel 
was prepared by dissolving 1.75 g of Agarose in 175 mL of Trisborate-EDTA buffer (TBE 
0.5x) and placing the solution into the gel tray. After 1 h, the gel was placed into the 
electrophoresis chamber, which is filled with TBE buffer. The sample was mixed with a 
specific volume of a gel-loading buffer to increase the density of the sample and loaded to the 
gel. 20 µL of 10 nm commercial gold particles stabilized with triphenyl phosphine (bis(p-
sulfonatophenyl) phenylphosphine dehydratwere loaded to the gel and used as reference[136]. 
After that, an electric field of 10 V·cm-1 was applied for 1 h and the particles started to move 
through the gel because of their surface charge. After that, the piece of gel was removed from 
the gel chamber and filmed using digital camera. 
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The migration of the particles after PMA through the gel is an indication for the colloidal 
stability of the particles, which is due to electrostatic repulsion of -COOH. As shown in 
Figure 35, the motion speed of the particles depends on the size and the charge of NPs. Also, 
all the particles have single and narrow band through the gel and this is an indication of that 
all NPs are uniformly wrapped by the polymer due to the good coating process.  
 
 
 
 
Figure 35. Mothion path of PMA coated a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-
GNRs and e) 1100-GNRs through a 1% agarose gel and the electric field was 10 V·cm-1 for 1 
h. 
 
 
!
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In the following Figure 36, the motion path of the particles through the gel is broaden due to 
the attachment of the PEI (used as cross-linker) to the surface of the NPs during the polymer 
coating process as I mentioned in section 2.3. 
 
 
 
Figure 36. Motion path of PMA+PEI coated a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-
GNRs and e) 1100-GNRs through a 1% agarose gel and the electric field was 10 V·cm-1 for 1 
h. 10 nm GNPs phosphine-capped was used as control. 
 
As I mentioned before, the PMA coating make the NPs surface rich in negative –COOH 
groups. These groups are used during the linkage of mPEG-NH2 to the surface of NPs via 
EDC chemistry. Then, the surface of the NPs will be rich with non-charged methoxy groups, 
which decrease the negativity of the NPs surface. As shown in Figure 37, the motion speed of 
the particles after PMA is much faster than the speed of the particles after PEGylation and in 
some cases, especially in case of 60-GNPs and 850-GNRs, the particles didn’t move (or just 
a little bit) through the gel when the surface is saturated with PEG. 
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Figure 37. Mothion path of the particles coated with PMA+PEI and PMA+PEI+PEG through 
a 1% agarose gel run at 100 V for 1 h. From left to right: (A1, A2) correspond to 60-GNPs 
coated with PMA+PEI and with PMA+PEI+PEG (Mw of PEG = 10 kDa) respectively; (B1, 
B2) correspond to 50-GNPs coated with PMA+PEI and with PMA+PEI+PEG (Mw of PEG = 
5 kDa) respectively; (C1, C2) corresponds to 25-GNPs coated with PMA+PEI and with 
PMA+PEI+PEG (Mw of PEG = 750 Da) respectively; (D1, D2) correspond to 850-GNRs 
PMA-coated with PMA+PEI and with PMA+PEI+PEG (Mw of PEG = 5 kDa) respectively; 
and (E1, E2) correspond to 1100-GNRs PMA-coated with PMA+PEI and with 
PMA+PEI+PEG (Mw of PEG = 10 kDa) respectively. 10 nm GNPs phosphine-capped was 
used as control. 
 
1.1.3. Transmission electron microscopy (TEM) 
 
TEM was used to get information about the particles core dimensions, shape, monodispersity 
and agglomeration. For TEM measurement, the sample was prepared depend on the type of 
solvent. For the sample dispersed in organic solvent, the sample was placed at the copper grid 
and dried for short time at room temperature. For the sample dispersed in aqueous solvent, 
the copper grid was converted to be hydrophilic by dipping it in a little bit of ethanol in 
closed tube for about 4 hours. Then, 20 µL of the sample was placed at the copper grid and 
the tube was opened overnight to allow the sample to dry. 
 
As shown in the following Figures 38-42, the Au cores appear as black spots  (in case of 
SGNPs) and gray spots (in case of GNRs) with high contrast. The intermediate space 
between NPs is indication for the presence of surfactants, which prevent the Au cores from 
agglomeration. 
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Figure 38. TEM picture of 25-GNPs: a) DDA-capped; b) PMA-coated NPs; and core 
diameter (dc) size distribution (N(dc)) graph of c) DDA-capped with dc =24.7 ± 3.0 nm and d) 
PMA-coated NPs with dc =24.1 ± 3.0 nm. The scale bars correspond to 100 nm. 
 
Figure 39. TEM picture of 50-GNPs: a) DDA-capped and b) PMA-coated NPs; and core 
diameter (dc) size distribution (N(dc)) graph of c) DDA-capped with dc =45.7 ± 7.7 nm and d) 
PMA-coated NPs with dc =50.4 ± 6.9 nm. The scale bars correspond to 100 nm. 
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Figure 40. TEM picture of 60-GNPs a) conjugated with mPEG-SH (750 Da) b) PMA-coated 
NPs; and core diameter (dc) size distribution (N(dc)) graph of c) conjugated with mPEG-SH 
with dc =63.8 ±7.6 nm and d) PMA-coated NPs with dc =60.5 ± 7.8 nm. The scale bars 
correspond to 100 nm. 
 
 
Figure 41. TEM picture of 850-GNRs: a) CTAB-capped and b) PMA-coated NPs; core 
diameter (dc) size distribution (N(dc)) graph of the GNRs thickness of c) CTAB-capped with 
dc =24.5 ± 4.8 nm and d) PMA-coated NPs with dc =24.4 ± 5.3 nm. The core length (Lc) size 
distribution (N(Lc)) graph of the GNRs length of e) CTAB-capped with Lc=92.1 ±11.8 nm 
and f) PMA-coated with Lc=92.3 ± 14.8 nm. The scale bars correspond to a) 50 nm and b) 
100 nm. 
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Figure 42. TEM picture of 1100-GNRs: a) PMA-coated NPs; b) core diameter (dc) size 
distribution (N(dc)) graph of the GNRs thickness with dc= 11.3 ±1.7 nm and c) core length 
(Lc) size distribution (N(Lc)) of the GNRs length with Lc= 77.3 ± 12.8 nm. The scale bar 
corresponds to 100 nm. 
 
3. Stability assays 
 
Aiming to understand and assess the colloidal stability of the NPs. The NPs stability at 
different media, see Table 8, was tested using different techniques (e.g. UV/Vis spectroscopy 
and DLS). Those media were selected to prove the effect of the presence of high ionic 
strength, protein concentration, and a combination of both. All of them are media used in the 
most tradition in vitro experiments. 
 
Table 8. Composition of all media used for studying the stability of NPs[137]. aFresh Mili-Q 
water.bPhosphate buffered saline.cDulbecco’s modified Eagle's medium. 
dPenicillin/streptomycin. eL-glutamin.fBovine serum albumin.gFetal bovine serum. 
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             Medium 
Compound 
# 1 # 2 # 3 # 4 # 5 # 6 # 7 # 8 
Solvent Watera PBSb DMEMc PBS DMEM PBS DMEM DMEM 
1% P/Sd - - - yes yes - yes yes 
1% L-Glue - - - yes yes - yes yes 
800 µM BSAf - - - - - yes yes 10% FBS g 
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3.1. Stability of three surface coating (NPs@PMA, NPs@PMA+PEI and 
NPs@PMA+PEI+PEG) in complete cell media. 
 
In this case, the stability of all NPs with three surface coating (NPs@PMA, NPs@PMA+PEI 
and NPs@PMA+PEI+PEG (PEGylated NPs)) in complete cell media[137] (media 8, Table 7) 
was tested using UV-Vis spectroscopy. The particles were incubated in complete cell media 
for 3 days (d) and at different points of time, the UV spectra were recorded as shown in the 
following Figures 43-45. 
As indicated by the UV spectra, at the initial stages of NPs immersion in cell media, a SPR 
broadening was observed for PMA-coated 50 and 60-GNPs indication for the NPs stability 
defect. This broadening was disappearing gradually with time due to adsorption and the 
arrangement of the proteins on the NPs surface. The attachment of the PEI to the NPs surface 
help to avoid this SPR broadening, which is prevented completely after PEGylation of the 
same NPs. Notice that, all the particles after PEGylation are highly stable in the cell media 
for at least 3 d. 
! 50! 
 
 
Figure 43. Normalized absorption spectra of the PMA-coated NPs in complete cell media for 
3 d: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 44. Normalized absorption spectra of the PMA+PEI-coated NPs in complete cell 
media for 3 d; a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 45. Normalized absorption spectra of the PEGylated NPs in the media 8, up to 3 days, 
for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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3.2. Stability of PEGylated NPs in different media. 
 
The colloidal stability of all PEGylated NPs was studied in different media as shown in Table 
7 by using UV-Vis spectroscopy and DLS. The NPs were incubated in the different media for 
3 days and at different time-points, the UV spectra and the hydrodynamic diameter were 
recorded. Results are shown in the following Figures 46-57. The concentration of 1100-
GNRs, 850-GNRs, 60-GNPs, 50-GNPs and 25-GNPs were 0.094 nM, 0.16 nM, 0.016 nM, 
0.04 nM and 0.42 nM respectively. The original media were taken as blank in the UV-Vis 
measurements and then the changes in absorption could be identified as interaction between 
medium and the NPs. 
 
Study of the stability of NPs in different media by UV-Vis spectroscopy: 
 
The aggregation of all NPs was observed when the NPs were incubated in media (2, 3, 4 and 
5) due to the high ionic strength of the media. In some of the free-protein media, most of NPs 
were completely aggregated after 8 h. This indicates that the presence of salt in the media 
will compromise the NPs stability due to the screening of the NPs surface charge. In the 
media containing proteins (6, 7 and 8), the stability of all the NPs was improved compared to 
the stability in free-protein media and this due to adsorption of proteins (protein corona) on 
the NPs surface, which improve their stability. Shifting the SPR a few nanometers to higher 
wavelength in UV spectra is indication to the formation of protein corona around the NPs. 
These results were also confirmed by DLS. 
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Figure 46. Normalized absorption spectra of the PEGylated NPs in the media 1, at different 
time points, for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 47. Normalized absorption spectra of the PEGylated NPs in the media 2, at different 
time points, for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 48. Normalized absorption spectra of the PEGylated NPs in the media 3, at different 
time points, for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 49. Normalized absorption spectra of the PEGylated NPs in the media 4, at different 
time points, for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 50. Normalized absorption spectra of the PEGylated NPs in the media 5, at different 
time points, for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 51. Normalized absorption spectra of the PEGylated NPs in the media 6, up to 3 days, 
for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 52. Normalized absorption spectra of the PEGylated NPs in the media 7, up to 3 days, 
for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Figure 53. Normalized absorption spectra of the PEGylated NPs in the media 8, up to 3 days, 
for: a) 25-GNPs; b) 50-GNPs; c) 60-GNPs; d) 850-GNRs and e) 1100-GNRs. 
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Study of the stability of NPs in different media by DLS: 
DLS results are in agreement with the UV-Vis results where the aggregation of the NPs was 
detected after 8 h in protein-free media (2, 3, 4 and 5). On the other hand, the particles are 
more stable in proteins containing media (6, 7 and 8) and the hydrodynamic diameter was 
shifted to higher values due to the formation of protein corona around the NPs. The DLS was 
used for GNRs as quantitative method for checking the colloidal stability and has no physical 
meaning. In the following figures (Figure 54-57) the results for all the NPs in all the media 
are summarized. 
 
Figure 54. Summary of the a) number, dh,Ni, and b) intensity, dh,i, hydrodynamic diameter 
distributions for the 8 media versus time for 25-GNPs. 
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Figure 55. Summary of the a) number, dh,Ni, and b) intensity, dh,i, hydrodynamic diameter 
distributions for the 8 media versus time for 50-GNPs. 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
0 10 20 30 40 50 60 70 80
0
20
40
60
80
100
120
140
t+[h]
d
h
,N
i+[
n
m
]
+med ia+1
+media+2
+media+3
+media+4
+media+5
+media+6
+media+7
+media+8
0 10 20 30 40 50 60 70 80
40
80
120
160
200
t+[h]
d
h
,i+
[n
m
]
+med ia+1
+media+2
+media+3
+media+4
+media+5
+media+6
+media+7
+media+8
a) 
b) 
! 64! 
 
 
Figure 56. Summary of the a) number, dh,Ni, and b) intensity, dh,i, hydrodynamic diameter 
distributions for the 8 media versus time for 60-GNPs. 
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Figure 57. Summary of the intensity hydrodynamic diameter distributions, dh,I, for the 8 
media versus time for a) 850-GNRs and b) 1100-GNRs. 
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3.3. Stability of different surface coating of NPs vs different pH values  
 
As described above, the properties of NPs, including their stability, aggregation behavior, 
sensing abilities, etc. are controlled by their size, shape, surface coating, surface charge, etc. 
The predictions of the interaction between the two NPs as a function of the surface coating, 
pH, size and shape of the NPs enable us to gain insight into the stability of the NPs under 
different conditions. So, the successful application of the NPs requires that they be highly 
stable at a wide range of pH values. For this study, the stability of two different samples of 
GNPs with different shapes (spheres and rods) and different surface coating  (PMA and PEG) 
was tested against different pH values with titration system by using Malvern Zetasizer Nano 
ZS. For this purpose, 60-GNPs and 850-GNRs were coated firstly with PMA (as described in 
section 2.3) and then, PEGylated with ɑ-Methoxy-ω-amino PEGs (Mw= 10 kDa) following 
the same protocol described in section 2.4 (see Table 9).  
 
Table 9. PEgylation conditions for 60-GNPs and 850-GNRs.  CNP, CEDC and CPEG refers to 
concentration of NPs, EDC and PEG respectively. 
 
!!!!!!!!!
Starting from a colloidally stable of NPs at high pH; the solution was acidified upon addition 
of a titrant. After each addition, the zeta potential and hydrodynamic diameter of the NPs 
were measured as shown in Figures 58-59. At higher pH values, the NPs surface is highly 
gained negative charge due to the deprotonation of carboxylic acids. Upon addition of acidic 
solution, the negatively charged surface gradually decreases (protonated) to be close to zero. 
However, the particles are stable at all pH values (under high, moderate, and low pH 
conditions) indicating that pKa value of PMA and PEG-coated NPs is less than 5.5, which is 
the lowest pH value tested. 
Sample 
PEGylation 
CEDC/ CNP Mw CPEG/ CNP 
60-GNPs 30 · 106 10 
[kDa] 
2 · 106 
850-GNRs 5 · 106 2 · 106 
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Figure 58. ζ-potential distribution (N(ζ)) vs different pH values using titration system of a) 
60-GNPs and b) 850-GNRs coated with PMA (black line) and PMA+PEG (red line). 
 
 
 
Figure 59. Hydrodynamic diameter distributions in intensity (dh,i) vs different pH values of 
a) 60-GNPs and b) 850-GNRs coated with PMA (black line) and PMA+PEG (red line). 
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4. Toxicity tests 
 
The toxicity of the PMA coated NPs was tested against two kinds of cells; HeLa and 3T3 
cells. These cells were seeded at a cell density of 5 · 103 cells/well of HeLa and 10 · 103 
cells/well of 3T3 in a 96 well plate in 100 µL of DMEM media (10% FBS, 1%P/S and 1% L-
Glu) and incubated overnight. Next day, the cells were incubated for 24 h with different 
concentration of NPs as indicated in Figure 58. After that, the cells were washed one time 
with PBS and 100 µL of 10 % Resazurin solution (blue, non-fluorescent sodium salt) were 
added to each well in growth solution and incubated for 4 h at 37 0C. The viability date were 
presented as percentage to the untreated cells with particles (control) depending on the 
emission (fluorescence) intensity of Resorufin which is resulted due to reduction process of 
the Resazurin by metabolically active cells. This reduction process needs continually 
mitochondrial activity by the cells, which is inactivated immediately after their death. The 
fluorescence spectrum was recorded using Fluorometer at excitation wavelength of 560 nm.  
NPs molar concentration was determined based on the UV-Vis absorbance values, as 
described in Section 2.5. To convert those molar values into µg/mL, the molecular weight 
(Mw) for each NP was calculated by Formulas 7-9. The volume of one NP (VNP) was 
calculated by Formula 7 and 8 for spheres and rods respectively. The rods volume was 
assumed as a cylinder and the core length (dL) and diameter (dc) was determined by TEM.  
!!" = ! 43 !×!!!× ! dc2 3                                           (7) 
 
!!" = !!!× ! dc2 2 ×!!                                          (8) 
 
The molecular weight of one NP (Mw) was calculated by following Formula 9: 
!! ! = !!"×!!!"#$×!!                                         (9) 
 
Where p is the gold density and NAis the A vogadro number.  
With neglecting the contribution of the polymer coating to the mass of the NPs[138], The 
conversion of mol to mass can be caculated by using the following Formula 10: 
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mNPV = (C×!MW)                                                                          (10)
 
Where C is the concentration [M], m is the mass [mg], Mw is the molecular weight [g/mol] 
and V, the volume of the NPs solution [mL]. Table 10 shows the molecular weights and the 
volumes for all NPs. 
 
Table 10. Summary of the VNP and Mw of each NP type. 
 
 
 
 
 
As indicated by the following Figure 60, the toxicity of particles was decreased especially, in 
case of GNRs. This means that the concentration of CTAB was decreased during the round 
trip process of the phase transfer and polymer coating as confirmed by Figure 18-19. 
Therefore, the cells are still alive with GNRs concentration up to 2.5 nM. In case of SGNPs, 
we found that the viability trend is size-dependent where the cells are still alive with NPs 
concentration up to 4.5, 0.3 and 0.2 nM in case of 25-GNPs, 50-GNPs and 60-GNPs 
respectively. 
 
 
Sample VNP [cm-3] Mw [g/mol] 
25-GNPs 4.2 · 10-18 4.9 · 107 
50-GNPs 6.5 · 10-17 7.6 · 108 
60-GNPs 1.3 · 10-16 1.3 · 109 
850-GNRs 4.3 · 10-17 5.0 · 108 
1100-GNRs 7.6 · 10-18 8.8 · 107 
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Figure 60. Resazurin results after 3T3 and HeLa cells exposure to a) 25-GNPs, b) 50-GNPs; 
c) 60-GNP, d) 850-GNRs and e) 1100-GNRs for 24 h at the concentrations indicated. 
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5. Biocompatibility Study 
!
For this purpose, I have prepared library of GNPs with different sizes (up to 100 nm), shapes 
(spheres and rods), and surface coating ((PVP, PMA, and PMA+PEG), Figures 61)) to study 
their behavior and interaction with plasma proteins and blood cells. This study was done in 
collaboration with the group of Prof. Sijin Liu at Research Center for Eco-Environmental 
Sciences Chinese Academy of Sciences/China. 
 
 
Figure 61.  Schematic diagram (upper) and TEM images (lower) of all synthesized GNPs 
with different sizes, shapes and surface modifications. 
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A. Synthesis of GNPs 
 
A.1. Synthesis of SGNPs  
 
SGNPs with core diameter of 30 nm, 60 nm, and 100 nm  (presented as 30-GNPs, 60-GNPs 
and 100-GNPs) were prepared by following the same protocol described in section 2.1.1. 
SGNPs with core diameter of 4 nm (presented as 4-GNPs) were prepared by following 
Martin method[53] (afterward coated with PVP) and Brust Method[52] (afterward coated with 
PMA and PEGylated with PEG) as described below: -  
 
! Protocol I 
 
Aqueous solution of 4-GNPs was prepared by mixing 1 mL of 50 mM of hydrogen 
tetrachloroaurate (dissolved in 50 mM of HCl) with 3 mL of 50 mM of NaBH4 (dissolved in 
50 mM of NaOH) in glass vial under gentle stirring. The solution changed color from light 
yellow to orange immediately, and then to red while the vial was stirred for 1 min and heated 
for 100 s to release hydrogen gas molecules. In order to calculate the concentration of NPs, 
the absorbance at 450 nm (as measured in UV-Vis; extinction coefficient ε(450) = 3.62⋅106 
M-1⋅cm-1) was used, as previously reported. 
 
! Protocol II 
 
At room temperature, aqueous solution of hydrogen tetrachloroaurate (25 mL, 0.9 mmol) was 
mixed with 80 mL of toluene contains tetraoctylammonium bromide (TOAB, 3.9 mmol)) in a 
500 mL separation funnel, and were shaken vigorously for about 5 min. The AuCl4 ions were 
gradually transferred into the organic phase through the formation of tetraoctylammonium-
gold tetrachloroaurate ion pairs. The toluene solution was transferred to a 250 mL round 
bottom flask. Then, a freshly prepared aqueous solution of NaBH4 (25 mL, 8.8 mmol) was 
added under strong stirring of gold precursors in toluene. After 1 h stirring, the solution was 
transferred to a 500 mL clean separation funnel and 25 mL of 0.01 M HCl were added to 
remove the excess of sodium borohydride. The mixture was vigorously shaken and the 
aqueous phase was discarded. Then, 25 mL of 0.01 M NaOH were added in order to remove 
the excess of acid and finally, 4 x 25 mL of Milli-Q water were added to reduce the ion 
excess. The aqueous phase was discarded and the remaining solution was transferred to a 250 
mL round bottomed flask. Then, the solution was stirred overnight to allow the NPs reaching 
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a thermodynamically stable size distribution, in a process called Ostwald ripening. In order to 
increase the colloidal stability of the NPs, 10 mL (41.7 mmol) of 1- dodecanethiol (DDT) 
was added to NPs and the solution was stirred at 65 °C for 3 h. After that, the solution of 
DDT-coated Au NP was cooled down to RT and cleaned by cycles of centrifugation. The 
larger agglomerates were first removed by centrifugation at 2000 rpm and the supernatant 
was collected. Then, methanol was added until the solution turned cloudy by precipitation of  
Au NPs and then, the solution was centrifuged (2000 rpm). After discarding the supernatant, 
the precipitate containing the GNPs was dissolved in toluene upon vigorous shaking. Again, 
methanol was added to the NPs solution until it turned cloudy, followed by centrifugation. 
The supernatant was removed and the precipitate containing the purified Au NPs. In order to 
calculate the concentration of NPs, the absorbance at 520 nm (as measured in UV-Vis; 
extinction coefficient ε(520) = 8.7⋅106 M-1⋅cm-1) was used, as previously reported[139].  
 
A.2. Synthesis of GNRs 
 
GNRs with Length diameter of 100 nm  (presented as 100-GNRs) were prepared by 
following the same protocol described in section 2.1.2. GNRs with Length diameter of 30 nm 
and 60 nm  (presented as 30-GNRs and 60-GNRs) were prepared by following the report 
reported by Murray et al. [63] as described below: - 
 
Seed solution: seed solution was prepared by the same protocol described in section 2.1.2. 
 
Growth solution: growth solution was prepared by following the protocol reported by Murray 
et al. [63] Briefly, 9.0 g of CTAB and 0.8 g of sodium salicylate in case of 30-GNRs (or 1.1 g 
of 5-bromosalicylic acid in case of 60-GNRs) were dissolved in 250 mL of warm water (60 
oC) in a 500 mL Erlenmeyer flask. The solution was allowed to cool to 30 oC and a specific 
amount of AgNO3 (4 mM) was added. The mixture was kept undisturbed at 30 oC for 15 min, 
after which 250 mL of 1 mM HAuCl4 solution was added. After 15 min of slow stirring (400 
rpm), a specific amount of 0.064 M of AA (Table 11) was added, and the solution was 
vigorously stirred for 30 s until it became colorless. Finally, a small amount of seed solution 
(freshly prepared as described above) was injected into the growth solution (Table 11), stirred 
for 30 s and kept at 30 °C without stirring overnight for GNRs growth. The final products 
were isolated by centrifugation and its concentration was calculated by UV-Spectroscopy. 
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 Table 11. Growth conditions for GNRs. VHCl refers to the volume of HCl which used to 
optimize the pH of growth solution, VAgNO3 refers to the volume of AgNO3, VAA refers to the 
volume of ascorbic acid and Vseed refers to the volume of seed solution 
 
 
 
!
!
B. GNPs surface functionalization 
!
GNPs were coated with three different surface coating: PVP, PMA and PEGylation of PMA 
coating as described below: - 
!
B.1. PVP coating 
 
At room temperature, SGNPs and GNRs were coated with PVP (Mw=10 kDa) by using the 
equations (1-5) as described in section 2.3. Briefly, a specific amount of 0.5 M of PVP in 
water (Rp/Area= 3000) was added dropwise to the SGNPs solution, and the mixture was 
further stirred at room temperature for 24 hours. The PVP-stabilizd SGNPs were collected by 
centrifugation (Table 12), washed by water for two times, and final dispersed in water. In 
case of GNRs, the particles were coated firstly with PSS (Mw= 70 kDa) and then coated with 
PVP (Mw=10 kDa). Briefly, The GNRs suspensions were subjected to centrifugation (Table 
10) for one time. The supernatant was discarded, and the pellet was redispersed again in 
water. A specific amount of 0.25 M of PSS in water (Rp/Area= 500) was added dropwise to the 
GNRs solution, and the mixture was further stirred at room temperature for 5 h in order to 
exchange the CTAB. The PSS-stabilized GNRs were collected by centrifugation, washed by 
water twice and final dispersed in water.  For this solution, a specific amount of 0.5 M of 
PVP in water (Rp/Area= 3000) was added dropwise, and the mixture was further stirred at 
room temperature for 24 h. The PVP-stabilized GNRs were collected by centrifugation 
(Table 12), washed by water for two times, and final dispersed in water. The PVP-GNPs 
dispersions were stable at room temperature for at least several months. 
 
 
 
 
Sample pH 
VAgNO3     
[mL] 
VAA 
[mL] 
Vseed 
[mL] 
λLSPR [nm] 
30-GNRs 3.05 6 1 0.8 650 
60-GNRs 2 18 2 0.4 825 
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B.2. PMA coating 
 
For this purpose, the particles were transferred from water to chloroform and then coated 
with DDA-grafted PMA by using the same protocol reported in section 2.3. 4-GNPs 
(synthesized by Brust Method (protocol II)) were coated directly by DDA-grafted PMA. For 
phase transfer and polymer coating conditions see Table 12. 
 
Table 12. Experimental conditions for all NPs. CNP, CDDA, CEDC and CPEG refers to 
concentration of NPs, DDA, EDC and PEG respectively. Rp/Area refers to the number of PMA 
monomer added nm2 v refers to centrifugation speed and t refers to the centrifugation time. 
!
B.3. PEGylation of PMA coating 
 
After polymer coating, the NPs surface is rich in –COOH groups. Therefore, by using EDC 
chemistry as reported in section 2.4, they can be activated and functionalized with ɑ-
Methoxy-ω-amino PEGs (Mw= 10 kDa). The reaction was left overnight and after that, the 
NPs were cleaned using dialysis for 1 h and concentrated by centrifugation (see Table 12). 
 
Due to the huge number of date, I am going to present only some date of the biocompatibility 
studies of PMA and PEGylation of 4-GNPs and 100-GNRs. 
 
 
Sample 
Phase transfer Polymer coating PEGylation 
CPEG/ 
CNP 
CDDA [M] Rp/Area 
Centrifugation 
CEDC/ 
CNP 
PEG 
[kDa] 
CPEG/ CNP v 
[rpm] 
t [min] 
4-GNPs - - 350 
Cleaned by gel 
electrophoresis 
128 · 103 
10 
1 · 105 
30-GNPs 3 · 104 75 3000 9000 30 · 106 5 · 106 2 · 106 
60-GNPs 5 · 105 75 3000 6000 30 · 106 30 · 106 2 · 106 
100-GNPs 6 · 105 75 4000 3000 10 · 106 10 · 106 2 · 106 
30-GNRs 3 · 104 75 3000 9000 8 · 106 8 · 106 2 · 106 
60-GNRs 3 · 104 75 3000 9000 8 · 106 8 · 106 2 · 106 
100-GNRs 8 · 104 75 3000 6000 8 · 106 5 · 106 2 · 106 
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5.1. Biocompatibility in Blood Stream  
 
Blood circulation is the most important way for the nanoparticles translocation and immune 
response[140]. Therefore, the behavior of GNPs in blood stream is critical for understanding its 
final in vivo metabolism and distribution. First, hemolysis assay was carried out to evaluate 
the interaction between four GNPs and red blood cells (RBC). Fresh mouse RBCs were 
isolated by centrifugation and washed with PBS for at least five times, then aliquots of 100 
µL RBCs were diluted to 1 mL with PBS and deionized water as the negative and positive 
control. Samples were prepared in the same manner as the above negative control except 
adding 40 µg GNPs. After 30 min incubation at 37 °C, the samples were centrifuged and the 
released hemoglobin from damaged RBCs in supernatant was measured (Figure 62a). 
Unexpectedly, only the PMA@4-GNPs induced a serious hemolysis (59±1%), while the left 
three have a good hemocompatibility (<5%). It is supposed that the strong negative charge 
and ultra-small size of PMA@4-GNPs may cause the disruption of RBC membrane to release 
the hemoglobin. However, the PMA@100-GNRs with the same negative charged coating 
nearly has no effect (<1%) on the RBCs, while the PEG@4-GNPs exhibited a slight 
hemolysis (ca. 4.3%). Therefore, the hemolysis of PMA@4-GNPs on RBCs is resulted by a 
combination of two factors (i.e. its negative surface charge and ultra-small size), which is 
usually ignored in previous nanoparticle studies[139-143]. Following, in order to find a safe 
condition for the later animal experiments, the does-response of PMA@4-GNPs on RBCs is 
tested with three concentrations of 2, 20 and 40 µg/mL without or with 10% FBS. As 
expected, the hemolysis phenomenon can be effectively reduced with decreasing PMA@4-
GNPs concentration, and nearly be undetectable for 2 µg/mL (Figure 62b and 62c). Besides, 
the addition of FBS could also reduce the hemolysis extent because of the formation of 
protein corona on its surface as described above. Finally, the does of 2 µg/mL was chosen for 
the in vivo animal experiments in this work.  
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Figure 62. (a) Hemolysis assay of four GNPs (n=4). The negative and positive control is 
PBS and deionized water; (b) and (c) are the hemolysis assay of PMA@4-GNPs at 2, 20 and 
40 µg/mL; (d) the red blood cell (RBC) count, hematocrit (volume percentage of RBCs in 
blood) and white blood cell (WBC) count of BALB/c mouse (n=5) at 0, 1, 3 and 24 h after 
GNPs administration. 
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Based on the reported work, the blood volume of mouse accounts its 6.7% of total body 
weight[144]. For the BALB/c mouse used in this study, their blood volume is estimated to be 
1.7 mL according to their average body weight (25 g). So a does of 4 µg SGNPs in 100 µL 
PBS was intravenous injected. After 1, 3 and 24 h administration, mouse were anesthetized 
and euthanized. The blood was withdrawn and the organs and tissues (liver, spleen, kidney, 
lung, heart, brain, muscle, bone marrow, etc.) were collected for latter analysis. After blood 
collection, the relevant clinical parameters used for evaluating hematic condition, including 
RBC count, hematocrit (volume percentage of RBCs in blood) and WBC counts were 
immediately assessed for each group (n=5). Comparison of these parameters between control 
and GNPs-injected groups, distinct changes could be observed in the PMA@4-GNPs group 
with decreasing RBC count and hematocrit (Figure 62d), indicating that even a relative safe 
does (4 µg) was applied based on the in vitro hemolysis assay, its adverse effects on blood 
system may still exist. Meanwhile, the WBC count increased within 1 h after GNPs 
administration, meaning the immune system quickly response to these foreign particles. 
 
Besides direct hemolysis effect on RBCs, if the GNPs could induce the apoptosis of blood 
cell has rarely been studied based on our knowledge, which is able to affect the 
differentiation and maturity of RBCs and lead to the decreasing RBCs in blood vessel as 
observed. To inspect this hypothesis, a MEL (murine erythroleukemia) cell line that is 
erythroid precursors useful in examining factors regulating terminal differentiation, was 
employed as an in vitro model. After exposed to the GNPs for 24 h, the MEL cell viability of 
PMA@4-GNPs, PMA@100-GNRs and PEG@100-GNRs show no difference to control 
group even at 4 µg/mL (data not shown here). Similarly with above observation of PMA@4-
GNPs, the MEL cell viability markedly decreased even at 0.4 µg/mL, and the percentage of 
apoptosis cell reached 99% at 2 µg/mL (Figure 63). Thus, we can make a conclusion that 
PMA@4-GNPs shows toxicity to blood cells even at a low concentration and could impair 
the RBCs.  
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Figure 63. The viability, morphology and flow cytometry images of MEL cells exposed to 0, 
0.4, 1 and 2 µg/mL PMA@4-GNPs after 24 h. 
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5.1. In vivo Translocation and Distribution 
 
As shown in Figure 64, major organs and tissues of GNPs-injected mouse were collected, 
digested and analyzed by ICP MS to study the in vivo distribution and biokinetics. In 
agreement to previous reported work, at the time point of 24 h, the GNPs major accumulated 
in liver and spleen as shown in Figures 65-66. Compared to 100 nm-GNRs in liver at 24 h 
(>80%), only 41 ± 10% and 32 ± 9% PMA@4-GNPs and PEG@4-GNPs accumulated, 
indicating their ultra-small size is helpful for retaining in the blood circulation. Except liver, 
the 4-GNPs nanosphere seemed to preferentially accumulate in the spleen, kidney, lung, heart, 
muscle and bone marrow, probably because of their easier passing through the blood vessel 
to reach these organs/tissues during the blood circulation. Surprisingly, although only the 
bone marrow from two mouse hind legs was sampled (containing ca. 0.1% 4-GNPs), under 
consideration of the whole body bone marrow, non-negligible amount of PMA@4-GNPs 
could reach this place. It is probably because the bone marrow contains high numbers of 
macrophages as liver and spleen. In consideration of PMA@4-GNPs and PEG@4-GNPs nm, 
the former more easily accumulated in the organs/tissues such as spleen, lung and bone 
marrow, respectively about 2, 3 and 1.3 times higher than the latter.  
 
Figure 64.  Schematic illustrations of the animals experiments for in vivo distribution and 
biokinetics analysis  
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Figure 65. GNPs distribution among different organs/tissues (liver, spleen, kidney, lung, 
heart, brain and muscle). (c) in vivo biokinetics analysis of GNPs in organs/tissues at 1, 3 and 
24 h after GNPs administration. 
 
Figure 66. In vivo biokinetics analysis of GNPs in organs/tissues at 1, 3 and 24 h after GNPs 
administration. 
!
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6. Conclusion and Outlook 
 
In the present work, GNPs with different sizes and shapes were synthesized in aqueous media 
and their surface was subjected to some modifications with three steps. First, the NPs were 
capped with short PEG chains (Mw= 750 Da), which used as stabilizers at the point of 
transferring to organic solvent. Second, the NPs were transferred from aqueous media (water) 
to organic solvent (chloroform) by using DDA. This protocol is very versatile, as it allows 
the transference of aqueous NPs within a long range of sizes to the organic phase and does 
not affect on the optical properties of the NPs. Third, the NPs were transferred again to 
aqueous media using modified polymer (PMA) that allows to form a universal surface for all 
the NPs. Also, PEI as cross-liker was attached to PMA-coated NPs during the coating process 
to improve their stability. This polymer can be used as platform for attachment additional 
biomolecules for different applications and then different molecular weights of PEG (mPEG-
NH2) were attached to surface of the NPs by EDC chemistry. The NPs were characterized 
with different techniques as reported in the thesis that exhibit a good colloidal stability for all 
the NPs after each step of surface modifications.  
 
Afterwards, the stability of NPs@PMA, NPs@PMA+PEI and PEGylated NPs was tested in 
complete cell medium using UV-Vis spectroscopy that reported that the particles stability 
improved in case of using of PEI and more better in case of attachment of PEI and PEG to 
PMA-coated particles. Also, the stability of PEGylated NPs was tested in free-proteins media 
and contain-proteins media using UV-Vis spectroscopy and DLS, which reported that the 
particles aggregation was detected after 8 h in free-proteins media due the presence of salt 
which screen the surface charge of the NPs. But the NPs were stable in contain-proteins 
media due to the adsorption of NPs on the surface of the NPs, which improve their stability. 
 
Furthermore, the toxicity of the NPs@PMA and PEGylated NPs was tested for two kinds of 
cells; HeLa and 3T3 cells. The test reported that the nanorods are not toxic for both cell lines 
up to 1 mg/mL but in case of spherical NPs, the viability trend is size-dependent as 60-GNPs 
are more toxic and can be used for both cell lines up to 200 µg/mL. 
 
Additionally, it can be concluded that physicochemical properties of the nanoparticles (e.g. 
size, shape, surface functionalization, surface charge, etc.), along with the administration 
routes/doses, can play critical roles in determining the biodistribution pattern of nanoparticles. 
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A major task for the future is encapsulation of GNRs inside zeolitic-imidazolate-framework 
(ZIF-8) as core–shell nanostructures, which can be used as drug carrier in biological system. 
Taking the advantage of the porous provided by the outer ZIF-8 shell and loading these 
porous with anticancer. Then, the therapeutic efficacy can be improved with the combination 
of external near-infrared (NIR) photothermal therapy of GNRs and the local specific 
chemotherapy of anticancer. 
 
. 
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7. Publications: 
 
This thesis is written in a cumulative way and displays parts of the results of the scientific 
researches that are published and the contribution of the author is described. 
 
7.1. Metal NPs, Synthesis, Surface Modification, Characterization and Bio-Interaction. 
 
 
! [82] Soliman, G. M.; Pelaz, B.; Parak, W. J.; Del Pino, P., Phase Transfer and Polymer 
Coating Methods toward Improving the Stability of Metallic Nanoparticles for 
Biological Applications. Chem. Mater. 2015, 27, 990−997. 
 
Indispensable requirements are colloidal stability, water solubility and non-toxicity for using 
the NPs for biological applications. Ligand molecules capped aqueous NPs from the 
synthesis process are often weak ligands and they cannot stabilize the particles in biological 
environment. Therefor, these ligands were exchanged with other ligands by transferring the 
particles from aqueous media to organic solvent by using DDA, which stabilize the particles 
in this new medium by hydrophobic chains. To get water solubility, Another hydrophobic 
chains at one side of modified-amphiphilic polymer interact with those chains on the NPs 
surface and the -COOH on the other side of the polymer will generate a net negative charge 
and represent anchor points for the further functionalization. After each step of surface 
modifications, the particles were characterized by different techniques including UV-Vis 
spectroscopy, TEM, gel electrophoresis, DLS, and LDA. Also, the stability of the particles 
was studied in different media containing and non-containing-proteins. The NPs were not 
stable for long time in protein-free media compared with the same particles in protein-contain 
media, which their stability was improved due to the formation of protein corona around the 
NPs. In addition to, the toxicity of particles was tested in cancer and non-cancer cells 
showing non-toxic in the cells lines. 
 
The author did all samples synthesis, surface modification, characterization and most of 
biological interaction. Also, he did all data evaluation and wrote part of the manuscript and 
supporting information and did the editing before the submission. He as well did part of the 
revision before final acceptance. 
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! [136] Tan, G.; Kantner, K.; Zhang, Q.; Soliman, M. G.; Del Pino, P.; Parak, W. J.; 
Onur, M. A.; Valdeperez, D.; Rejman, J.; Pelaz, B., Conjugation of polymer-coated 
gold nanoparticles with antibodies - synthesis and characterization. Nanomaterials, 
2015, 1297-1316. 
 
In this article, the preparation and characterization of GNPs were highlighted. GNPs were 
conjugated with fluorescent labeled-protein and the number of antibodies bound per NP was 
determined. The toxicity of antibody-conjugated NPs and their interaction with cells were 
studied. 
 
The author contributes in the GNPs synthesis, characterization and functionalization with 
antibody. 
 
! Nold, P.; Hartmann, R.; Kantner, K.; Feliu, N.; Soliman, M. G.; Pelaz, B.; Lim, M.; 
Sjöqvist, S.; Jungebluth, P.; del Pino, P.; Hackstein, H.; Macchiarini, P.; Parak, W. J.; 
Brendel1, C., Labelling of mesenchymal stromal cells (MSCs) with gold 
nanoparticles - an initial in vitro study towards optimized detection conditions for 
future in vivo tracking of MSCs. In preparation. 
 
To further assess the biocompatibility and suitability of GNPs for mesenchymal stem cells 
(MSC) tracking, we investigated cellular responses to GNP labelling in mesenchymal stem 
cells derived from rats (rMSCs) and humans (hMSCs), such as uptake, cytotoxicity, 
proliferation, migration, morphology and immunophenotype. For MSC detection via mass 
spectrometry we elucidated the detection sensitivity by quantifying the required number of 
labeled cells to be able to prove MSC presence in a population of cancer cells. 
 
The author contributes preparing of GNPs with different sizes and shapes, stabilizing them 
through the polymer coating technique and fully characterize them. Currently, the author is 
involved in the manuscript preparation. 
 
! Pelaz, B.; Hühn, J.; Carrillo-Carrion, C.; Kantner, K.; Sabir, N.; del Pino, P.; Feliu, 
N.; Valdeperez, V.; Soliman, M. G.; Nelissen, I.; Jackons, A.; Gounko, I.; Parak, 
W.J., Can doping reduce the cytotoxicity of cadmium containing quantum dots? In 
preparation. 
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In the present work we wanted to investigate if QDs toxicity can be reduced by appropriate 
doping. Doping of QDs is widely reported in literature for several different QD materials. 
However, effects on toxicity are not investigated in detail so far. !
The author contributes GNPs as reference material for the experiments with QDs. Currently, 
the author is involved in the manuscript preparation. 
 
 
7.2.  Reviews 
 
! [120] Nazarenus, M.; Zhang, Q.; Soliman, M. G.; Del Pino, P.; Pelaz, B.; Romero, S. 
C.; Rejman, J.; Rutishauser, B. R.; Clift, M. J. D.; Zellner, R.; Nienhaus, G. U.; 
Delehanty, J. B.; Medintz, I. L.; Parak, W. J., In vitro interaction of colloidal 
nanoparticles with mammalian cells: What have we learned thus far? Beilstein J. 
Nanotechnol. 2014, 5, 1477–1490. 
 
This review article is focus in the interaction of colloidal NPs with mammalian cells in vitro. 
The fate of NPs in biological media depends on several parameters like core material, the 
surface coating which is used to stabilize the particle, bio-conjugated molecules (e.g. affinity, 
number or ratio per NPs, etc.), the functionalization for specific and non-specific targeting, 
etc. All these parameters affect the absorption of proteins on the surface of the NPs forming 
protein corona, which influence the interaction of the NPs with cell plasma membrane and 
the mechanism of their internalization to the cells.  
 
The author contributes in the literature research and in the manuscript writing and edition. !
! [121] Ashraf, S.; Pelaz, B.; Del Pino, P.; Carril, M.; Escudero1, A.; Parak, W. J.; 
Soliman, M. G.; Zhang, Q.; Carrionl, C. C., Gold-based nanomaterials for 
applications in nanomedicine. Top Curr Chem. 2016, 370, 169-202. 
 
In this review, the synthesis methods for GNPs with different sizes and shapes were indicated. 
The easy preparation, high colloidal stability, biocompatibility, low cytotoxicity and unique 
physico-chemical properties make the GNPs widely used in nano-medicine including 
detection, sensing, drug delivery, photothermal therapy, clinical trials, etc. The stabilization 
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and functionalization of GNPs by using different ligands and biomolecules, respectively, 
were presented.  
 
The author contributes in the literature research and in the manuscript writing and edition. 
 
! [146] Ashraf, S.; Carrion, C. C.; Zhang, Q.; Soliman, M. G.; Hartmann, R.; Pelaz, B.; 
Del Pino, P.; Parak, W. J., Fluorescence-based ion sensing with colloidal particles. 
Current Opinion in Pharmacology 2014, 18, 98–103. 
 
This review article is regarding the function of colloidal NPs based on ion sensing. Particles 
based fluorescence sensing can be made by linking a sensitive organic fluorophores to the 
surface of carrier particles or by using fluorescent particles (quantum dots, carbon dots, etc.). 
Using this methodology in the field of sensing in life science applications is very convenient 
due to its high sensitivity, simplicity, and diversity of fluorescent materials available. 
Problems (and their solution) involved with using particles based fluorescence sensing for 
detection of ion concentrations in cells were highlighted. 
 
The author contributes in the literature research and in the manuscript writing and edition. 
 
! Soliman, G. M.; Pelaz, B.; Del Pino, P.; Parak, W. J., Functionalized GNPs for 
biomedical applications. In preparation. 
 
In this review, the different methods of stabilization of gold nanoparticles were reported. 
Also, the functionalization of gold nanopartilces by using different strategies and 
biomolecules in order to be used for different biomedical applications was described. 
 
The author contributes in the literature research and in the manuscript writing and edition. 
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Chemicals and Techniques 
 
The following chemicals were used for synthesis and modification of the NPs. All these 
chemicals were used without additional purification. 
 
Strem Chemicals: 
Hydrogen tetrachloroaurate (III) hydrate (#16903-35-8). 
 
Sigma-Aldrich: 
Hexadecyltrimethylammonium bromide (#H9151), sodium citrate (#W302600), silver nitrate 
(#209139), ascorbic acid (#A7506), sodium borohydride (#71321), dodecylamine (DDA, # 
325163), tetraoctylammonium bromide (#29413-6), PMA (#531278), polyethylenimine 
(#408727), Polyvinylpyrrolidone (#PVP10), Poly(sodium 4-styrenesulfonate) (#243051) 
sodium oleate (#O7501), 1-ethyl-3-(3- (dimethylamino)propyl) carbodiimid (#E6383), TBE 
(#T3913), hydrochloric acid (#320331), streptomycin/penicillin (# P4333), L-glutamine (# 
G8540), Dulbecco’s modified Eagle's medium (DMEM, # D5796), Bovine serum albumin (# 
A9647) and Resazurin (#199303). 
 
Rapp-Polymer: 
CH3-PEG-SH (Mw= 750 Da) and CH3-PEG-NH2 (Mw= 750, 5000 and 10000 Da). 
 
Biochrom: 
Phosphine buffered saline (PBS, # L1825) and Fetal bovine serum (FBS, # S0615). 
 
Carl Roth:  
- Chloroform (#Y015.2), Ethanol (#9065.2), Methanol (#8388.6), Sodium chloride 
(#HN00.2), Tetrahydrofuran (#AE07.1), Sodium hydroxide (#6771.3), Dialysis 
membrane (MW = 50 kDa, # 1893.1), syringe filter (0.22 m, # P818.1) 
Fluka 
- Toluene (#89682). 
Invitrogen: 
- Ultra PureTMAgarose (#16500500), 
 
British Biocell International: 
- Au NPs (10 nm colloidal gold, #EM.GC10). 
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The following Techniques were used for preparation, purification and characterization of the 
NPs. 
 
! UV-Vis spectroscopy and Fluorometer: Agilent Technologies 8453 UV-Vis and 
Horiba FluoroLog. 
! Gel electrophoresis: Bio Rad PowerPac Basic.  
! Centrifuge: Hettich Universal 320 R. 
! Dynamic light scattering (DLS) and laser Doppler anemometry (LDA): Malvern 
Zetasizer Nano ZS. 
! Transmission electron microscopy (TEM): JEOL JEM-1400PLUS. 
! Rotavap (Laborota 4000, Heidolph). 
! Flow cytometry. 
! Inductively coupled plasma mass spectrometry. Agilent 7900 ICP-MS. 
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Abbreviations 
 
AA  Ascorbic acid 
AuNPs  Au seeds 
WBC  white blood cell 
CTAB  Hexadecyltrimethylammonium bromide 
CuAAC  Cu(I)-catalyzed azide alkyne cycloaddition 
DCC  Dicyclohexylcarbodiimide 
DCHA  Dicyclohexylamine 
DDA  Dodecylamine 
DDT  Dodecanthiol 
DLS  Dynamic light scattering 
DMAP  Dimethylamino pyridine 
DMEM  Dulbecco’s modified Eagle's medium 
DNA  Deoxyribonucleic acid 
EDC  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
FBS  Fetal bovine serum 
GNPs  Gold nanoparticles 
GNRs  Gold nanorods 
h  Hour 
LDA  Laser Doppler anemometry 
LBL  Layer-by-layer 
L-Glu  L-glutamine 
MAA  Mercaptoacetic acid 
MEL  Murine erythroleukemia 
MHA  Mercaptohexanoic acid 
MUA  Mercaptoundecanoic acid 
NNI  National nanotechnology initiative 
NP(s)  Nanoparticle(s) 
OA  Oleylamine 
PAA  Poly(acrylic acid) 
PAH  Poly(allylamine hydrochloride) 
PBS  Phosphate buffered saline 
PEG(s)  Polyethylene glycol(s) 
PEI  Polyethylenimine 
PDI  Polydispersity index 
PMA  Poly(isobutylene-alt-maleic anhydride) 
P/S  Penicillin/streptomycin 
PTT  Photothermal therapy 
PSS  Poly(sodium 4-styrenesulfonate) 
PVP  Poly(vinylpyrrolidone) 
RBC  Red blood cell 
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s  Second 
SGNPs  Sperical gold nanoparticles 
SOP  Standard operating procedure 
SPR  Surface plasmon resonance 
TBE  Tris-borate-EDTA 
TEM  Transmission electron microscopy 
THF  Tetrahydrofuran 
t  Time 
TOAB  Tetraoctylammonium bromide 
Tris  Tris(hydroxymethyl)aminomethane 
UV  Tltra violet 
v  Speed 
vis  Visible 
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ABSTRACT: This paper describes a general method to
generate noble metal nanoparticles (NPs) with polymer
coatings. One of the widely used approaches to stabilize NPs
in aqueous solution involves wrapping NPs with amphiphilic
polymers. This methodology has been extensively employed
for polymer coating of small hydrophobic NPs (diameter of
inorganic core < 20 nm), thereby enabling phase transfer of
NPs from an organic solvent to aqueous solution. The polymer
coating approach is herein extended to NPs originally
synthesized in aqueous solution by a two-step method. First,
NPs are subjected to aqueous-to-organic phase transfer. The
phase transfer protocol is demonstrated for NPs made of
different materials (Au and Ag), sizes (up to 100 nm), and
shapes (spheres, rods, and flat-triangular prisms). Second, NPs are coated with an amphiphilic polymer. The colloidal stability of
a variety of the newly designed NPs is assayed against different media of biological relevance. In preliminary cellular studies, the
biocompatibility of polymer coated Au NPs is investigated in different cell lines.
■ INTRODUCTION
Current bottom-up chemical methods allow the synthesis of
nanoparticles (NPs) with a large range of possible size, shape,
and composition. This is possible with a high degree of control
in terms of monodispersity and size distribution.1−4 Synthesis
can be carried out either in organic solvents or in aqueous
solution. In addition to being able to control the
physicochemical properties of the end products by chemical
methods, colloidal stability of NPs in physiological media is
critical if these are to be used in biological applications.5 This
implies that NPs should be stable in aqueous media with high
ionic strength, high protein concentration, and a specific range
of pH values. In contrast to NPs synthesized in aqueous media,
methods to stabilize hydrophobic NPs require a phase transfer
step which can be effectively achieved by different methods,
such as the replacement of the hydrophobic chains by
hydrophilic ones (ligand exchange)6 or the use of amphiphilic
polymers.7 Two main advantages of the latter compared to
other existing methods are to be highlighted. First, the original
surface of the inorganic material (be it metal, semiconductor, or
metal oxide) is a priori not affected, and therefore, the physical
properties of the core such as quantum yield, absorption,
scattering, or magnetism are in general less disturbed as
compared to ligand-exchange procedures. Second, the NPs
surface is uniformly wrapped with a common polymer, which
translates into the generation of a common surface chemistry
for different materials. Notably, the latter allows the production
of NP models with similar surface chemistry yet with different
physicochemical properties due to different inorganic cores.
Magnetic, semiconductor, and metallic NPs, with different size,
shape, and composition, have been successfully stabilized by the
latter.7−11
In the literature, the number of works which attempt to
evaluate the impact of NPs in cells, or even complex organisms,
is overwhelming.12 Yet correlating physicochemical properties
of NPs and their biological fate and impact is still not
straightforward.5 This is partly so because of the enormous
variety of NP models employed to date, which will even
continue to grow as new methods and materials arise. Besides
the variety of NP models, it appears clear that the biological fate
of NPs is highly influenced by the NPs’ surface chemistry,
which has been also demonstrated to be very important in the
formation of the so-called protein corona.13 As proven already
with different NP models, varying the coating of NPs greatly
influences several important biological parameters such as
cellular uptake, NP localization inside cells, toxicity, circulation,
biodistribution, protein corona, etc. The design of the surface of
NPs represents a key step toward multifunctional NPs, which
are typically achieved by anchoring distinct molecules of
biological relevance onto the NPs’ surface. The biological fate
of NPs is also determined by the protein corona. Ultimately,
the protein corona formation can be responsible for different
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results observed using similar nanosystems.14 The use of
amphiphilic polymers to coat NPs would eliminate the surface
factor from the equation, providing thereby a NP model in
which it is possible to determine the role of one parameter at a
time, such as size, vectors, stiffness, ions release, etc.
Additionally, this methodology provides NPs with a high
colloidal stability in cell media, against high salt concentration,
and in a broad pH range.8,15 These reasons make this technique
highly interesting to produce NP models for biological
applications. However, to date, this methodology has been
traditionally limited to small NPs, typically with inorganic cores
with diameter < 20 nm, originally synthesized in organic
solvent, and therefore, many biorelevant NPs originally
synthesized in aqueous media (e.g., anisotropic plasmonic
NPs) have not benefited from this technique. In order to apply
this methodology to such NPs (e.g., CTAB-coated gold
nanorods, where CTAB stands for the cationic surfactant
cetyltrimethylammonium bromide), a previous phase transfer
to an organic solvent should be performed.
For the aqueous-to-organic media transfer of Au NPs the
ligand exchange technique has been applied by using aliphatic
chains with a terminal thiol group such as dodecanethiol
(DDT)16 or by using chains with a terminal amine group such
as dodecylamine (DDA) or hexadecylamine (HDA).17 The
main limitation of the ligand-exchange method is again the size,
as it typically works with NPs of diameters smaller than ca. 20
nm, in the case of free-surfactant capped NPs. To our
knowledge, only a few examples with NPs > 20 nm have
been described in the literature.18,19 The need of surfactants to
transfer large particles is obvious according to the published
works in this direction, in which CTAB or similar surfactants
are typically involved, be it as additives for the phase transfer
process or in the NPs synthesis.16,20 For anisotropic Au NPs,
the phase transfer of gold nanorods using DDT has been used,
with the aim of washing out the excess of the cytotoxic
surfactant CTAB. The toxic effects of CTAB have been
extensively proved.21,22 In order to decrease the amount of
CTAB, a round trip from aqueous phase to organic media and
again to aqueous media has been previously reported.23−25
Herein, we report on a straightforward method which allows
for aqueous-to-organic phase transfer of relevant Au NPs with
different sizes (inorganic cores with diameters of 25, 50, and 60
nm up to nanorods with 90 nm in length) and shapes (spherical
and rods). As a proof-of-concept to extend this methodology to
an additional shape and another plasmonic material, Ag
nanoprisms were also successfully polymer coated using
equivalent methods as for Au NPs. The basis of the proposed
method relies on a prestabilization step using short (low
molecular weight) polyethylene glycol (PEG) chains. A recent
work in which long alkyl-PEG chains has been described as
ligands to transfer nanorods to the organic phase using
centrifugal forces has been recently reported.26 NPs smaller
than 20 nm were transferred using mixed chains containing an
aliphatic domain and a hydrophilic PEG chain, which allow the
NPs to be colloidally stable in both solvents.27 In the present
work, short PEG chains were used as prestabilizers and active
agents for the phase transfer of NPs. The prestabilization step
was required to warrant colloidal stability in the phase transfer
process. In case the NP size > 15 nm; i.e., inorganic cores with
diameters larger than 15 nm, ligands such as DDT or HDA
yielded unsatisfactory results. Thus, as an alternative to toxic
surfactants such as CTAB or didecyldimethylammonium
bromide (DDAB), the use of short PEG chains was
investigated. PEGylated NPs can be driven to an organic
phase (chloroform) containing DDA under vigorous stirring at
room temperature. The time required depended on the original
coating of the NPs. For instance, CTAB-coated gold nanorods
(GNRs) required longer times than citrate capped Au NPs. The
use of ethanol helped to complete the transfer faster.28 DDA
can then intercalate with the amphiphilic polymer dodecyl-
grafted-poly(isobutylene-alt-maleic-anhydride) (PMA), ena-
bling aqueous transfer for different colloids. In order to
enhance the stability of the polymer-coated NPs in cell media,
further PEGylation was employed. Finally, stability and toxicity
studies are shown as examples to illustrate the potential of this
method to provide NP models for biological applications.
■ EXPERIMENTAL SECTION
Materials. Prior to use, all glassware was washed with aqua regia
and rinsed thoroughly with Milli-Q water. All the chemicals were used
as received. For the synthesis and modification of the NPs, hydrogen
tetrachloroaurate (III) hydrate was purchased from Strem Chemicals;
sodium citrate, silver nitrate, CTAB, sodium borohydrade, ascorbic
acid, hydrogen peroxide, dodecylamine, poly(isobutylene-maleic-alt-
anhydride), hydrochloridric acid, sodium borate, 1-ethyl-3-(3-
(dimethylamino)propyl) carbodiimide, and sodium oleate were
purchased from Sigma-Aldrich. All the different polyethylene glycol
polymers (PEG) were obtained from Rapp-Polymere. For the stability
studies, phosphine buffered saline (PBS) was purchased in Biochrom,
and DMEM, penicillin, streptomycin, and L-glutamine were purchased
from Sigma-Aldrich. They were used as received. For the viability tests,
resazurin was purchased from Sigma-Aldrich and was used as received.
Synthesis of NPs. Citrate-capped spherical gold NPs with
diameters of ca. 25, 50, and 60 nm, in the following referred to as
25-GNPs, 50-GNPs, and 60-GNPs, respectively, were synthesized
using a seed-growth method reported elsewhere, cf. Supporting
Information (section 1).1 CTAB-capped GNRs with plasmon band
(i.e., localized surface plasmon resonance, LSPR) centered at ca. 850
and 1100 nm in the following are referred to as 850-GNRs and 1100-
GNRs, respectively, and were prepared by using the seed-mediated
growth method recently published by Murray and co-workers, which
allows the production of GNRs with a large variety of aspect ratios. We
choose as NP models2,29 short 850-GNRs (low aspect ratio) and long
1100-GNRs (high aspect ratio), cf. Supporting Information (section
1). Citrate-capped silver nanoprisms (ca. 60 nm in length) with
plasmon band centered at ca. 600 nm (in the following referred to as
AgNPRs) were obtained by the reduction of silver nitrate with H2O2
and sodium borohydride in aqueous solution, as reported elsewhere,4
cf. Supporting Information (section 1).
NP Stabilization: Ligand Exchange with PEG. After synthesis,
the GNPs were cleaned from the free citrate by centrifugation using
centrifugal filters (20 mL, 100 kDa, Millipore) at 110 g for 5 min (one
time). The GNRs were cleaned by centrifugal precipitation at 7080g
for 25 min (one time). In all cases the NPs were diluted in Milli-Q
water (1.37, 0.41, 0.13, 5.1, and 0.74 nM for 25-, 50-, and 60-GNPs
and 850- and 1100-GNRs, respectively) and stabilized by mPEG−SH
(CH3O-PEG-SH, Mw = 750 Da (Rapp Polymere)) dissolved in Milli-
Q water. A total of 30 μL of NaOH (100 mM) per mL of GNPs and
10 μL of NaOH (1 M) per mL of GNRs was added to increase the pH
to ca. 10, aiming to increase the reactivity of the thiol group.3 The
stoichiometric ratio of PEG molecules to NP (CPEG/CNP) was 5 × 105.
The solution was mixed with stirring (400 rpm) overnight. Please note
that 5 × 105 is the maximum amount required to transfer successfully
the “bigger” NPs. To transfer small particles using lower PEG:NP
molar ratios is also possible, cf. Table S2 and section 2 in the
Supporting Information for further details.
Phase Transfer. Upon PEG stabilization of the NPs, i.e.,
PEGylation, they were transferred from aqueous media to organic
solvent (chloroform) by using DDA (0.75 M) dissolved in chloroform
with strong magnetic stirring (1200 rpm). The transference for “small”
NPs was also feasible by using lower concentrations of DDA, cf. Table
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S2 in the Supporting Information. The phase transfer requires 12 h for
GNPs and 4 days for GNRs. Stirring has to be strong enough to mix
the two phases perfectly. After this, the water was removed and the
samples were washed twice with chloroform by precipitation. To clean
25-GNPs and 1100-GNRs, 8960g during 30 min was used. Meanwhile
to clean 50 and 60-GNPs and 850-GNRs, 2240g for 40 min were
selected. Then, the supernatant was removed. GNPs and GNRs were
redispersed in chloroform again prior to polymer coating.
Polymer Coating. The NPs were water transferred using the
polymer coating technique as described in previous reports.7,30 Briefly,
polymer coating for GNPs and GNRs was done by dissolving an
appropriate amount of polymer monomers per NP surface unit (Rp/area
[nm2]). In all the samples we added 3000 monomers of poly-
(isobutylene-alt- maleic anhydride) modified with dodecylamine
(hereinafter referred to as PMA) dissolved in chloroform per nm2 of
NPs. For details about the synthesis of the amphiphilic polymer used
here we refer to the previous work of Lin et al.7 Briefly, the PMA was
synthesized by grafting dodecylamine onto the poly(isobutylene-alt-
maleic anhydride) backbone through spontaneous amide linkage,
which converts one maleic anhydride into one corresponding amide
and one free carboxylic acid. In the amphiphilic polymer used in our
work, 75% of its maleic anhydride rings have been reacted with
dodecylamine, leaving 25% of its anhydride rings intact. To increase
the stability the use of a cross-linker has been also previously
proposed.7,31 We tested two different cross-linkers, bis(6-aminohexyl)-
amine and polyethylenimine (branched, Mw = 800 Da). More details
about the use of the cross-linker can be found in the Supporting
Information. After addition of the polymer, the solvent was slowly
evaporated using a low-pressure system, until the sample was
completely dry. Then, more chloroform was added and the drying
process was repeated. The NPs were quickly dissolved in 0.1 M
NaOH, which hydrolyzes the remaining maleic anhydride rings,
leaving two carboxylic groups per newly opened anhydride ring. Then,
the solution was filtered through a 0.22 μm syringe filter. After this, the
NPs were precipitated by centrifugation (same conditions as for the
phase transfer) twice, in order to remove the residual empty polymer
micelles.32 Washing out empty micelles and unwanted byproducts is
also possible by gel electrophoresis. After purification, the GNPs and
GNRs were redispersed and kept in Milli-Q water. Extinction
coefficient values and further calculations for the polymer coating
method can be found in the Supporting Information.
Surface Modification of PMA-Coated NPs: PEGylation. The
surface of PMA-coated gold NPs was modified with mPEG−NH2
(CH3O-PEG-NH2, Rapp Polymere). The carboxylic groups of the
polymer (note: generated by grafting of dodecylamine and hydrolysis
of the anhydride rings) and the amine groups of PEG were cross-
linked by using EDC chemistry in Milli-Q water according to Table 1.
After PEGylation, NPs were cleaned from free PEG by applying an
electric field of 10 V/cm for 1 h in an electrophoresis tank. The
agarose bands with the NPs were transferred to a dialysis membrane
(molecular cutoff (MWCO) = 50 kDa), and then, NPs were extracted
from the agarose by electrophoresis using the conditions above-
described. Lastly, NPs were centrifuged once using the conditions
above-described; the supernatant was removed and the NPs were
redispersed and kept in Milli-Q water.
Characterization. All NPs were characterized by UV/vis spec-
troscopy (Agilent 8453 spectrometer), dynamic light scattering (DLS),
laser Doppler anemometry (LDA) (Nanosizer, Malvern), electron
microscopy (Jeol 1400 plus), and inductively coupled plasma mass
spectrometry (ICP-MS) (Agilent 7700 series ICP-MS).
Stability Studies. In order to evaluate the NP stability against
media of biological relevance, solutions with the same concentration of
NPs were dispersed in the following eight different media: (1) water
(Milli-Q), (2) phosphate buffered saline (PBS, Biochrom), (3)
Dulbecco’s modified Eagle’s media (DMEM, Sigma-Aldrich), (4)
PBS 1% penicillin and streptomycin (P/S, Sigma-Aldrich) and 1%
glutamine (L-Glu, Sigma-Aldrich), (5) DMEM 1% P/S and 1% L-Glu,
(6) 800 μM bovine serum albumine (BSA, Sigma-Aldrich) in PBS, (7)
800 μM BSA DMEM 1% P/S, 1% L-Glu, and (8) DMEM 1% P/S, 1%
L-Glu, and 10% fetal bovine serum (FBS, Biochrom).15 Their
hydrodynamic radii and UV−vis spectra were monitored at different
time points, from 0 h to 3 days.
Cytotoxicity Evaluation: Resazurin Test. The 5 × 103 tumoral
human cells (HeLa) and 10 × 103 mouse fibroblasts (3T3) were
incubated for 24 h in a 96-well plate at 37 °C and 5% CO2 with
complete DMEM media (10% FBS, 1%P/S, and 1% L-Glu). After this
period, different concentration of NPs dispersed in cell media were
added. Three measurements were done for each concentration. Then,
after another 24 h of incubation at 37 °C and 5% CO2, cells were
washed three times with PBS. A total of 100 μL from a 10% solution of
resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide; Sigma-Aldrich)
in cell media was added into the wells. After 3 h of incubation, the
fluorescence spectra (ranging from 572 to 650 nm) were recorded in a
fluorescence spectrometer (Horiba Jobin), upon excitation at 560 nm.
This test is based on the irreversible oxidation of resazurin to the pink
and highly fluorescent resorufin. To analyze the data, the average of
the background was subtracted from the maximum value. To get the
percentage of viable cells, control wells where just cells were incubated
equivalently were considered as 100% viable cells.8
■ RESULTS AND DISCUSSION
The main aim of this work is to establish methods for the phase
transfer and polymer coating of noble metal NPs with
diameters larger than 20 nm and high anisotropy. The polymer
coating procedure can be thus extended to a wide variety of
NPs with numerous bioapplications. The realization of this
approach requires a water−chloroform−water round trip for
the NPs, cf. Figure 1.
First, a prestabilization of the NPs in the aqueous phase was
required. Indeed, without this prestabilization step, we were
unable to transfer bare NPs with sizes >15 nm. Small NPs and
surfactant-capped NPs (e.g., CTAB capped or TOAB capped)
did not require this prestabilization step, but the use of the PEG
chains improves the yield of the transference in all of the cases.
Short chains of PEG (750 Da) were employed as prestabilizing
agent. The selected heterofunctional chains bear a thiol group
in one end and a methoxy group in the other. Notice that we
used thiolated molecules because, in this study, Ag and Au NPs
were our targets (Figure 2), which can readily bind thiolated
molecules. This chain, in particular, was selected due to its
length and the noncharged methoxy end.
Notice that the approach here described focused on metallic
NPs synthesized in aqueous solution, and thus, alternative end-
terminal groups might be more efficient to prestabilize with
PEG other NPs in aqueous solution. For materials other than
Au or Ag, such as metal oxides (e.g., Fe3O4, ZnO, TiO2, NiO,
MnO, CeO, etc.) or QDs, end-terminal groups other than thiol
might be required. For instance, one might speculatively
hypothesize that PEG−silane, PEG−siloxane, PEG−phosphine
oxide, or PEG−phosphoric acid might be used for prestabiliza-
tion of a variety of metal oxides.33−36 By a more general
approach, poly(histidine)−PEG could be used to prestabilize
carboxyl-terminated NPs (independently of the inorganic core),
as recently shown by Wegner et al. for poly(histidine)-
Table 1. Conditions for PEGylation of PMA-Coated NPs
NPs CEDC/CNP
mPEG−NH2 (Mw,
kDa)
mPEG−NH2
(CPEG/CNP)
25-GNPs 5 × 106 0.75 6 × 106
45-GNPs 30 × 106 5 3 × 106
60-GNPs 30 × 106 10 3 × 106
850-GNRs 9 × 106 5 7.5 × 105
1100-GNRs 9 × 106 10 7.5 × 105
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derivatized biomolecules and QDs.37 Yet, in case of “water-
soluble” CdTe QDs38 thiolated PEGs might efficiently
prestabilize them as in the case of Au and Ag. Although as
previously stated the use of the prestabilization step is required
for “big” metallic NPs, adapting the proposed method to other
materials and PEGs (if needed) will need further optimization
due to different binding energies.
As previously explained, the main aim is to coat the NPs with
PMA as a model polymer, although other polymers and PMA
modified with functional molecules (dyes, chelators, SERS tags,
etc.)39 have been successfully employed in previous works. This
actually illustrates the versatility of the method proposed in
terms of achieving multifunctional NPs. We anticipated that the
PEG chains would stabilize the NPs, and due to their short
length, they would not prevent the interaction of the aliphatic-
PMA domain with the aliphatic chains that will be introduced
on the NPs later on in the organic phase. The amphiphilic
nature of PEG chains is well-known,40 and it is supported by
the dual solubility either in aqueous solution or organic
solvents, such as chloroform. Taking advantage of this double
behavior, PEG chains were expected to work as stabilizers and
phase transfer helpers. The modification of NPs with PEG is a
straightforward procedure extensively used to stabilize
NPs.3,41,42 Once stabilized with PEG, the NPs were ready to
be transferred to the organic phase.
In the early stage of the development of the proposed
method, different combinations of solvents and aliphatic chains
were tested (see Table S2 in the Supporting Information). The
combination of chloroform and DDA was found to be the best
combination for our purposes. To successfully transfer the NPs,
it was only required to let the two phases interact (aqueous and
organic) by using vigorous stirring. DDA-capped NPs
presented high stability in organic media, and their absorption
bands remained very similar to the original ones. Please notice
that we cannot rule out the presence of short PEG intercalated
within the DDA coating. As expected, only a small red shift was
observed due to the change of the NPs environment (see
Figure 3, and section 2 from Supporting Information). The
DDA-capped NPs were precipitated by centrifugation to
remove free, unbound ligands. Although our main aim is
toward biological purposes, having plasmonic NPs in organic
solvent is very interesting for other applications (e.g., the
production of thin films which contain NPs or nano-
composites). The transfer procedure worked similarly for all
Figure 1. (a) Schematic representation of the coating strategy for both spherical GNPs and GNRs. (b) GNRs in water after their synthesis (1),
PEGylated GNRs before the phase transfer (2), in chloroform after the phase transfer using DDA (3), and after their polymer coating with PMA (4).
Notice that we cannot rule out the presence of short PEGs intercalated within the DDA coating. UV/vis spectra corresponding to all the steps of the
process for 60-GNPs (c) and 850-GNRs (d). See Supporting Information for the UV/vis spectra of the other NPs, section 2).
Figure 2. Transmission electron microscopy (TEM) micrographs of
the NPs: spherical GNPs (a) 25-GNPs, (b) 50-GNPs, and (c) 60-
GNPs and anisotropic NPs (d) 850-GNRs, (e) 1100-GNRs, and (f)
AgNPRs.
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the NPs reported in this work, the only difference residing in
the required time for the transfer. This time depended on the
nature of the original ligand on the NPs surface. The transfer
time could be shortened by the addition of ethanol to improve
the contact between the interfaces.28 It is interesting to
highlight that some NPs could be transferred to the organic
phase just by the use of the PEG chains. Nevertheless, the yield
of the transferred NPs was much lower compared with the yield
obtained using DDA (almost 100%; this yield was determined
by ICP-MS, see Table S6 in the Supporting Information).
Recently, Alkilany and co-workers have proposed a protocol for
aqueous-to-organic phase transfer of gold NPs which combines
thiolated PEG chains (with molecular weight > 1 kDa) and
methanol.19
Once the NPs were dissolved in chloroform, the classic
polymer coating technique was applied. To this end an
optimization step was done regarding the amount of polymer
needed to coat the NPs (see Supporting Information, section
3). In agreement with previous work,7 the amount of polymer
required is expressed in the number of monomers per effective
NP surface (RP/area). The NPs used here required higher RP/area
values as compared to typical values previously reported for
smaller NPs. Also in comparison with smaller NPs, the polymer
coating procedure worked best when the solvent was removed
using reduced pressure conditions, i.e., the pressure was kept
high and the temperature in the bath was also high (60−70
°C). The high colloidal stability of PMA-coated NPs typically
allows for cleaning steps, both by using gel electrophoresis (see
Supporting Information, Section 4) and by centrifugation.
Aiming to achieve a higher stability (stable in water or
biological media for months), the use of cross-linkers was also
tested. Cross-linkers were meant to act as stabilizer to
Figure 3. Stability tests against complete cell media of 50-GNPs followed by UV−vis spectroscopy versus time of NPs stabilized with (a) just PMA,
(b) PMA−PEI, and (c) PMA−PEI PEGylated. Stability of PEGylated PMA−PEI 50-GNPs in water (d) and in PBS (e). Stability followed by DLS
for PEGylated PMA−PEI 50-GNPs in water (medium 1), PBS (medium 2), and complete cell media (medium 8).
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“polymerize” the different polymer molecules which wrap the
NPs. Initially, the short molecule bis(6-aminohexyl)amine was
used as cross-linker as previously reported.7,31 In this case,
probably due to the bigger size of these NPs, this short
molecule did not improve the stability of the NPs, and
therefore, we tested another cross-linker: poly(ethylenimime)
(PEI, 800 Da). After testing the stability of the NPs coated with
PMA only, the short cross-linker and PEI, we determined that
0.75% of PEI improved the stability of the NPs (see the data in
the Supporting Information, for nanorods) in complete cell
media (and for all the NPs, section 6 from Supporting
Information).
In order to further improve the colloidal stability of the NPs,
stabilization with PEG (mPEG−NH2 chains), i.e., PEGylation,
was carried out by 1-ethyl-3-(3-(dimethylamino)propyl)-
carbodiimide (EDC) chemistry.33 The molecular weight of
the PEG chains was varied between the different samples (from
0.75 to 10 kDa). In general, the molecular weight of the PEG
was increased as the size of the inorganic core increased. The
stability of these NPs was tested against 8 different media,
which are important in biological applications.15 The stability
was tested for time points up to 3 days by dynamic light
scattering (DLS) and UV/vis spectroscopy (Supporting
Information section 7). The stability role of the cross-linker
(PEI) and PEGylation were also tested using UV/vis
spectroscopy (see Figure 3 and section 7 from Supporting
Information). To compare the effect on the stability of the
individual elements used to wrap the NPs, the same
concentrations of NPs coated with PMA only (Figure 3a),
coated with PMA and the cross-linker (PEI, Figure 3b), and
PEGylated-PMA-PEI coated NPs (Figure 3c) were incubated in
complete cell media (media 8), and the changes of their UV/vis
spectra were monitored over time, from time 0 to 3 days. The
addition of PEI prevents slightly the initial broadening of the
plasmon band, which disappears with time, presumably, due to
absorption of proteins onto the NPs surface. This broadening is
completely prevented by the PEGylation of the NPs. In all the
cases the colloidal stability of the NPs is very high, even after 3
days (see Supporting Information for the rest of the stability
tests).
The stability of PEGylated NPs against the eight above-
described media was tested. Our results indicated that the
stability of all the NPs in the media containing proteins (6, 7,
and 8) was greatly improved, as compared to their stability in
free-protein media (2, 3, 4, and 5) (Figure 3c,e,f). In some of
the free-protein media, NPs were not stable for longer than 24
h. This indicates that the presence of salt in the media
compromises the NP stability due to the screening of the NPs’
charge. Our data seem to indicate that the salt effect is
counteracted by the absorption of proteins, i.e., the protein
corona.43 The protein absorption was evidenced by a redshift in
the LSPR (Figure 3b) of the NPs in the UV/vis spectra and by
an increment in the hydrodynamic radius, as resulted from the
DLS analysis. (See section 7 from Supporting Information for
all the results.)
Notably, the increment of the hydrodynamic radius observed
for media 6 and 7, which contain BSA (0.8 mg/mL), differs
from the increment observed for medium 8, which contains
FBS (10%). Our results allow us to speculate whether these
changes might be due to the different concentrations of BSA in
the corresponding medium or due to the presence of different
proteins. Indeed, the concentration of BSA in medium 8 was ca.
2.3 mg/mL, considerably higher than in media 6 and 7 (i.e., 0.8
mg/mL). Protein binding, and thus the size and composition of
the protein corona, is highly influenced by the concentration of
protein species.43 The major constituent of FBS is BSA. Indeed,
it has been previously proposed that the main component of
the protein corona is BSA.44 However, our data do not allow us
to rule out that the differences between media 6/7 and 8 are
instead due to the absorption of other proteins than BSA and/
or due to a PEG conformational change. For media 6 and 7 the
trend is very similar, except for 25-GNPs, which has a behavior
closer to that in medium 8. Our qualitative studies do not allow
this out-of-trend behavior of 25-GNPs to be clarified, which
might be due to its different size (also, curvature radius),
different PEG length (750 Da), and/or different protein
corona. In general protein absorption is a time dependent
process.44,45 For all the other NPs in media 6 and 7, the size
increment is observed immediately after the addition of the
medium, that is, there is no increase over time. In contrast, in
the case of medium 8, the hydrodynamic radius increases
significantly after ca. 10 h until reaching a plateau at ca. 20 h,
which indicates that longer incubation times are required.
These results are supported by the previous work of Maiorano
and co-workers.46 They used citrate-capped Au NPs and
evaluated the protein corona evolution along the time. They
found that using DMEM supplemented with FBS, the
hydrodynamic radius of the NPs needs more than 50 h to
reach a plateau. Note that this time is comparable with our
results. These qualitative results demonstrate that even though
the NPs were saturated with PEG, as indicated by their ζ-
potential values and their electrophoretic motilities (see
Supporting Information, section 4, and Table S7), the
unspecific absorption of proteins was not avoided. These
results will lead to further studies regarding the PEG
conformation on these kinds of surfaces.
Aiming at proving that this double round trip of the GNRs
can be used to remove CTAB47 or at least to minimize CTAB-
release from the NP surface, the toxicity of the GNRs was
evaluated. In this case, 3T3 fibroblast cells and HeLa cells were
incubated with increasing amounts of PMA-coated GNRs
(plasmon band placed at ca. 850 and 1100 nm) for 24 h. For
completeness, the impact on cell viability of the rest of the Au
NPs was also investigated. In all the cases no acute toxicity
features were observed (Figure 4). For the GNRs no acute
toxicity was observed in both cell lines when working with
concentrations up to 2.5 nM (see Figure 4b). To test viability,
the resazurin test was chosen. By this test, the mitochondrial
respiration was evaluated, which can be in general related with
the cell viability. Interestingly, we found that the viability trend
is size-dependent, as 60-GNPs started to exhibit toxicity at 0.2
nM (263 μg/mL), cf. Supporting Information section 8.
However, this trend should be further investigated and
confirmed by a multiparametric methodology.48
■ CONCLUSIONS
This work reports on a phase transfer strategy for NPs with
different sizes, shapes, and materials. The use of short PEG
chains (750 Da) as prestabilizers of NPs for their transfer to
organic solution is reported. This approach is very versatile, as
it allows the transference of NPs within a long range of sizes to
the organic phase. Nowadays, different functionalized PEG
molecules are commercially available, which makes this
approach accessible for any kind of laboratory. Additionally,
the use of PEG as stabilizer of NPs has been widely reported,
and thus, to adapt this strategy to other materials should be
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very straightforward. The transferred NPs keep their plasmonic
properties and a good colloidal stability after their transfer.
Notably, the transfer works with big volume samples (more
than 500 mL), and the NPs can be dried and redispersed again,
keeping their optical properties. The transferred particles were
successfully coated with the amphiphilic polymer PMA, which
allows equivalent coatings to form for different NPs. This is
very interesting for comparing the interaction of different NPs
with living cells. This methodology has been typically restricted
to aliphatic-coated NPs, typically with inorganic diameters <20
nm, in organic media. Here we have demonstrated that a variety
of “big” NPs, after polymer coating, exhibit high colloidal
stability in biological media containing high protein concen-
tration. The coated NPs were found to be under realistic
concentrations without acute toxicity for either mouse
fibroblasts (3T3 fibroblast) or human cells (HeLa).
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Müllen, K.; Nienhaus, G. U.; Klapper, M.; Parak, W. J. ACS Nano
2013, 7 (4), 3253−3263.
(16) Lista, M.; Liu, D. Z.; Mulvaney, P. Langmuir 2014, 30 (8),
1932−1938.
(17) Yang, J.; Lee, J. Y.; Ying, J. Y. Chem. Soc. Rev. 2011, 40 (3),
1672−1696.
Figure 4. Viability V results for (a) 25-GNPs and (b) 850-GNRs after
24 h of incubation for 3T3 and HeLa cells.
Chemistry of Materials Article
DOI: 10.1021/cm5043167
Chem. Mater. 2015, 27, 990−997
996
(18) Wang, X.; Xu, S.; Zhou, J.; Xu, W. J. Colloid Interface Sci. 2010,
348 (1), 24−28.
(19) Alkilany, A. M.; Yaseen, A. I. B.; Park, J.; Eller, J. R.; Murphy, C.
J. RSC Adv. 2014, 4 (95), 52676−52679.
(20) Goulet, P. J. G.; Bourret, G. R.; Lennox, R. B. Langmuir 2012,
28 (5), 2909−2913.
(21) Alkilany, A. M.; Nagaria, P. K.; Hexel, C. R.; Shaw, T. J.;
Murphy, C. J.; Wyatt, M. D. Small 2009, 5 (6), 701−8.
(22) Alkilany, A. M.; Thompson, L. B.; Boulos, S. P.; Sisco, P. N.;
Murphy, C. J. Adv. Drug Delivery Rev. 2012, 64 (2), 190−199.
(23) Wijaya, A.; Hamad-Schifferli, K. Langmuir 2008, 24 (18), 9966−
9969.
(24) Huschka, R.; Zuloaga, J.; Knight, M. W.; Brown, L. V.;
Nordlander, P.; Halas, N. J. J. Am. Chem. Soc. 2011, 133 (31), 12247−
12255.
(25) Kinnear, C.; Dietsch, H.; Clift, M. J. D.; Endes, C.; Rothen-
Rutishauser, B.; Petri-Fink, A. Angew. Chem., Int. Ed. 2013, 52 (7),
1934−1938.
(26) Liu, M.; Law, W.-C.; Kopwitthaya, A.; Liu, X.; Swihart, M. T.;
Prasad, P. N. Chem. Commun. 2013, 49 (81), 9350−9352.
(27) Sekiguchi, S.; Niikura, K.; Matsuo, Y.; Ijiro, K. Langmuir 2012,
28 (13), 5503−5507.
(28) Yang, J.; Lee, J. Y.; Deivaraj, T. C.; Too, H.-P. J. Colloid Interface
Sci. 2004, 277 (1), 95−99.
(29) Ye, X.; Zheng, C.; Chen, J.; Gao, Y.; Murray, C. B. Nano Lett.
2013, 13 (2), 765−771.
(30) Li, W. H.; Zamani, R.; Gil, P. R.; Pelaz, B.; Ibanez, M.; Cadavid,
D.; Shavel, A.; Alvarez-Puebla, R. A.; Parak, W. J.; Arbiol, J.; Cabot, A.
J. Am. Chem. Soc. 2013, 135 (19), 7098−7101.
(31) Pellegrino, T.; Manna, L.; Kudera, S.; Liedl, T.; Koktysh, D.;
Rogach, A. L.; Keller, S.; Rad̈ler, J.; Natile, G.; Parak, W. J. Nano Lett.
2004, 4 (4), 703−707.
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Abstract: The synthesis of polymer-coated gold nanoparticles with high colloidal stability 
is described, together with appropriate characterization techniques concerning the colloidal 
properties of the nanoparticles. Antibodies against vascular endothelial growth factor 
(VEGF) are conjugated to the surface of the nanoparticles. Antibody attachment is probed 
by different techniques, giving a guideline about the characterization of such conjugates. 
The effect of the nanoparticles on human adenocarcinoma alveolar basal epithelial cells 
(A549) and human umbilical vein endothelial cells (HUVECs) is probed in terms of 
internalization and viability assays. 
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1. Introduction 
The synthesis in colloidal nanoparticles (NPs) is well advanced [1–6]. Nowadays, a high control 
concerning material composition, size, shape, etc., is possible [7]. There are also many strategies 
available to provide water-solubility of these NPs with high colloidal stability [8]. Some correlation of 
the (nonspecific) interaction of such NPs with cells with their physicochemical properties is possible 
and some general tendencies are well accepted in literature [9,10]. However, in order to warrant for 
specific interaction of NPs with cells, their surface has to be modified with ligands targeting cellular 
receptors. The purpose to bind proteins to the surface of NPs is to provide them a special ligand coat 
that they interact specifically with cells, etc. While there are many reports in literature about the 
conjugation of NP surfaces with specific ligands, characterization of these NPs is not always sufficient. 
Bioconjugation in particular may result in unwanted agglomeration, due to crosslinking of NPs.  
Thus, characterization of the colloidal properties of such conjugates is of high importance. In addition, 
the ligand density may significantly vary, depending on the used conjugation protocol. In principle, 
solutions to these hurdles exist, and NPs with a controlled ligand density and controlled ligand 
orientation can be synthesized [11–13]. However, these synthesis strategies require typically sophisticated 
protocols, and thus most commonly in literature more simple and less controlled strategies are employed. 
In the present work, it will be shown that also by simple conjugation strategies, together with appropriate 
characterization techniques, NP-antibody conjugates can be generated. As, in particular, characterization is 
crucial in the following, all experimental steps will be presented in the form of a general protocol. 
2. Materials and Discussions 
2.1. Synthesis of Gold Nanoparticles 
Au NPs are standard model systems, which are extensively used in literature to study the interaction 
of NPs with cells. This is in particular due to the fact that Au is an intrinsically nontoxic material. In 
the following, a protocol for the synthesis of hydrophilic Au NPs is described according to standard 
protocols from literature [14–17]. 
For the synthesis of Au NPs of dc = 20 nm core diameter, hydrogen tetrachloroaurate (III) hydrate  
(Alfa Aesar #12325, Ward Hill, MA, USA) and sodium citrate dehydrate 99% (Sigma Aldrich #W302600,  
St. Louis, MS, USA) were used as chemicals. All chemicals were used without further purification. 
Ultrapure water with a resistance greater than 18.2 mΩ·cm−1 was used for all experiments. All 
glassware was cleaned in aqua regia and rinsed with ultrapure water. For the synthesis, a solution 
containing 150 mL (2.2 mM) trisodium citrate dihydrate (Na3C6H5O7·2H2O) was heated in a 250 mL 
flask to 100 °C with stirring under reflux. Using a syringe, 1 mL of 25 mM HAuCl4·3H2O was injected 
into the flask and stirred at 100 °C. Upon formation of Au NPs, the solution turned deep red. The 
temperature was then reduced to 90 °C, and the solution was stirred continuously for another  
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30 min. For further NP growth, then 1 mL sodium citrate (60 mM) and 1 mL of HAuCl4 solution  
(25 mM) were sequentially injected with a time delay of two minutes between the two injections [17]. 
After 30 min, the reaction was cooled down to room temperature using an ice bath. 
While this protocol virtually always will lead to the formation of Au NPs (as visible by the red color 
of the solution) the quality of the NPs can vary significantly. Concerning colloidal solutions, the two 
most important quality indicators are dispersion (i.e., the NPs are individually dispersed and do not 
agglomerate) and size distribution of the NPs (i.e., the diameter of all NPs should be as similar as possible). 
Even by using the same synthesis protocol over and over, the quality of the resulting NPs may vary for 
each batch, which warrants a mandatory quality control. 
The size distribution of inorganic NPs, i.e., NPs with a core composed out of an inorganic material 
such as gold, can be determined with transmission electron microscopy (TEM). Note that organic 
molecules often do not provide sufficient contrast for being visualized with TEM. For TEM analysis, a 
diluted drop of Au NPs was dried on a copper grid, and NPs were imaged with TEM. From such 
images (cf. Figure 1), a histogram about the distribution of the core diameter, i.e., the diameter dc of the 
inorganic NP core can be obtained. In the present case, the core diameter was determined by analysis 
of more than 300 NPs, using the free software Image J. From the histogram, the mean diameter of the 
Au cores was determined to be dc = 20.9 ± 4.3 nm, cf. Figure 1. 
 
Figure 1. TEM images of the Au NPs at different magnifications (scale bars corresponding to 
100 nm, 50 nm and 2 nm), and the corresponding histogram N (dc) of the core diameter dc. 
The state of dispersion cannot be unequivocally deduced from TEM images, as those are recorded 
on NPs in dried state. In other words, even well dispersed NPs can form clusters on TEM grids. While 
the most common method to probe for NP dispersion is measuring the hydrodynamic diameter directly 
in solution (for example by dynamic light scattering (DLS), as will be described later in more detail), 
in the case of Au NPs simple analysis can be done by recording UV/Vis absorption spectra. As shown 
in the absorption spectrum in Figure 2, Au NPs exhibit a peak due to surface plasmon resonance [18]. 
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In case NPs are not well dispersed and start to form agglomerates, this peak is shifted to higher 
wavelengths and the solution turns from red to blue-black. Agglomeration also leads to scattering at 
high wavelengths >800 nm. In case of poor size distribution, the plasmon peak broadens. 
 
Figure 2. UV/Vis absorption spectrum A (λ) of Au NPs dispersed in water, directly 
recorded after their synthesis as described in this chapter. 
Besides giving an indication about the quality of the NP synthesis, UV/Vis absorption spectra are 
also helpful for the determination of the concentration of the Au NPs. According to the Lambert-Beer 
Law, the absorption A of a solution of NPs (with a length of the light path L) is proportional to the NP 
concentration cNP: 
A = ɛNP·L·cNP (1)
The proportionality factor is the molar extinction coefficient, which is well determined in the case of Au 
NPs with different sized. In the present case of NPs with a core diameter of dc ≈ 20 nm the extinction 
coefficient at 450 nm is given as ɛNP (450nm) = 5.41× 108·M−1·cm−1 [19]. For the present case, 20 μL of  
Au NP solution directly taken after their synthesis, after dilution 500 µL with water, lead to an absorbance 
of A = 0.23 at 450 nm (L = 1 cm). That means that the Au NP concentration was around cNP ≈ 11.1 nM. 
As citric acid capped Au NPs as prepared above are not highly colloidally stable in cell culture media 
(due to screening of their surface charge by adsorption of counter ions), the NPs were further stabilized by 
modification with polyethyleneglycol (PEG) [20]. In this work, the as-prepared Au NPs were modified 
with a heterofunctional PEG chain with a thiol group at one, and a carboxylic group at the other end 
(molecular mass Mw = 3 kDa, Rapp polymer #133000-4-32, Tuebingen, Germany). 105 PEG molecules 
were added per each NP, and the pH was risen to 12 with NaOH (1 M). Alkaline conditions facilitate 
deprotonation of the thiol terminal, which, in this way, attaches faster to the Au surface [21]. Afterwards, 
the PEGylated NPs were cleaned by centrifugation in order to remove unbound PEG (three times using 
14,000 rpm for 30 min, supernatant containing free PEG is discarded and replaced by fresh buffer). 
2.2. Fluorescence Labelling of Proteins 
Protein concentrations are often determined by absorption measurements, for example by the 
Bradford assays, as described later. However, as NPs heavily absorb in the same range of wavelengths 
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absorption measurements are not well suited for determining protein concentrations in NP-protein 
conjugates. In contrast, in order to quantify protein conjugation to NPs, it is useful to label proteins 
with a fluorophore. In this way, protein concentration can be determined by measuring fluorescence 
emission intensities. In the following, a protocol for conjugation of proteins with fluorescein 
isothiocyanate (FITC) is given. FITC can be directly linked to the proteins as depicted in Figure 3 [22]. 
 
Figure 3. Scheme for FITC-labelling of proteins. 
First, a calibration curve based on the Bradford assay [23] (Coomassie Blue, Thermo Scientific 
#23236, Hampton, NH, USA) to determine protein concentrations was obtained. Under the presence of 
proteins, a shift in the absorption spectrum of Coomassie Blue occurs and protein concentration is 
proportional (in a certain range) to the (offset-corrected) absorption A at 595 nm. The calibration curve 
was done following the fabricant specifications [24]. As protein standards, bovine serum albumin 
(BSA) was used (Thermo Scientific #23029). Two different calibration curves were recorded, one for 
high protein concentrations (working range of 100–1500 μg/mL protein concentrations CP) and a 
second one for low protein concentrations (working range 1–25 μg/mL protein concentrations CP). The 
standard solutions of different protein concentrations CP were prepared as indicated in the protocol, 
using 2-(N-Morpholino)ethanesulfonicacidhydrate (MES) pH 6.5 as buffer. Following the indication of 
the guide, in order to get the high concentration curve, 10 μL of NP solution sample were mixed with 
300 μL of Coomassie reagent, previously equilibrated at room temperature. To obtain the low 
concentration curve instead of using 10 μL NP sample and 300 μLCoomassie reagent, 150 μL of 
sample and 150 μL of reagent were used. After mixing for 30 s and incubating for 10 min for each 
protein concentration, CP, the absorption of the protein—Coomassie Blue mix at 595 nm—was 
recorded with an UV/Vis absorption spectrometer (Agilent 8450 spectrometer, Palo Alto, CA, USA). 
Single-use plastic cuvettes were used to hold the samples. Samples were prepared by triplicate and 
measured individually. As an offset, the absorption of Coomassie Blue without protein was subtracted. 
The offset-corrected absorptions A are plotted versus the protein concentrations CP in Figure 4.  
A polynomial fit was applied to obtain the final calibration curves. 
FITC conjugation was performed using the following protocol. First, the concentration of proteins 
was determined with the Bradford method as described above. Then, a FITC stock solution was 
prepared in sodium borate buffer (SBB) at pH = 9, equaling 750 FITC molecules per protein. FITC 
was added to the proteins and the mixture was incubated for at least 4 h at 4 °C. For removal of 
unbound FITC, the sample was run through a PD 10 or a PD 25 column (depending on the solution 
volume, GE Healthcare #52-1308-00 and #28-9180-07, respectively, Little Chalfont, UK) and only the 
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protein containing fraction was collected. After the column purification the protein solution becomes 
diluted, the protein concentration CP (of the now FITC-conjugated proteins) was determined again with the 
Bradford assay. A dilution series of the proteins was obtained and, for each protein concentration, the 
fluorescence intensity I at 519 nm (the emission wavelength of FITC) was determined. By plotting, the 
fluorescence intensity versus the protein concentration as calibration curve was obtained, cf. Figure 5. 
 
Figure 4. Coomassie assay calibration curves to determine the protein concentration CP of 
solutions with (a) high concentration and (b) low concentrations by measuring the  
offset-corrected absorption A at 595 nm. The fitting curves are (a) A(CP) = 0.029 +  
(0.001 mL/μg)·CP − (3 × 10−7 mL2/μg2)·CP2, and (b) A(CP) = −0.005 + (0.017 mL/μg)·CP – 
(6.789 × 10−4 mL2/μg2)·CP2 – (1.97 × 10−5 mL3/μg3)·CP3 and the coefficients of determination 
(r2) are equal to 0.994 and 0.989, respectively. 
 
Figure 5. Calibration curve in which the fluorescence intensity I at 519 nm is determined 
for protein solutions of different concentration CP. Data are shown for antibodies against 
(a) horseradish peroxidase (HRP) and (b) vascular endothelial growth factor (VEGF).  
A linear fit leads to the following correlation between fluorescence intensity I and  
concentration CP: (a) I(CP) = I0 + (ΔI/ΔCP)·CP = −464.28 + (4447.1 mL/µg)·CP;  
(b) I(CP) = −3549.4 + (5498.3 mL/µg)·CP. The coefficients of determination (r2) are equal 
to 0.998 and 0.995 for HRP and VEGF, respectively.  
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2.3. Conjugation of NPs with Proteins 
Here, an often used strategy based on N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC, Sigma Aldrich) was employed [22]. Note that while EDC chemistry is straightforward for the 
formation of peptide bonds between amine groups (here present on the protein ligands) and carboxyl 
groups (here present on the NP surface at the PEG terminal pointing towards solution), it may result in the 
formation of agglomerates, and thus characterization of the resulting conjugates is required.  
In addition, amine groups which belong to the functional part of the proteins can be deactivated upon 
linkage (reaction will occur statistically on the present amine groups of the proteins), and some proteins 
may lose their biological activity—in the present case, antibodies against HRP (anti-peroxidase, Sigma 
Aldrich) or against VEGF (anti-VEGF, R&D systems, AB-293-NA) where they are linked to the NPs. As 
described above, the antibodies were optionally tagged with FITC. In addition to the proteins,  
5-(6)-carboxytetramethylrhodaminecadaverine (“TAMRA”, Anaspec #81507, Fremont, CA, USA) was 
also attached as additional fluorophore via its amine group to the NP surface. Third ligand short 
metoxy-PEG-amine (amine-PE; Mw = 750 kDa, Rap Polymer #12750-2, Tuebingen, Germany) was 
attached via its amine group to the NP surface, in order to preserve the activity of the antibodies [25] and to 
prevent nonspecific protein absorption [26,27]. In other words, three different ligands (proteins, TAMRA, 
PEG) were attached to the PEGylated NPs using EDC chemistry. The ratios were chosen that per  
1 Au NP 7.5 × 106 EDC molecules, 50 antibodies, 103 TAMRA molecules, and 2.5 × 104 amine-PEG 
molecules were added for reaction. The reaction scheme is presented in Figure 6. 
 
Figure 6. Scheme of the NP modification with antibody, dye and PEG (as passivating agent). 
For the reaction 19.23 μL of Au, NPs dispersed in water (corresponding to 4pmol) with concentration 
cNP = 208 nM were taken, and mixed with 923.5 μL of 4-morpholineethanesulfonic acid (MES, Sigma 
Aldrich #M8250, 50 mM, pH 6.5) and 57.3 µL of EDC stock solution (100 mg/mL). After 20 min, the 
sample with a total volume V = 1 mL containing the activated NPs was cleaned from unreacted EDC and 
the salts, using a pre-packed column PD-10 desalting column (GE healthcare #17-0851-01, Bucks, UK) 
equilibrated with MES (50 mM, pH 6.5). During this step, the NP volume was roughly diluted twice. 
In addition, using a high pH such as 8 was tried, with the motivation to take advantage of linking 
antibodies in an oriented manner [28], but the activation process was not working as well as at pH 6.5, 
and thus, throughout this work, pH 6.5 was used. The volume of the eluted NP solution was adjusted 
with MES buffer to 2 mL. Immediately after the NP cleaning, 30 μg of antibodies were added.  
After incubation for 15 min, 2 μg of TAMRA were added. Finally, after another 15 min of incubation, 
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75 μg of amine-PEG were added to block the remaining reactive carboxylic groups. The reaction 
mixture was incubated for another 1 h at room temperature and then incubated at 4 °C overnight. 
Unbound proteins, dye molecules, and PEG were removed by repetitive centrifugation (14,000 rpm  
30 min), until no fluorescence was detected in the supernatant. This required at least five cleaning 
cycles (pelleting of NPs, discarding of supernatant, resuspending the NP pellet in fresh buffer). In the 
first washing step, 10 μL of sodium dodecylsulfate (SDS, 10%) was added to remove nonspecifically 
adsorbed dyes or proteins. Following this protocol, NPs conjugated with anti-HRP or anti-VEGF (with 
optional FITC label) were synthesized. As a control, the reaction was carried out without adding 
antibodies, but only TAMRA and PEG, leading to control NPs. In the following, the PEGylated  
Au NPs before bioconjugation will be referred to as Au-PEG NPs. The NPs after bioconjugation with 
anti-HRP, anti-VEGF, or without having antibody added will be referred to as Au-PEG-anti-HRP NPs, 
Au-PEG-anti-VEGF NPs, or Au-PEG-control NPs. In case the antibodies had been labelled with FITC, 
this is indicated as “*”: Au-PEG-anti-HRP* NPs, Au-PEG-anti-VEGF* NPs. 
In the vicinity of the Au surface, organic fluorophores may be quenched. Distance dependent 
measurements have been demonstrated that quenching can occur well up to separation distances of the 
fluorophores from the Au surface of 10 nm [29]. In the present work, no direct contact of fluorophores 
with the Au surface is possible due to the layer of 3 kDa PEG. This layer will keep the fluorophores at 
≈4 nm distance to the Au surface [30]. In the case of TAMRA, conjugation directly to the PEG 
terminal pointing towards solution quenching does not impose any problem, as no quantitative 
fluorescence measurements are performed. The TAMRA merely serves as a label for qualitative 
fluorescence imaging of NPs that have been internalized by cells and thus quenching does not interfere 
with experiments. In the case of the FITC-labelled proteins, partial quenching of their fluorescence 
upon binding to the surface of the PEGylated Au NPs cannot be excluded. However, the proteins will 
randomly orient on the NP surface. Only in the case that the FITC attached to the protein is oriented 
towards the NP surface, significant quenching is expected, as in the case FITC attached to the protein 
is oriented towards solution, away from the NP surface, the distance between FITC and the Au surface 
is further increased by the size of the protein. Together with the PEG spacer, which is always present, 
one clearly cannot exclude quenching, though it is not estimated to play a huge role. Due to quenching, 
there is less fluorescence signal from proteins attached to the NP surface as in comparison to the 
fluorescence of the free proteins, which have been used for obtaining the calibration curve. In this way, 
in the procedure described here, the number of proteins attached per NP is underestimated. 
2.4. Determination of the Number of Antibodies Bound per NP 
The number of antibodies per NP (RP/NP) can determined from separately measuring the protein 
concentration cP and the NP concentration cNP of NP-antibody conjugates: 
RP/NP = cP/cNP (2)
The NP concentration can be obtained from the absorption spectra of the conjugates at the wavelengths 
of the surface plasmon peak, at which the antibodies barely absorb. The protein concentration is determined 
from fluorescence spectra (cf. Figure 7) and the calibration curve shown in Figure 4. 
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Upon excitation of FITC (at 494 nm), there is also some fluorescence of TAMRA, which however 
can be clearly distinguished from the FITC fluorescence (cf. the green curve in Figure 7). From the 
FITC fluorescence spectra (cf. the green curve in Figure 7), the emission I at 519 nm was determined. 
Based on the calibration curve given in Figure 5, the protein concentration CP can be determined as: 
CP = (I−I0)/(ΔI/ΔCP) (3)
using the fit parameters I0 and ΔI/ΔCP from the calibration curve given in Figure 5. The mass 
concentration CP of the proteins can be converted in molar concentrations cP by using the molecular 
mass MW of the proteins: cP = CP/Mw. The results as obtained for the Au-PEG-anti-HRP* and  
Au-PEG-anti-VEGF* NPs are given in Table 1, based on the data shown in Figures 5 and 7.  
For each sample, two different dilutions were measured. 
 
Figure 7. Left side: Fluorescence spectra recorded for (a) Au-PEG-control NPs,  
(b) Au-PEG-anti-HRP* NPs, and (c) Au-PEG-anti-VEGF* NPs at a NP concentration of  
cNP = 2 nM. Excitation was performed at 545 nm (TAMRA, drawn in red) or at 494 nm 
(FITC, drawn in green). Fluorescence spectra were recorded under the same conditions as 
the spectra recorded for the calibration curve Figure 5. Right side: Fluorescence spectra 
recorded for (d) Au-PEG-anti-HRP NPs, and (e) Au-PEG-anti-VEGF NPs for TAMRA 
excitation (545 nm) at a NP concentration of cNP = 2 nM.  
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Table 1. Summary of the calculations for the amount of proteins per nanoparticles (NP). 
Sample 
Au-PEG-anti-
HRP* NPs 
Au-PEG-anti-
HRP* NPs 
Au-PEG-anti-
VEGF* NPs 
Au-PEG-anti-
VEGF* NPs 
cNP (nM) 2.2 1.5 2.0 0.5 
MW (g/mol) 150,000 150,000 150,000 150,000 
ΔI/ΔCP (mL/μg) (cf. Figure 5) 4,447.1 4,447.1 5,498.3 5,498.3 
I0 = I (CP= 0) (a.u.) (cf. Figure 5) −464.28 −464.28 −3,549.4 −3,549.4 
I (a.u.) (cf. Figure 7) 3,999 2,420 10,212 2,600 
CP (μg/mL) 1.0 0.65 2.5 1.12 
cP (nM) 6.67 4.33 16.67 7.47 
RP/NP 2.7 2.4 6.2 6.3 
2.5. Physicochemical Characterization of the NP-Antibody Conjugates 
As already mentioned, bioconjugation may change the colloidal properties of NPs. Thus, 
characterization should be also performed with the resulting samples. The UV/Vis absorption spectra 
shown in Figure 8 indicate that upon bioconjugation, no significant agglomeration occurred, as 
scattering for wavelengths >800 nm can be neglected. 
 
Figure 8. Normalized UV/Vis spectra of the NP-antibody conjugates. (a) Au-PEG-control, 
Au-PEG-anti-HRP*, and Au-PEG-anti-VEGF* NPs; (b) Au-PEG-control, Au-PEG-anti-HRP, 
and Au-PEG-anti-VEGF NPs. Spectra were recorded in a spectrometer Agilent 8453. 
While UV/Vis absorption spectra can be a first indication about the presence of bigger 
agglomerates, it is hard to determine the existence of smaller agglomerates from these data. For this 
purpose, measurements of the hydrodynamic diameter dh of the NPs are best suited. One common 
technique in this direction is dynamic light scattering (DLS; Malvern Zetasizer set-up). However, in 
the case of small NPs, proteins have similar size to the NPs and thus measurements in cell culture 
media containing serum are complicated [31]. In Figure 9, DLS measurement for the NP-antibody 
conjugates are displayed. The hydrodynamic diameters dh as determined from these data (cf. Table 2) 
demonstrate that any larger agglomerates can be excluded. However, in general, no significant increase 
in size of the NPs upon antibody attachment could be observed, though the FITC fluorescence clearly 
proves the presence of the antibodies. 
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Figure 9. Number distribution N (dh) of the hydrodynamic diameter recorded or different 
NPs. (a) Au-PEG NPs, (b) Au-PEG-control NPs, (c) Au-PEG-anti-HRP* NPs,  
(d) Au-PEG-anti-VEGF* NPs, (e) Au-PEG-anti-HRP NPs, and (f) Au-PEG-anti-VEGF 
NPs. The concentration of the NP solutions were cNP ≈ 5 nM, and the measurements were 
performed in milliQ water. Each sample was measured at least three times and the mean 
value of the hydrodynamic diameter was determined. 
In the same Malvern Zetasizer set-up, the zeta-potential ζ was also determined based on laser 
Doppler anemometry, cf. Figure 10. The data shown in Table 2 show that despite attachment of 
antibodies, the NPs retained their negative zeta-potential. In the case of conjugation with antibodies 
without FITC, the NP-antibody conjugates have a less negative zeta potential than the NPs without 
attached antibodies. 
As proteins can also nonspecifically adsorb to the surface of NPs, the conjugation reactions were 
repeated but without addition of EDC. In this way, all attached proteins are not covalently attached  
(as due to the lack of EDC, no amide bonds can be formed), but are nonspecifically attached to the 
NPs. These samples are termed Au-PEG/control, Au-PEG/anti-HRP, and Au-PEG/anti-VEGF NPs. 
Hydrodynamic diameters and zeta-potentials as determined with these NPs are enlisted in Table 3. 
There is less reduction of negative zeta potential upon presence of the antibodies. Thus, less antibodies 
are present per NP and, in this way, attachment of antibodies under the presence of EDC should be 
mainly of covalent nature. 
Table 2. Summary of mean hydrodynamic diameters and zeta-potentials determined in water. 
Sample 
Au-PEG  
NPs 
Au-PEG-
Control NPs 
Au-PEG-anti-
HRP* NPs 
Au-PEG-anti-
VEGF* NPs 
Au-PEG-anti-
HRP NPs 
Au-PEG-anti-
VEGF NPs 
dh (nm) 27.4 ± 0.4 27.8 ± 0.8 28.0 ± 0.2 38.0 ± 1.9 27.0 ± 0.6 28.9 ± 0.9 
ζ (mV) −32.8 ± 0.6 −20.0 ± 0.9 −18.4 ± 1.6 −24.1± 3.8 −6.3 ± 0.2 −11.8 ± 0.7 
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Figure 10. Number distribution N (ζ) of the zeta-potential of (a) Au-PEG NPs,  
(b) Au-PEG-control NPs, (c) Au-PEG-anti-HRP* NPs, (d) Au-PEG-anti-VEGF* NPs,  
(e) Au-PEG-anti-HRP NPs, and (f) Au-PEG-anti-VEGF NPs. The concentration of the NP 
solutions were cNP ≈ 5 nM, and the measurements were performed in milliQ water. Each sample 
was measured at least three times and the mean value of the zeta-potential was determined. 
Table 3. Summary of mean hydrodynamic diameters and zeta-potentials determined in water. 
Sample Au-PEG NPs Au PEG-Control NPs Au-PEG-anti-HRP NPs Au-PEG-anti-VEGF NPs 
dh (nm) 27.4 ± 0.4 27.4 ± 1.6 26.1 ± 2.1 29.3 ± 1.7 
ζ (mV) −32.8 ± 0. 6 −30.1 ± 1.2 −24.3± 0.9 −31.4± 1.3 
2.6. NP Interaction with Cells 
NPs can be internalized by cells via endocytosis, as they may trigger toxic effects. In the following, 
this is investigated for two different cell lines, human adenocarcinoma alveolar basal epithelial cells 
(A549) and human umbilical vein endothelial cells (HUVECs). A549 cells, purchased from ATCC, 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Aldrich) supplemented with 
10% fetal bovine serum, 2 mM L-glutamine (Sigma Aldrich), and 100 U/mL penicillin/streptomycin 
(Sigma Aldrich). HUVECs, purchased fromPromoCell, were cultured in Endothelial Cell Basal 
Medium (ECBM, PromoCell, Heidelberg, Germany) supplemented with 2% fetal calf serum 
(PromoCell), 0.4% Endothelial Cell Growth Supplement (PromoCell), Epidermal Growth Factor  
(0.1 ng/mL, PromoCell), Basic Fibroblast Growth Factor (1 ng/mL, PromoCell), heparin (90 μg/mL, 
PromoCell) and hydrocortisone (1 μg/mL, PromoCell). The cells were grown at 37 °C in a humidified 
atmosphere containing 5% CO2. 
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For uptake experiments, cells were incubated with NPs and after 24 h the amount of incorporated 
NPs was determined. A549 cells and HUVECs were incubated with Au-PEG NPs of different 
concentration within medium with or without serum. After 4 h of incubation, the cells were intensively 
washed and further cultured. Since serum components are known to alter physicochemical 
characteristics of NPs, we studied their internalization in the presence and absence of serum.  
Twenty-four hours after adding the NPs, the cells were lysed and the samples were analyzed for their 
gold content with inductively coupled plasma mass spectrometry (ICP-MS). The protein content of 
each sample was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA). The results are 
presented in Figure 11 as ppb of gold per mg of protein. 
 
Figure 11. Internalization of Au-PEG NPs by A549 cells and HUVECs. A549 cells and 
HUVECs were incubated with Au-PEG NPs of cNP = 0.6 nM and cNP = 1 nM concentration 
cells in medium with (white bars) or without (black bars) serum. Twenty-four hours after 
adding the particles, the gold concentration cAu and the protein concentration CP  
was determined. 
For all formulations tested, more NPs were taken up if they were incubated with the cells in the 
absence of serum, which is consistent with previous findings [31]. We speculate that proteins and other 
constituents of serum that interact with the NPs change their properties in such a way that they are 
internalized by an endocytic pathway as it has been previously described [32]. Interestingly, the 
PEGylated NPs were taken up well by cells. This indicates that coating Au NPs with PEG does not 
completely preclude their internalization. In addition, NP-antibody conjugates were incorporated by 
cells, as shown in the fluorescence microscopyimages in Figure 12. 
The toxic effect of the NPs to the cells was analyzed with a standard viability assay. Ten thousand 
cells per well were seeded in 96-well-plates one day before planned experiments. A549 cells and 
HUVECs were incubated for 4 h with Au-PEG NPs at different concentrations cNP ranging from 0.2 to 
1 nM. Subsequently, the cells were intensively washed and further cultured. Cell viability was 
evaluated 24 h after NPs had been added to the cells by the MTT assay (Roche, Germany) according to 
the manufacturer’s instructions, cf. Figure 13. The assay is based on conversion of the tetrazolium dye 
3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazoliumbromide to its insoluble formazan, which is purple 
in color. Data demonstrate that Au-PEG NPs reduce cellular viability in a concentration-dependent manner. 
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Figure 12. Internalization of functionalized Au NPs by human umbilical vein endothelial 
cells. HUVECs were exposed to TAMRA-labeled Au NPs functionalized with  
(a) anti-VEGF (Au-PEG-antiVEGF NPs), and (b) anti-HRP antibodies (Au-PEG-anti-HRP 
NPs). The NP-antibody conjugates were removed after 2 h and the cells were intensively 
washed. The images were taken 1 h later by employing a Zeiss fluorescent microscope. 
Images show the fluorescence and bright field channel, as the overlay of both channels. 
 
Figure 13. Toxicity induced by Au-PEG NPs in A549 cells (a) and HUVECs (b)Au-PEG NPs, 
at concentrations ranging from cNP = 0.2 to 1 nM, were incubated for 4 h with A549 cells 
or HUVECs in media containing serum. Cell viability (V) was determined 24 h after 
adding the NPs to the cells. The viability was normalized to 100% for untreated control 
cells, *p < 0.01; **p < 0.001(versus control value). 
2.7. Effect of Au NPs with Anti-VEGF on VEGF Stimulation of Cells 
Under physiological conditions VEGF binds to its receptor (VEGFR) present on the membrane  
of HUVECs, which initiates cascades of signals that stimulate many processes including  
angiogenesis [33,34]. VEGF receptors convey information to other signal transduction molecules via 
autophosphorylation of distinct residues in their structure. If VEGF binds to its receptor, HUVECs 
proliferate. If one blocks the receptor with an antibody [33,35] or NP [36,37], there is reduced 
proliferation. Antibody-based therapies relay on a sequestering of VEGF molecules by specific 
antibodies. In this way, VEGF binding to its receptor is prevented [38]. 
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In a first set of experiments, we tested the response of HUVECs to stimulation with VEGF. To that 
end, the cells were exposed for 24 or 48 h to VEGF at different concentrations (CVEGF = 2–16 ng/mL). 
As demonstrated in Figure 14, VEGF stimulated proliferation of HUVECs in a dose-dependent 
manner. At concentrations ≥ 10 ng/mL the number of cells in culture increased by more than 20% 
after 24 h and by more than 50% after 48 h. Based on these results, we chose to stimulate HUVECs 
with VEGF at concentrations of 12 and 16 ng/mL in all subsequent experiments. 
Next, in order to verify whether proliferation elicited by VEGF can be neutralized by anti-VEGF 
antibodies, we pre-incubated HUVECs with the antibody, which was followed by stimulation with 
VEGF. The results presented in Figure 15 demonstrate that soluble anti-VEGF antibodies inhibit 
proliferation of endothelial cells induced by VEGF in a dose dependent manner. Note that this is not 
due to blocking of the VEGF receptor but by binding of anti-VEGF to VEGF, which cancels the 
biological activity of VEGF. 
We next assessed whether a similar effect could be achieved by the anti-VEGF antibodies attached 
to Au NPs (Au-PEG-anti-VEGF NPs). HUVECs were first incubated with Au-PEG-anti-VEGF NPs 
for 2 h. This was followed by the stimulation with VEGF for 24 and 48 h. To verify whether the 
observed effects were specific, in this set of experiments, we also tested Au NPs functionalized with 
the irrelevant antibody anti-HRP (Au-PEG-anti-HRP NPs). 
As demonstrated in Figure 16, Au NPs functionalized with anti-VEGF antibody (Au-PEG-anti-VEGF 
NPs) exhibited some effect on the proliferation of HUVECs upon stimulation with VEGF over a longer 
period of time. However, the same trend was observed for NP carrying anti-HRP (Au-PEG-anti-HRP NPs). 
Therefore, it is likely that the recorded decrease in the number of cells in culture was not caused by a 
specific interaction of the functionalized Au NPs with VEGF but rather was associated with NP 
induced toxic effects on cells. 
 
Figure 14. Response of human umbilical vein endothelial cells to vascular endothelial 
growth factor. The endothelial cells were plated in 96-well plates (5000 cells/well) one day 
before planned experiments. The cells were exposed for 24 h (a) and 48 h (b) to different 
concentrations CVEGF of VEGF. The normalized numbers of cells N in culture were 
evaluated by performing a proliferation test. Data correspond to the mean value ± standard 
deviation obtained from n = 4 experiments, *p < 0.001 (versus control value, no VEGF). 
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Figure 15. Proliferation of human umbilical vein endothelial cells triggered by VEGF and 
neutralization induced by anti-VEGF antibody. HUVECs were first exposed for 2 h to  
anti-VEGF antibody at two concentrations (Canti-VEGF = 50 and 100 ng/mL). This was 
followed by the incubation with VEGF (CVEGF = 12 and 16 ng/mL) for (a) 24 and (b) 48 h. 
The number of cells was normalized to 100% for untreated control cells. *p < 0.01;  
**p < 0.001(versus cells treated with VEGF only). 
 
Figure 16. The effect of Au NPs functionalized with anti-VEGF or anti-HRP antibody on 
the proliferation of human umbilical vein endothelial cells triggered by VEGF. HUVECs 
were first exposed to Au NPs functionalized with (a,b) anti-VEGF or (c,d) anti-HRP 
antibodies. The NPs were added to the cells to reach concentrations of the antibodies equal 
to Canti-VEGF and Canti-HRP of 50 (grey bars) and 100 ng/L (black bars) (adjusted by the NP 
concentration by knowing the number RP/NP of antibodies per NP as shown in Table 1). 
This was followed by the incubation with VEGF (CVEGF = 12 and 16 ng/mL) for (a,c) 24h 
and (b,d) 48 h. The number of cells was normalized to 100% for untreated control cells.  
*p < 0.01; **p < 0.001 (versus cells treated with VEGF only). 
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3. Conclusions 
A protocol for functionalizing Au NPs with antibodies has been presented, together with 
characterization procedures, which quantify the number of antibodies per NP. It is demonstrated that 
biocojungation did not induce agglomeration. While successful bioconjugation could be demonstrated, 
this does not provide information about the biological activity of the attached antibodies. For this, 
profound characterization is also required. With the presented data, a biological effect of the  
NP-antibodies is demonstrated. However, this example demonstrates that such data can be misleading. 
As the same effect was observed with NP-antibody conjugates with an irrelevant antibody, the effect 
can’t be ascribed to a specific antibody effect but rather to general NP-induced toxicity. This example 
points out that antibodies can be deactivated, and that controls with irrelevant antibodies are required 
to demonstrate specific biological activity of NP-antibody conjugates. 
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Abstract 
 
The use of inorganic nanoparticles (NP), in particular of Au NPs with a core diameter of 4 
nm for labelling mesenchymal stem cells (MSCs) for the purpose of future in vivo MSC 
tracking was investigated. Time dependent uptake efficiencies of NPs by MSCs at different 
exposure concentrations and times was investigated. Incorporated NPs were visualized with 
transmission electron microscopy (TEM). The fate of the MSCs was determined in terms of 
the amount of excocytosed NPs versus the amount of initially endocytosed NPs, 
demonstrating that at high NP concentrations the internalized NPs are exocytosed over time, 
leading to a loss of label. While exposure to NPs did not significantly reduce cell viability 
and expression of MSC-characteristic surface markers, even at concentrations bigger than 
typically used for cell labelling, at those concentrations MSCs were significantly effected in 
their proliferation, migration. These results demonstrate that viability assays are not sufficient 
to claim that labelling of MSCs with NPs does not harm cells, but in fact labelling can alter 
cells in more subtle ways such as reducing their proliferation or migration. Thus, while 
labelling of cells with a large amount of NPs improves contrast for imaging, on the other 
hand the amount of added NPs should be reduced in order to avoid alterations in the MSCs. 
An estimate about the detection limits of Au NP labelled MSCs within tissue by inductively 
coupled plasma mass spectrometry (ICP-MS) is provided. 
1. Introduction 
 
Mesenchymal stromal cells (MSCs) exhibit a high ex vivo expansion capacity and have 
already entered the clinics as cellular products for various applications [1,2]. They possess 
anti-inflammatory and regenerative potential and migrate into sites of inflammation, tissue 
repair and neoplasia [3-5]. Due to their properties and safety, they are considered as a 
promising tool in regenerative medicine and oncology. About 200 clinical phase I/II and III 
studies revealed no side effects, even in allogenic settings. In oncology new therapeutic 
concepts envision e.g. genetically modified MSCs as a vehicle to selectively deliver anti-
tumorigenic proteins or compounds to neoplastic tissue [6]. The efficacy of these approaches 
as well as the extent of side effects is directly linked to the potential of MSCs to accumulate 
in tumors after systemic administration. However, the exact mechanism remains unknown. In 
regenerative medicine MSCs have been used to form transplants.... However, the clinical use 
of MSCs is still in its infancy steps and thus many details still remain to the unraveled. This 
involves for example the mechanisms of homing and in particular also the in vivo fate of 
MSCs. This circumstance evokes the necessity for a noninvasive in vivo MSC tracking 
method that does not influence their biological properties and cellular function. Stem cell-
tracking methods being currently used are limited in sensitivity and low cell labeling 
efficiency. Combined with poor stem cell homing efficiency revised labeling considerations 
are needed.  
 
Noninvasive imaging of MSC after labeling with inorganic colloidal nanoparticles (NPs) is a 
promising tool is that allows for recording distributions and the long-term tracking of the 
MSC after systemic application [7-9]. In comparison to organic molecules NPs may allow for 
higher contrast in certain imaging techniques, such are magnetic resonance imaging (MRI) 
and computer tomography (CT). In MRI FeOx NPs have been demonstrated to provide good 
contrast in transversal relaxation time (T2) -based imaging [10,11]. In CT elements with high 
atomic number obtain best contrast. Thus Au NPs are good candidates [12,13]. NPs are in 
general readily endocytosed by cells [14,15], and thus labelling of MSCs in principle is 
straightforward. Upon cell division the NPs are passed to the two daughter cells [16]. 
 
However, while in principle easily to carry out labelling of MSCs with NP has to be 
performed under a delicate balance. From the imaging point of view, more NPs inside each 
MSC would relate directly to better contrast in imaging. On the other hand it is reasonable to 
reduce the amount of NPs inside each MSC as much as possible in order to avoid potential 
cytotoxic effects. Thus labelling conditions need to be optimized. Au NPs are promising 
candidates, as their biocompatibility at low doses is well-accepted [17]. Gold has been used 
for example as clinical therapeutic in patients with severe rheumatologic disorder for many 
years with well known safety profit and limited side effects. Gold is usually not present in 
living organisms and thus tracing of Au NPs by mass spectrometry benefits from low 
background signals, in contrast to FeOx NPs, as there is a significant level of endogenous 
iron. Recent studies have shown that Au NPs at least partially fulfill basic requirements for 
efficient long term labeling of MSCs, i.e. long term stability, low cytotoxicity and most 
importantly, no interference with cellular functioning. Ricles et al. have demonstrated that 
lysine coated Au NPs of hydrodynamic diameters of around 50 nm do not interfere with 
differentiation [18]. Long term tracking for a period of two weeks seems feasible due to high 
retention times and low cytotoxicity. In contrast with these findings, some studies revealed a 
negative effect of Au NPs on certain cellular functions such proliferation [19,20]. In addition 
the morphology of subcellular structures seems to be disturbed depending on the applied dose 
[21].  
 
To further assess the biocompatibility and suitability of Au NPs for MSC tracking, we 
investigated cellular responses to Au NP labelling in mesenchymal stromal cells derived from 
rats (rMSCs) and humans (hMSCs), such as uptake, cytotoxicity, proliferation, migration, 
morphology and immunophenotype. For MSC detection via mass spectrometry we elucidated 
the detection sensitivity by quantifying the required number of labeled cells to be able to 
prove MSC presence in a population of cancer cells.  
 
2. Materials and Methods 
 
2.1. Synthesis and characterization of NPs 
 
Polymer-coated Au NPs with a core diameter of dc = 4.25 ± 0.88 nm (as determined by 
transmission electron microscopy, in the following referred to as “dc = 4 nm”), a 
hydrodynamic diameter of dh = 10.4 ± 0.7 (as determined by dynamic light scattering in 
water), and a zeta-potential of ζ = - 25.1 ± 0.36 mV (as determined from laser Doppler 
anemometry in water) were prepared according to previously published protocols. The 
experimental protocol is described in detail in the Supporting Information. In addition also 
bigger spherical Au NPs, rod-shaped Au NPs, and FeOx NPs were prepared as controls 
according to previously published protocols [22]t. The NPs were overcoated with an 
amphiphilic polymer, poly(isobutylene–alt–maleic anhydride)–graft–dodecylamine (PMA) 
[23-26]. After synthesis, the NPs were purified by gel electrophoresis and by diafiltration. 
The concentration of the coated NPs was determined by ICP-MS. Optionally the fluorophore 
tetramethylrhodamine cadaverine (TAMRA) was integrated in the polymer shell. For detailed 
characterization of the physicochemical properties of these NPs we refer to previous studies 
[22,27]. 
 
2.2. Isolation, expansion and culture of human mesenchymal stem cells (hMSCs) 
 
hMSCs were isolated from bone pieces obtained from hip fragments. The procedure had been 
approved by local ethic committees (study no. 64/01 and 25/10) and patients had been given 
written informed consent. 10. Dulbecco’s Modified Eagles Medium (DMEM, Sigma-Aldrich, 
#D5546) was supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin 
(P/S, Sigma-Aldrich, #P4333) and 2 mM L-glutamine (Sigma-Aldrich, #G7513). The cells 
were cultivated in flask at 37 °C and 5 % CO2 until they reached 80% confluence. With every 
splitting procedure the passage number was increased. hMSC where used in passages ≤ 5 due 
to observed adverse effects on MSC functional capabilities for higher passages.   
 
2.3. Isolation, expansion and culture of rat mesenchymal stem cells (rMSCs) 
 
Male Lewis rats were utilized use as donors of femurs and tibiae for bone marrow harvest 
and rMSCs isolation. The animals were treated in fulfilment with the Principles of laboratory 
animal care” formulated by the National Society for Medical Research and the “Guide for 
the care and use of laboratory animal organized by the Institute of Laboratory Animal 
Resources, National Research Council, and published by the National Academy Press, 
revised 1996. The ethical permission was obtained by the Stockholm South Ethical 
Committee (with registration number S8-11). rMSCs were isolated from rat bone marrow by 
means of adhesion to cell culture flasks as previously reported [28]. Briefly, rats were 
euthanized by an intraperitoneal barbiturate before the hind limbs were harvested. Then, the 
femur and tibia were cleared of soft tissue and the bone marrow was flushed out with 
containing calcium and magnesium using a needle and syringe. The resulting suspension was 
collected and after centrifugation the cell pellet was suspended in complete cell culture 
medium Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, Sweden) with 10% fetal 
bovine serum (FBS, Invitrogen, Sweden) and 1% antibiotic-antimycotic (Invitrogen, 
Sweden). rMSCs were then seeded to a 25 cm2 cell culture flask  (Corning, New York, USA) 
and were incubated at 37 °C in 5 % CO2. After 24 h of incubation, the medium was 
discarded, cells were washed once with phosphate buffered saline (PBS) to remove non-
adherent cells, and fresh cell culture medium was added. The cells that adhered to the cell 
culture flask were defined as MSCs of passage 0. MSCs cultured to passage 12 or below were 
used for the experiments. 
 
2.4. Quantification of Au NP uptake by hMSCs 
 
The labeling efficiency of MSCs with Au NPs (dc = 4 nm) was examined by inductively 
coupled plasma mass spectrometry (ICP-MS, Agilent 7700 Series). Cells were seeded into 6-
well plates (TPP, Switzerland, #92006) at a density of 5000 hMSCs/cm² and each well with a 
surface of xx cm2 was filled with Vmedium = .. mL of medium. In each well there were thus 
Ncell = xx cells. After 24 h Au NPs were added at different concentrations (cNP = 0 – 100 nM) 
and cells were incubated for 5 h, 24 h and 48 h or 7 days, respectively. After exposure, the 
cell medium was removed followed by three washing steps with PBS to remove non-
internalized NPs. Then, cells were detached with 500 µL trypsin-EDTA (0.05 % trypsin-
EDTA, Life Technologies, #25300-054), collected by centrifugation at 280 rcf for 5 min, and 
washed with PBS followed by an additional centrifugation step. The recovered cell pellets 
were treated with 100 µL of lysis buffer (Luciferase Cell Culture Lysis Buffer, Promega, 
#E153A) for 30 min. Finally, the samples were prepared for ICP-MS analysis by digestion in 
aqua regia. Hereby 50 µL sample was diluted in 150 µL aqua regia, consisting of three parts 
concentrated (35 wt%) HCl (Fisher Chemical, #7647010) and one part of (67 wt%) HNO3 
(Fisher Chemical, #7697372), and left for digestion for at least 3 hours. The sample 
containing acid was diluted 1:10 in 2 wt% HCl prior to measuring the elemental Au 
concentration in the sample with ICP-MS. The initial cell number was determined by 
performing a Lowry protein assay (Sigma-Aldrich, #TP0300) with the lysed cell pellets [29].  
 
2.5. Quantification of Au NP uptake by rMSCs 
 
rMSCs were seed at a density of 5 x 104 cells/mL in a 24-well plate with each well filled with 
Vmedium = .. mL of medium and exposed to fluorescently labelled Au NPs (dc = 4 nm, 
TAMRA) at different concentrations and time points. There were thus Ncell = xx cells in each 
well. Then, cells were washed with phosphate buffered saline (PBS), centrifuged at 280 rcf 
for 5 min, and the cells pellet was re-suspended with PBS. Flow cytometry (FCM) was 
performed using a FACSCalibur (Becton Dickinson) operating with CellQuestPro software. 
Experiments were performed with cells from three independent rat MSC donors. 
 
2.6. Imaging of incorporated rMSCs with transmission electron microscopy 
(TEM) 
 
Internalization of NPs was visualized by TEM analysis. rMSCs were seeded at a density of 5 
x104 cells/mL in a 24-well plate and were exposed to desired concentration NPs for 24 h. At 
the indicated time-points, cells were harvested and washed three times with PBS and fixed in 
2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. Next cells were rinsed in 0.1 M 
phosphate buffer and centrifuged. The pellets were post-fixed in 2% osmium tetroxide in 0.1 
M phosphate buffer, pH 7.4 at 4 °C for 2 h, and then dehydrated in ethanol followed by 
acetone and embedded in LX-112 (Ladd, Burlington, VT). Ultrathin sections were cut on a 
Leica EM UC6 microtome (Leica, Wien, Austria) and contrasted with uranyl acetate 
followed by lead citrate. Then samples were examined in a Tecnai 12 Spirit Bio TWIN 
transmission electron microscope (FEI Company, Eindhoven, Netherlands) at 100 kV. Digital 
images were collected using a Veleta camera (Olympus Soft Imaging Solutions, GmbH, 
Münster, Germany) as previously reported (Krais et al 2014). While in the main manuscript 
result for spherical Au NPs of dc = 4 nm are reported, in the Supporting Information also 
TEM images of rMSCs with incorporated Au NPs of bigger diameter and of rod-shape are 
shown. In addition in the Supporting Information also fluorescence microscopy images of 
fluorescence-labelled FeOx NPs inside rMSCs are presented. 
 
2.7. Assessment of long term labeling efficiency of hMSCs with Au NPs by 
reporting exocytosis versus endocytosis 
 
For evaluation of the long-term labeling efficiency the fraction of exocytosed NPs was 
determined after exposure to Au NPs. hMSCs (adherent in 25 cm² culture flasks) were 
exposed to cNP = 2 – 100 nM of Au NPs for 24 h or 48 h. After labeling, hMSCs were 
detached with trypsin-EDTA, washed with PBS and plated into new 25 cm² culture flasks. 
After 24 h or 48 h, the Au content remaining inside MSCs (i.e. the remaining endocytosed 
NPs) and present in growth medium (i.e. the exocytosed NPs) was determined. The 
intracellular Au was quantified by ICP-MS as described above for the quantitative uptake 
analysis of Au NPs by hMSCs. The exocytozed fraction of the Au NPs was determined from 
the Au concentration of the growth medium which was diluted 1:4 in aqua regia first, 
followed by 1:10 dilution in 2 wt% HCl prior to ICP-MS measurements. Results are 
represented as Au mass fractions of intracellular versus the intracellular + extracellular Au.  
 
2.8. Viability/recovery of rMSCs labeled with Au NPs 
 
rMSCs were seeded at a density of 5 x 104 cells/mL in a 24-well plate with each well filled 
with Vmedium = .. mL of medium and exposed to Au NPs for 24 h – 72 h. There were thus Ncell 
= xx cells in each well. Then, cells were washed 3 times with PBS and grown for further 48 
h. Afterwards, cells were seed at constant density in a 6-well plate and grown for further 7 
days. Finally cells were seed at constant into 96-well plates for evaluation of cell viability. 
Briefly, AlamarBlue® reagent (Invitrogen) was added in each well and incubated for desired 
time at 37 ºC. The fluorescence was measured at 560 nm excitation and 590 nm emission 
wavelength using a spectrophotometer (SpectraMax 250, Molecular Devices, USA). Results 
are expressed as percentage of cell viability V versus control (i.e. untreated cells). 
Experiments were performed in three independent rat MSC donors in triplicates for each 
time-point and concentration. Data in the main manuscript describe results for dc = 4 nm Au 
NPs. Viability data for all other NPs are presented in the Supporting Information. 
 
 
2.9. Proliferation of hMSCs 
 
The effect of exposure of hMSCs to Au NPs on their proliferation rate P was determined with 
carboxyfluorescein succinimidyl ester (CFSE) and flow cytometry (FCM). Cells were labeled 
with a certain amount of membrane-impermeable CFSE whose fluorescent intensity 
decreases upon cell division [30]. 2.5·105 cells per sample were labeled with 1 µM CFSE 
(Molecular Probes, #C34554) for 10 min at 37 °C in 1 mL of PBS. Subsequently, the cells 
were washed twice with 5 mL of pre-warmed supplemented DMEM and plated in 25 cm² 
culture flasks. After 24 h NPs (cNP = 0 – 50 nM) were added and a negative control was 
prepared containing 5 µM of the mitosis inhibitor cholchicine (Sigma-Aldrich, #C9754). 
After subsequent culturing for additional 6 days, cells were detached with trypsin-EDTA, 
counter-stained with 1 µM propidium iodide (PI, Sigma-Aldrich, #P4170) and signals were 
acquired with a BD LSR II FCM device with FACS Diva software (BD Biosciences). Data 
were analyzed with FlowJo version 9.5.3 (TreeStar Inc.) and GraphPad Prism software. 
CFSE was excited at 488 nm and emission was detected at 521 nm. Living cell were gated 
after 4’,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, #D9542) staining. Results are 
normalized to the positive (P = 1, no Au NPs) and negative control (P = 0, cholchicine) and 
are representing the mean values ± standard deviations of the median values of the CFSE 
fluorescent intensity/cell for 3 independent experiments.  
 
2.10. Migration of hMSCs  
 
The migration potential of hMSCs was assessed by analyzing cell migration through 
membrane inserts by fluorescent microscopy [Maijemburg et al 2010]. MSCs were labeled 
with Au NPs in 25 cm² culture flasks filled with .. mL of medium at cNP = 0 – 25 nM for 2 
days. Subsequently, cells were detached with trypsin-EDTA and transferred in serum free 
medium into the upper chamber of membrane inserts (8 µm, Greiner Bio One, #662638) 
placed into the wells of a 24 well plate (Greiner Bio One, #622160, xx cm2 surface area per 
well) at a concentration of X cells/cm² with Vmedium = xx mL medium in each well. There 
were thus Ncell = xx cells in each well. The lower chambers were filled with growth medium 
containing 10% humand platelet lysate (HPL, manufactured at the Institute for Clinical 
Immunology and Transfusion Medicine, Giessen, Germany in a GMP-compliant manner as 
described in [31]) to stimulate hMSC migration from the upper to the bottom side of the 
membrane inserts. After 16 h cells were fixed with methanol and nuclei were stained with 50 
µM of 4',6-diamidino-2-phenylindole (DAPI, Life Technologies, #D1306) for 5 min. For 
each sample migrated and non-migrated hMSCs were counted at fixed positions each 
comprising an area of 0.38 cm². The counting was based on fluorescent images acquired with 
a confocal laser scanning microscope (CLSM 510 Meta) from Zeiss using a Plan-
Apochromat 20x/0.8 M27 objective (pinhole size: 1 airy unit, lateral sampling rate: 0.6 
µm/pixel). DAPI (nuclei) was excited with a 405 nm-laser diode an emission was gated with 
a 420 nm long-pass filter. For imaging the inserts were placed on a microscope slide in a drop 
of PBS. For 4-6 randomly chosen positions two images were acquired: Non-migrated cells 
were captured by acquiring an image at a plane above the membrane and migrated cells were 
imaged below the membrane, cf. the Supporting Information for a sketch of the set-up. For 
each position (A = 0.38 mm²) the number of cells above (Nnon-mig) and below the membrane 
(Nmig) was determined based on their nuclear staining by employing CellProfiler [32] and the 
ratio Nmig/(Nmig+Nnon-mig) was calculated. Results are displayed as mean values ± standard 
deviations for 3 independent experiments. 
               
 
3. Results and discussion 
 
3.1. Au NPs are incorporated by MSCs 
 
As expected MSCs readily incorporate Au NPs in a dose- and time-dependent manner, cf. 
Figure 1. In the present study NP concentrations ranging from cNP = 1 to 100 nM were used 
for 4 nm core size Au NPs. Uptake was quantified either by determination of elemental Au 
inside cells via ICP-MS (cf. Figure 1a), or by recording the cellular fluorescence due to 
internalized fluorescence-labelled NPs via flow cytometry (FCM, cf. Figure 1b). In general 
the amount of internalized NPs increased over time, whereby after long exposure (> 24 h) 
and high NP concentrations saturation effects could be observed, cf. Figure 1. Hereby it has 
to be stated that uptake efficiency significantly depended on the individual donor source of 
the MSCs. The data shown in Figure 1a allow for calculating the number NNP of Au NPs 
which are internalized by each cell as NNP = (mAu/MAu)·NA, with mAu being the mass of 
elemental Au inside each cell as detected with ICP-MS (cf. Figure 1a), MAu = 196 g/mol the 
molar mass of Au, and Avogadro’s constant NA = 6.02·1023 mol-1. In case of exposure to cNP 
= 10 nM Au NPs for 24 h this results in NNP = xx NPs per cell. This can be compared to the 
total number of NPs NNP,add to which on cell had been exposed: NNP,add  = 
cNP·Vmedium·NA/Ncell whereby Vmedium is the volume of medium in each well and Ncell is the 
number of cells per well. In case of exposure to cNP = 10 nM Au NPs this corresponds to 
NNP,add = xx per cell. This demonstrates that only a small fraction of NPs present in medium 
is actually incorporated by cells. There is an agreement in literature that the classical uptake 
pathway of NPs by cells in endocytosis [15], and thus internalized NPs are located in 
intracellular vesicles. TEM images showed the presence of NPs inside cells, cf. Figure 2a. In 
the Supporting Information TEM data are presented which demonstrate that also Au NPs 
with bigger size or with rod shape, as FeOx NPs are internalized by MSCs. Saturation for 
extended incubation times may be due to proliferation, as the internalized Au NPs are 
partitioned to daughter cells, or due to exocytosis. In Figure 2b data are presented in which 
NP excretion was investigated by measuring the increasing Au content in the extracellular 
medium 24 or 48 h after labeling. The data demonstrate that with increasing NP 
concentration the excretion via exocytosis is increasing, which is most probably taking place 
largely within the first 24 h. Thus, the maximum number of NPs with which a cell can be 
labelled is limited.  
 
3.2. Biocompatibility studies 
 
In order to investigate the biocompatibility of the 4 nm Au NPs cell viability of MCS 
exposed to the NP was assessed using the Alamar blue assay. The data shown in Figure 3 
indicate that the cell viability of MCS exposed to NPs for 24, 48 and 72 h was not strongly 
affected. Still a small trend for a decrease of cell viability was observed at high NP 
concentration (cNP > 50 nM). Data shown in the Supporting Information also for bigger Au 
NPs, rod-shaped Au NPs, and FeOx NPs further demonstrate that MSC labelling with NPs is 
possible without severely effecting cell viability. Cell viability however is not the most 
sensitive indicator for probing effects of NPs on MSCs. We thus carried out a NP-
concentration dependent proliferation assay, cf. Figure 4a. Relative cellular proliferation was 
significantly reduced for cNP = 50 nM, and in fact already at very low NP doses of 2 nM 
proliferation was shown to be affected. Another important parameter of MSCs to be 
maintained is their capacity to migrate. In several studies MSCs were used for homing and 
tracking experiments. Berlin et al. used for example Au NP-labeled neural stem cells (NSCs) 
to eliminate cancerous tissue via light mediated heat generation. For such applications 
migration of labeled NSCs/MSCs is mandatory. In Figure 4b we demonstrate that cellular 
migration through a porous membrane is affected in case cells have incorporated NPs. Our 
data suggest a dose dependent migration capacity of MSCs labeled with Au NPs. High 
concentrations of Au NP in MSCs may led to impaired homing. A significant negative effect 
was already visible for cNP = 50 nM. We note that in one study it is claimed that in contrast 
labelling of MSCs with FeOx NPs rather enhanced the migration capability the cells. Based 
on our data, we identified the least tolerable dose for 24 h exposure with 4 nm Au NPs to be 
around 10 nM. In order to probe if labeling of MSCs under these conditions affects the 
immunophenotype of MSC, expression of surface antibodies was determined by flow 
cytometric analysis. Au NP labeled hMSC proved to express the characteristic antigens 
CD73, CD90 and CD105, but lacked expression of CD14, CD19, CD34, CD45 and HLA-DR 
as shown in Figure 5. The immunophenotype of hMSCs labeled under these conditions is in 
accordance with the consensus criteria for MSCs [33]. This is in line with results obtained by 
Mailänder et al., who showed no impact on lineage markers and differentiation (Brüstle et al 
2015) upon NP labelling of MSCs. Thus, at reasonable Au NP concentrations (i.e. 10 nM for 
4 nm Au NPs), the NP labeling does not interfere with the immunophenotype and does not 
cause long-term cytotoxicity. However, our data reveal onset of negative effects on 
proliferation and migration potential already at these concentrations. This demonstrates that 
the amount of Au NPs which can be reasonably added as label per cell is clearly limited, 
which effects the maximum contrast which can be obtained for imaging. 
                                   
3.3. Limits of MSC detection with ICP-MS 
 
Using the above determined parameters for NP labelling of MSCs we wanted to 
determine the limits of detection of MSCs via NP labelling. We chose ICP-MS as 
detection technique, as it is a frequently used tool for determining of bio-distributions, in 
particular of Au NPs. With our set-up the detection sensitivity was determined to be 
around NMSC,limit ≈ 400 labelled cells. However, upon MSC homing MSCs actually will 
only form a small fraction of cells on the target site, and there will be many non labelled 
cells. For this purpose the fraction of labeled hMSCs (cNP = 10 nM, 24 h) in a population 
of 106 promyelocytic leukemia cells (HL-60) was varied do determine the number of 
MSCs required for verifying presence of MSCs. According to the data shown in Figure 6 
cell numbers down to 400 labeled MSCs/106 HL-60 cells are resolvable. This corresponds 
to 0.04% hMSC in a mixture of 1x106 unlabeled HL-60 cells. In addition the ratio 
between labeled expected cell numbers under optimal conditions and detected hMSC via 
ICP-MSC was linear (cf. Figure 6). This allows for some estimation about the minimum 
tissue volume Vmin which can be detected via homing of MSCs. A mentioned a highly 
relevant parameter is the amount NMSC of MSCs which can be integrated in tissue with 
Ncell cells, i.e. the ration NMSC/Ncell. In case one assumes a mean value Vcell for the volume 
of one cell, the tissue volume which can be resolved would be Vmin = 
Vcell·NMSC,limit/(NMSC/Ncell). In case of tumor homing of MSCs the fraction of MSCs inside 
the tumor will be relatively low. Using the experimentally determined value NMSC,limit ≈ 
400 and the numbers NMSC/Ncell = 10-5 and Vcell = 100 µm3 as example, the smallest 
structure which can be detected would be Vmin ≈ 4·109 µm3 = (1.6 mm)3. This would be 
the minimum size of a tumor which could be detected with ICP-MS upon MSC homing. 
In case of reseeding decellularized templates for implants all cells in the implant would 
be MSCs, and thus NMSC/Ncell = 1. Thus would result in Vmin ≈ 4·104 µm3 = (34 µm)3. 
While in this study ICP-MS was used for detection  
 
 
4. Conclusions 
 
On the first glance, the physical properties of Au NPs for MSC labeling seem well suited 
when looking on the potential perspectives for further applications in diagnosis and therapy. 
However, due to certain critical impacts on cellular function, their usage requires careful 
adaption of concentrations and a correct judgment of side effects to avoid a reduction in 
proliferation or migration. Both are essential parameters for successful application in vivo. 
While in this study we demonstrated that incubation of MSCs with Au NPs can have 
profound effects on the proliferation and migration the MSCs, the detailed molecular 
pathways were not investigated so far. In particular one may speculate that part of this 
impairment could be recovered over time. In fact research in this field is just in its beginnings 
and a large number of additional effects need to bee considered. MSCs administered 
intraveneously have shown to be prone to be stuck inside the lungs, while intraaterial 
administration seems to prevent this ‘first-pass’ effect [34-36]. Whether this unwanted effect 
is for example enhanced in Au NP labeled MSCs is subject of future studies.   
 
One potential advantage of using NPs as labels for MSC tracking is the potential of 
multiplexed detection. Different types of cells can be labelled with different types of NP, thus 
allowing for parallel imaging of different cells types. NPs of different materials, e.g. besides 
Au NPs also Pt NPs can be distinguished by ICP-MS as well as by CT imaging. 
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Figure 1: Quantitative determination of uptake of Au NPs by a) hMSCs and b) rMSCs. a) 
hMSCs were incubated with Au NPs (dc = 4 nm) at varying concentrations (cNP = 2 – 100 
nM) for different exposure times (5 h, 24 h, 48 h). After washing the mass mAu of 
intracellular Au was determined by ICP-MS and was normalized to the initial number of 
cells. Results are presented as mean value ± standard deviation (SD). b) rMSCs were 
incubated with fluorescence- labelled Au NPs (dc = 4 nm; TAMRA in PMA shell) at varying 
concentrations (cNP = 2.5 – 50 nM) for different exposure times (2 h, 4 h, 24 h, 48 h). The 
amount of intracellular Au mAu was assumed to be proportional to the TAMRA fluorescence 
as recorded from each cells as determined by FCM. The results shown correspond to the 
mean value ± SD from at least three independent experiments using cells from different rats.  
 
Figure 2: Endocytic uptake and exocytosis of Au NPs by MSCs. a) Localization of 
endocytosed rMSCs. rMSCs were incubated for with Au NP (dc = 4 nm) for 24 h at a NP 
concentration of cNP = 25 nM. Control rMSCs were not incubated with NPs. TEM images 
were recorded. The scale bars in the micrographs correspond to 2 µM (left) and 500 nM 
(right), whereby images on the right represent enlargements of the black quadrant in the 
images on the left. Prensence of NPs in intracellular vesicular structures can be seen. b) 
Exocytosis of hMSCs. hMSCs were exposed to Au NPs (dc = 4 nm) at the indicated doses cNP 
for 24 h or 48 h. After washing off residual NPs from the medium and the outer cell 
membran, i.e. NPs which had not been internalized by the hMSCs, culturing was continued in 
fresh growth medium for 24 h or 48 h. Then the amount of intracellular Au mAu (i.e. Au 
inside the cell pellet) and exocytozed Au (i.e. Au in the medium) mAu,exo was determined by 
ICP-MS. Then the fraction of exocytosed Au NPs was determined as mAu,exo/(mAu,exo + mAu) 
=  mAu,exo/(mAu,tot). For cells labeled with cNP = 2 nM (°) the Au content in the cell medium 
was below the detection limit. 
 
Figure 3: Viability of a) hMSCs and b) rMSCs after uptake of Au NPs (dc = 4 nm). MSCs 
were exposed to various concentrations cNP of Au NPs different incubation times t. Cell 
viability V was assessed using the Alarm Blue assay. The viabilities are normalized to the 
viability of cells which had not been exposed to NPs. Results are presented as mean value ± 
SD. In the case of rMSCs n = 3 (for 24 h and 48 h exposure) and n = 2 (for 72 h exposure) 
independent experiments using cells from different rats were carried out. No statistically 
significant differences were detected using one way ANOVA.  
 
 
 
Figure 1: a) Effect of Au NP exposure on hMSC proliferation. b) Proliferation ratio P upon 
exposure to Au NPs normalized to that of untreated cells (= positive control Ctr+ cNP = 0). As 
negative control Ctr- a mitosis inhibitor was used. Proliferation of hMSCs exposed to cNP = 
50 nM was significantly reduced (p < 0.05). b) Effect of Au NP exposure on hMSC migration 
through a membrane. The migration efficiency after exposure to Au NPs is displayed as the 
ratio of the number of migrated cells Nmig divided by the the total cell number, which is the 
sum of non-migrated cells Nnon-mig and migrated cells: Ntot = Nmig + Nnon-mig.  As negative 
control Ctr- ... was used. Migration of hMSCs exposed to cNP = 25 nM was significantly 
reduced (p < 0.0001). 
 
Figure 5: Effect of internalized Au NPs on the surface marker expression of hMSCs. 
Representative histograms of the distribution of the marker fluorescence N(Imarker) of MSC-
defining surface markers of untreated hMSCs (black solid line) and hMSCs exposed to cNP = 
10 nM (red dashed line) Au NP for 24 h are shown. The solid grey front curve represents the 
isotype control.  
 
 
Figure 6: Detection of Au NP-labelled hMSCs with ICP-MS. NMSC = 0-100,000 hMSCs 
labeled with cNP = 10 nM of Au NPs for 24 h were mixed with NHL = 1 x 106 unlabeled HL-
60 cells. The then the number NMSC,detect of hMSCs in the mixture was deteted with ICP-MS. 
The dashed line represents the expected results under optimal conditions. The Au noise 
background level was corresponding to ~400 labelled cells.   
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Abstract
The interfacing of colloidal nanoparticles with mammalian cells is now well into its second decade. In this review our goal is to
highlight the more generally accepted concepts that we have gleaned from nearly twenty years of research. While details of these
complex interactions strongly depend, amongst others, upon the specific properties of the nanoparticles used, the cell type, and their
environmental conditions, a number of fundamental principles exist, which are outlined in this review.
Introduction
There is a multitude of reports about the interaction of colloidal
nanoparticles (NPs) with mammalian cells [1], as this topic is
important for analyzing intended (e.g., medical applications
[2-4]) and non-intended (e.g., contamination [5-7]) exposure of
NPs to humans. However, there is a great number of available
NPs made of many different materials [8-10] with a wide range
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Figure 1: An overview of the “zoo” of different NPs concerning their composition, functionality, and fields of application. Reproduced with permission
from [11]. Copyright (2011) American Chemical Society.
of different functionalities, cf. Figure 1. For a classification of
NPs according to their composition, functionality, and fields of
application we refer to a recent review [11]. To complicate the
situation, most NPs do not consist of only one substance, but
typically are hybrid materials, involving surface coatings and
other modifications [12], cf. Figure 2 [13]. Even a homoge-
neous NP formed out of only one material will turn effectively
into a hybrid NP, when it is brought into contact with any bio-
logical system (e.g., biological media) because of an organic
coating that will form on the surface of the NPs [14]. This all
illustrates that virtually no two types of NPs are the same and
their inherent structure, properties, and constituent materials
will contribute to the way in which they are taken up by cells.
For example, a 20 nm diameter polymeric dendrimer may be
very flexible, whereas a 20 nm metal NP may not, which leads
to different interaction with cells. Furthermore, all of these
different NPs can be exposed to different cells (e.g.,
macrophages, endothelia, and tumor cells) under different expo-
sure scenarios (in vitro and in vivo), which as a consequence
culminates in a large, but diverse body of work reported in the
literature [15-17]. Due to this overwhelming amount of data, it
is not easy to obtain a comprehensive overview. Many studies
focus on the details of particular systems, but those can dramati-
cally vary from case to case, and even conflicting trends are
reported [17]. In addition, results will depend on the cellular test
model used. In order to simplify the discussion, this review
focuses on in vitro interaction of NPs with adherent,
mammalian, immortalized cell lines. This avoids for example
the problem of having to discuss how NPs reach and penetrate
tissue, which makes in vivo scenarios more complicated than in
vitro test systems. Despite these issues, it is still possible to
discern some general trends, as described within this review.
However, a limitation to having general trends equates to being
permissive of some specific details, though common agree-
ments reported here are clearly not trivial. It also automatically
involves the possibility that studies exist, which under particu-
lar experimental conditions claim the opposite to the general
statements. The most important of these trends will be
discussed. In this regard, the current review will focus on
physicochemically defined NPs, i.e., solutions of monodisperse
NPs with a defined ligand shell attached, and without residual
“left-over” impurities of the NP synthesis [13,18].
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Figure 2: Hybrid nature of typical NPs, comprising different structural
compartments. Reproduced with permission from [13]. Copyright
(2013) American Chemical Society.
Review
How do particles enter cells and where do
they go?
Virtually all cell lines internalize NPs, which are dispersed in
the growth medium [19]. Uptake of different NPs by different
cell lines, however, can vary significantly in biological kinetics
[20-22] (this is also true for larger microparticles [23]). This is
particularly important to keep in mind for specific (i.e.,
targeted) NP uptake, in which NPs modified by ligands (such as
folic acid), which bind to appropriate receptors on the cell
surface (such as folate receptors [24]), are specifically internal-
ized [25]. Ligand-mediated uptake (which depends also on the
ligand “valence”, i.e., the number of ligands per NP, their
density, and their orientation [26]) is faster and more efficient
than non-specific (i.e., not receptor-mediated) uptake [27,28],
although also plain or non-targeted NPs will be incorporated by
cells. Thus, an important parameter to compare amongst
studies, in which specific uptake is reported, is the time scale
used within the experimental approach. While after short times
of exposure huge differences in the amount of incorporated NPs
can exist (e.g., between ligand-modified and plain NPs), those
differences typically become less significant after longer expo-
sure times [29], e.g., by the presence of the protein corona [30],
as will be discussed later in more detail. Thus, statements which
claim that only specifically modified NPs, but not non-modi-
fied NPs are taken up by cells, have to be regarded highly criti-
cally and put into the correct context of the reported time-scale.
In fact, differences in uptake are not digital (i.e., "yes" or "no"),
but rather are based on different kinetics. However, non-adhe-
sive cell lines, i.e., cell suspensions, can be different and exam-
ples in which no significant internalization of NPs happened are
reported [31]. Coming back to adhesive cell-lines, the first step
in NP internalization obviously is the contact of the NP with the
cell plasma membrane. This is a concentration-dependent
process, which for high NP concentrations no longer
scales linearly with concentration (i.e., saturation effects may
occur). The first association of a non-targeted NP with a cell
surface is usually electrostatic. Positively charged NPs are, for
example, believed to interact with surface-displayed heparan
sulfate proteoglycans [32,33]. As a rule of thumb, NPs which
strongly interact with the cell plasma membrane, be it by
ligand–receptor-mediated or by charge-mediated adhesion, are
also internalized more efficiently [34]. Non-fouling polyeth-
ylene glycol (PEG)-modified NPs, for example, stick less to the
cell plasma membrane and are, therefore, incorporated by cells
less efficiently than other NPs [35-37] (this is also true in vivo
as manifested by enhanced retention times [38]). It is clear that,
while there are a number of portals through which NPs can gain
entry into the cell, they all have as the common denominator the
cell plasma membrane. Thus, the NP either must translocate
(diffuse) directly across the cell plasma membrane entering the
cytosol, or it must be internalized via any of the several routes
of cellular endocytosis. While some evidence exists to support
the direct membrane translocation of a select number of NP ma-
terials (typically partly hydrophobic and very small, as
discussed later) the overwhelming evidence to date supports
endocytosis as the common route of NP uptake. Thus, once NPs
are associated to the outer cell plasma membrane they are typi-
cally internalized by endocytosis [39,40]. While a variety of
different endocytotic pathways exist, which can be quite
different in detail (to appreciate the complexity of endocytosis,
we refer the reader to the review by Iversen et al. [41], cf.
Figure 3), all of them have in common that the NPs are
surrounded by membrane. Pinching-off of the membrane-
surrounded NPs from the cell plasma membrane leaves the NPs
incorporated into intracellular vesicles. These vesicles undergo
a cascade of intracellular trafficking steps passing the NPs to
more and more acidic vesicles [42,43], which also comprise
enzymes specialized in digesting nutrition (and thus also parts
of the NPs are digested in the lysosome [44,45]). In other
words, after incorporation, the majority of NPs is not “free” in
the cytosol, but inside intracellular vesicles (cf. Figure 4). Inside
those intracellular vesicles the NPs are in an environment
(acidic pH, enzymes) completely different from that in the
cytosol (cf. Figure 5). Endocytosis and the endosomal escape
dilemma have to be taken into account in particular concerning
the delivery applications of NPs, in which the goal is to deliver
something to the cytosol. Getting stuck inside intracellular vesi-
cles is redundant to the purpose of these applications. However,
in contrast to endocytosis as described so far, studies exist in
which it is claimed that NPs can directly translocate through the
cell membrane, thus indicating alternative pathways for NPs to
penetrate the cell plasma membrane [46,47]. Besides other
possible mechanisms, passive diffusion through (transient)
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Figure 3: Scheme depicting the different mechanisms of cellular endocytosis. Reproduced with permission from [41]. Copyright (2011) Elsevier.
Figure 4: Fluorescence microscopy image showing the granular struc-
ture of internalized NPs inside A549 lung cancer cells (two types of
iron oxide NPs with different surface chemistry, labelled with different
fluorophores (green and magenta)) after 24 h of incubation at a
concentration of 1 µg/mL, which are located in individual vesicles.
Nuclei are stained with DAPI (blue) and the cell membrane with Wheat
Germ Agglutinin (red). Note that due to limited lateral resolution of
optical microscopy the spots most likely do not correspond to indi-
vidual NPs, but to several NPs, which are entrapped inside intracel-
lular vesicles. The scale bar represents 5 μm. Adopted with permis-
sion from [65] und Creative Commons Attribution 4.0 International
Public License.
membrane pores and passive uptake by van der Waals or steric
interactions (subsumed as adhesive interactions) have been
suggested [48]. Still, it is always important to interpret such
studies critically [49]. Most of the time studies involve an
Figure 5: a) A microparticle has been internalized by an A549 lung
cancer cell into an intracellular vesicle (here the lysosome [165]) and is
thus clearly localized. The microparticle is filled with a pH-sensitive
fluorophore (SNARF, from Invitrogen, now LifeTech) linked to dextran
and the acidic pH of the lysosome is reported by the yellow fluores-
cence. b) After release of the pH-sensitive fluorophore linked to
dextran to the cytosol (by photothermal heating), the
fluorophore–dextran conjugates are freely dispersed, without any
visible granular structure. Due to the neutral pH in the cytosol the fluo-
rescence of the fluorophore–dextran conjugates has changed to red.
The scale bar corresponds to 10 μm. Adopted with permission from
[166]. Copyright (2012) Elsevier.
analysis of intracellular NP distributions, i.e., they rely on
images showing NPs distributed in the cytosol. Additionally,
these studies often rely on the observation that cellular NP entry
still occurs below physiological temperatures (e.g., 4 °C), at
which endocytosis and the active transport machinery are abro-
gated. However, without probing also for vesicular membranes
around the NPs it is complicated to claim that the NPs in fact
have passed the cell plasma membrane as "naked" NPs, without
having ever been inside any intracellular vesicle. Clearly, there
are a lot of indications (e.g., simulations) that NPs can enter
cells through transient pore formation, in particular very small
NPs [50,51]. Still, in many publications experiments do not
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unequivocally demonstrate this pathway, though it surely exists.
One possibility of experimental modification would involve, for
example, pH-sensitive fluorophores (such as SNARF [52,53])
attached to the surface of the NPs, which can distinguish
between the neutral cytosol and highly acidic intracellular vesi-
cles [54]. In a similar direction the reductive capacity of
glutathione (the cytosolic concentration of which is between 5
and 10 mM) may be used to displace a fluorescence resonance
energy transfer (FRET) acceptor on the surface of the NP as
confirmation of a successful NP localization to the cytosol [55].
Such experiments are in particular important for distinguishing
between direct translocation to the cytosol versus endocytotic
uptake followed by endosomal release. In fact, while there is
clear experimental proof that NPs can be transported to the
cytosol, the most straightforward pathway is uptake through
endocytosis followed by release from the intracellular vesicles
to the cytosol [56-58] (and not the diffusion through (transient)
membrane pores). Endosomal release is, for example, a scenario
which has been unraveled in detail for NPs coated with certain
cell penetrating peptides (CPPs) [59-62]. Thus, while NPs can
be free in the cytosol, this clearly does not automatically
involve that they are membrane-permeable and not endocy-
tosed. As pointed out above, observations based on merely
measuring intracellular NP distributions are not sufficient for
making profound statements about the uptake pathway. On the
other hand it is safe to say that different intracellular locations
for NPs exist. NPs have been reported in different intracellular
organelles such as mitochondria, the nucleus, and free in the
cytosol [63,64]. Most of the time such intracellular distribu-
tions are analyzed with transmission electron microscopy
(TEM), in which also the structure of the intracellular
organelles can be resolved (cf. Figure 6), or with fluorescence
microscopy, in which the intracellular organelles have been
co-stained with a fluorescent marker [65-67]. However, these
data have to be interpreted carefully. In particular, such data
should always include a quantitative distribution analysis,
which is highly time-consuming. Even plain NPs without any
particular surface capping can be found free in the cytosol [68],
however, only to a very low extent. Thus, images in which NPs
are shown in some particular intracellular organelles are only of
limited value if the fraction of NPs that resides in these
organelles is not quantified. Quantification, however, is not as
trivial as it seems, and there is a need for better quantitative
techniques for the future. While TEM offers the lateral resolu-
tion to visualize individual NPs, typically only a limited amount
of cell sections (i.e., thin slices cut from cells) can be observed
and thus for an absolute quantification, which is highly time-
consuming, stereological tools need to be employed [68,69].
Also in case of TEM studies knowledge and understanding of
cells under TEM conditions is essential. Fluorescence, on the
other hand, can be recorded quantitatively by assuming that the
Figure 6: Intracellular compartments after internalization of PEG-
coated gold NPs as visualized with TEM. The NPs (which are individu-
ally resolved due to the high lateral resolution of TEM) are located
within a lysosome (arrows I) and in the cytosol (arrow II). m and n
demark the nucleus and mitochondria, respectively. The scale bar
corresponds to 500 nm. Adopted from with permission from [68]. Copy-
right 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
emission intensity is proportional to the number of NPs.
However, fluorescence can be partly quenched in certain
organelles (for example at low pH), and it is impossible to
resolve individual NPs due to the limited lateral resolution of
optical microscopy [70]. In addition, as mentioned before, NPs
can be partly degraded after having been internalized [71,72]
and thus, in case fluorescently labeled NPs are used, it is
required to prove that the fluorescence (or any other) label is
still attached to the NPs inside the cells. Otherwise the recorded
intracellular distribution of fluorescence may originate from
detached labels and thus would not reflect the distribution of the
NPs [73]. Summarizing available data suggests that, while
translocation from intracellular compartments to the cytosol and
from there to other cellular organelles is possible, translocation
efficiencies still are moderate at best. In addition, NPs free in
the cytosol may later end up again in intracellular vesicles
through auto-phagocytosis [74]. Thus, for many applications,
such as intracellular sensing or drug delivery, translocation of
NPs to the cytosol after spontaneous endocytotic uptake
remains a major challenge. External stimuli may be helpful in
this direction [75]. In order to close this section it is also impor-
tant to think about what happens after endocytotic uptake. It is,
for instance, often overlooked that there is an eventual loss of
the total NP load per cell as a result of mitotic division, NP
exocytosis, and NP transcytosis [76]. This is largely due to the
fact that in most experimental systems the primary issues
addressed are uptake efficiency of the NPs and subsequent
intracellular fate. These parameters are typically asked over the
time course required for NP internalization and subcellular
localization, and are not tracked over long time courses. It is
generally accepted that NPs are partitioned during cell division,
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in which they are passed to the daughter cells [76,77]. Such
dilution effect of NP labels is in particular important for studies
involving NPs as long-term tracers. Here, the relevant question
arises whether upon cell division NPs are passed 50/50 to each
daughter cell. Summers et al. have done both a theoretical [78]
and experimental assessment [79] showing that, while parti-
tioning of endosomes to daughter cells is symmetric, the
number of NPs per endosome is a distribution and therefore NP
partitioning to daughter cells is asymmetric. Thus, after several
division cycles the NP distribution will not necessarily be
representative for the fate of the original “mother” cells
anymore. NPs also can be excreted to the extracellular medium,
which represents an additional source of NP dilution effects.
While endocytosis of NPs has been investigated heavily there
are only a limited number of reports investigating exocytosis of
NPs [80-82]. Excretion of NPs in exosomes (i.e., membrane
surrounded vesicles), however, clearly affects the long-term
cellular loading with NPs. In addition, for some particular cells,
transcytosis has also been reported, i.e., that NPs are passed
from one cell to another one [83].
What are the critical parameters involved in
in vitro nanoparticle internalization?
As mentioned before, virtually all NPs are spontaneously inter-
nalized by adherent cells, mainly cell lines, that are usually
grown on a certain support and covered with cell culture
medium under static conditions. In this case, NPs in the medium
can directly access cells, and issues like tissue penetration,
which need to be considered in in vivo experiments, can be
neglected. The kinetics of internalization can depend strongly
on the physicochemical properties of the NPs, the type of cells,
and other parameters. Cellular uptake studies of NPs require as
much characterization of the NP materials as currently possible.
Concerning the NPs, this is, unfortunately, hampered by our
incapability to synthesize “defined” NPs. For quantitative
studies NPs and their bioconjugates should be as monodisperse
as possible with regard to all relevant parameters, such as
charge and size, well-defined and well-characterized. Moreover,
in the case of bioconjugates, the biological molecule, be it
protein or drug, should be attached to the NP with control over
orientation [84,85], density, affinity, and number or ratio per
NP [85]. Although these goals are extremely hard to achieve,
the more they can be fulfilled, the less heterogeneity is present
in the NP material and the easier the results (i.e., the correlation
between the properties of the NPs and the observed interaction
of NPs with cells) can be interpreted [13,18,86]. With limita-
tions, a correlation of the spontaneous endocytotic uptake of
NPs to the physicochemical properties of the NPs can be found.
One, however, has to be aware that many physicochemical
properties of NPs, such as size, shape, charge, and colloidal
stability are highly entangled [14]. The physicochemical prop-
Figure 7: TEM images of a) dispersed and b) agglomerated Au NPs.
The scale bars correspond to 100 nm. Adopted with permission from
[30]. Copyright 2014 Royal Society of Chemistry.
erties are not intrinsically associated with the NPs, but result
from the interaction of the NPs with the surrounding particular
medium [87]. The colloidal stability is presumably the most
influential parameter. NPs with low colloidal stability will
agglomerate and thus, originally "small" NPs will transform
into agglomerates, resulting in large particles presented to the
cells (cf. Figure 7). However, “colloidal stability” is not a
defined physicochemical entity such as size, but needs to be put
in context with the measurement protocol, such as the tendency
to agglomerate. Any correlation to the size of the NPs without
any previous demonstration of colloidal stability in the incuba-
tion medium has to be seen very critically. Loss of colloidal
stability during incubation also complicates dosimetry. If NPs
are quantified in numbers, is an agglomerate of NPs considered
to be one particle or the number of NPs in the agglomerate
[14]? Agglomeration can have direct consequences on cellular
uptake [62]. If the cell cultures are turned upside-down, i.e., the
cells are hanging in the culture medium, NP agglomerates that
have precipitated at the bottom would not reach the cells and
thus the effective NP concentration would be dramatically
reduced [88]. In contrast, in conventional geometry, in which
the culture medium is on top of the cells, a reduced colloidal
stability leads to the precipitation of NP agglomerates onto the
cells and, thus, to enhanced uptake, which can influence the cell
viability negatively [89]. Such different exposure scenarios are
highly relevant for the prediction of NP interactions, for
instance, in the human body or in ecotoxicology. Some NPs
have been mistaken to elicit limited to no adverse effects upon
zebrafish assays, as they had precipitated to the bottom, and
thus, the fish had not been directly exposed to them. After
correct solubilization, however, the same NPs turned out to be
highly detrimental to zebrafish health [90]. Colloidal stability
does not only interfere with size but also with other parameters
such as shape. An agglomerated bundle of sharp NPs may no
longer be "sharp". Thus, colloidal stability is the paramount
parameter to consider for all correlations between the NP–cell
interactions and the physicochemical properties of the NPs.
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Reports, in which no characterization of colloidal properties has
been performed, therefore have to be regarded very critically.
Unfortunately, many NPs are not colloidally stable in cell
culture media [91]. The reason is that many NPs are stabilized
by charge (in contrast to stabilization through steric repulsion).
Salt (in particular NaCl, which always is present at high
concentration) in the media screens the NP charge and thus can
cause agglomeration [92]. Consequently, data which demon-
strate that NPs are colloidally stable in water do not provide any
proof that the same NPs also will be stable in cell culture media.
Besides salt, proteins are another key compound of (serum-
containing) cell media. As discussed later in more detail,
proteins adsorb to the surface of NPs, forming the so-called
protein corona [93,94], which in fact can increase or reduce
colloidal stability [95,96]. Thus, characterization of colloidal
stability and other physicochemical properties of NPs needs to
be carried out under the same conditions under which later on
cells are incubated with the NPs (i.e., in the respective cell
culture media [86,97,98]). Obviously, NPs also should be
appropriately purified [99], as otherwise effects from impuri-
ties rather than from the NPs themselves cannot be excluded.
Unfortunately, for unstable NPs (e.g., for NPs to which the
organic surface capping is only loosely attached) purification
can trigger a loss of colloidal stability and thus agglomeration
[14]. As lack of colloidal stability can overrule the other para-
meters, the following discussion about dependencies of other
parameters is done assuming colloidally stable NPs. Uptake of
NPs into the cells clearly depends on the size of the NPS. In
general, smaller NPs are incorporated by cells faster than bigger
ones, though there is some kind of size limit, i.e., the trend does
not continue down to ultrasmall NPs [40,100]. As mentioned,
upon endocytosis NPs are first wrapped by cellular membrane.
Due to intrinsic stiffness and other parameters for membrane
bending the radii of curvature cannot become infinitely small,
and thus, there is an optimal NP size [101,102]. Excluding
ultra-small NPs (smaller than 2–3 nm), smaller NP (smaller
than 20–25 nm) are internalized readily in endosomes with most
rapid kinetics [103]. Larger NPs (smaller than 60–70 nm) are
internalized with lower kinetics to the extent that they are
largely associated to the cell membrane over the time courses
that see an intake of smaller NPS [62]. This has also been
shown in fixed, permeabilized cells (to eliminate cell uptake
machinery and pathways) to directly assess the size restrictions
of plasma and intracellular membrane barriers on NP passage
[104]. In contrast, ultrasmall NPs may be small enough to
become membrane-permeable and thus bypass endocytotic
uptake. Size-dependent uptake has also been reported for in
vivo scenarios [105]. However, in particular for statements
concerning size-dependent internalization, the experimental size
determination of NP is important. Unfortunately, this is not a
straightforward task, as different techniques measure different
types of sizes. TEM only provides the geometric size of the NP
core which has sufficient contrast, but organic surface cappings
are typically not included [14]. In solution there is adsorption of
counter ions to the NP surface [106,107] and organic surface
coatings can swell, which results in hydrodynamic diameters
larger than the core diameters as determined with TEM. There
are several techniques for determining the hydrodynamic diam-
eters of NPs [108], of which dynamic light scattering (DLS)
might be the most common approach. All techniques have their
limitations, and it is always helpful to know the measuring prin-
ciple they are based on. DLS, for example, is based on calcu-
lating autocorrelation functions of the light-scattering signal of
the solution. In order to obtain quantitative values, these auto-
correlation data need to be fitted with a model, which is, for
example, often done by assuming free diffusion of three NP
species of different size. Thus, the results are based on the
model (which is hidden as "black-box" in the software). To give
an example, in case three species are assumed one always will
obtain three peaks in the size distribution spectra, even though
the sample may contain more different NP species. From the
model, diffusion coefficients are yielded as fit parameters,
which can be converted to hydrodynamic diameters by the
Stokes–Einstein relation. As NPs of larger size also scatter light
much more than smaller NPs, the results for DLS-derived size
distributions also are quite different depending on whether
number or intensity distributions are reported. Thus, simply
taking the mean hydrodynamic diameter as displayed by
commercial set-ups is prone to errors [109]. Calibration stan-
dards of NPs of known size are always a good help to bench-
mark size measurements and it is highly beneficial to apply
several techniques in parallel [108-110]. By applying existing
techniques correctly, the hydrodynamic diameters of NPs can
be determined with remarkable accuracy, in particular if rela-
tive size changes are determined. Detection can be sensitive
enough to resolve size-changes due to the attachment of indi-
vidual macromolecules to the NPs [84,85,111,112]. Besides
size, also shape has been proven to modulate the NP uptake of
cells. In general, elongated, sharp NPs (i.e., NPs with a prolate
spheroid shape) enter cells better than flatter NPs (i.e., NPs with
an oblate spheroid shape). This however does no longer hold for
very long fibers with high aspect ratios [100]. Flattening of NPs
has been used, for example, to reduce NP uptake by cells in a
way that flat NPs just adhere to the plasma cell membrane like a
“backpack”, without being internalized, in contrast to spherical
NPs that are readily incorporated [113,114]. Concerning a third
parameter, charged NPs usually are internalized more effi-
ciently than neutral ones, presumably due to enhanced charge-
mediated adhesion to the outer cell membrane. Note that the
charge pattern of the plasma cell membrane is patchy, and thus,
while the overall net charge of cells is negative, there are plenty
of positively charged domains. However, due to the overall
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negative net charge, positively charged NPs are typically incor-
porated more efficiently by cells than negatively charged ones
[65,97,115-119]. Indeed, the current consensus is that positive
charges on NPs, such as those provided by the TAT peptide or
surface functionalization, interact initially with the negatively
charged heparan sulfate proteoglycan groups on the exterior of
the cells. This allows them to then be present on the plasma cell
membrane as endocytosis starts. Thus, while details may be
very complex, clearly some tendencies for which physicochem-
ical parameters enhance the spontaneous endocytosis of NPs
can be given. In general, small, elongated, and positively
charged NPs are incorporated preferentially to big, flat, and
uncharged NPs. Dependency on other physicochemical parame-
ters such as stiffness [120] has not been investigated exten-
sively yet.
The role of the protein corona
In serum-containing media or inside cells all different types of
biologically relevant molecules adsorb to the surface of NPs.
i) Ions such as H+, Na+, K+ or Ca2+ in the case of negatively
charged NPs, or Cl− in the case of positively charged NPs
adsorb to the NPs. As a consequence of counter ion adsorption
the local ion concentration around the NPs surface is different
from the bulk [54,87,106,107]. ii) Also nucleic acids, such as
mRNA or siRNA, which are negatively charged due to their
phosphate groups attach to positively charged NPs [121,122].
iii) Lipids present in membranes or second-messenger lipids
wrap around NPs driven by hydrophilic/hydrophobic inter-
action and often result in formation of micelles [123,124].
iv) Thiols, present in glutathione or reduced proteins bind to the
surface of noble metal NPs, in particular to Au NPs [125,126].
v) Proteins, in general, tend to adsorb to surfaces, which is also
true on the nanometer scale. Adsorption of albumin is, for
example, an integral part of opsonization [127,128]. The
proteins adsorbed to the surface of NPs are typically termed
protein corona [93,94]. The protein corona has a significant
impact on how NPs interact with cells and thus will be
discussed in the following in more detail. NPs can, in principle,
be synthesized in water without any organic surface coating, for
example by laser ablation [129-131]. However, also to NPs just
stabilized by their surface charge (which can be directly on the
inorganic surface) proteins will adsorb in serum-containing cell
media and in this way can provide additional colloidal stability
[129]. Therefore, there are no "naked" NPs in serum-containing
cell culture media and inorganic NP cores are always
surrounded by an organic coating [14]. Adsorbed proteins can
significantly alter the surface properties of NPs and are of key
importance in defining the biological identity of NPs [132,133].
The corona formed around NPs is what the cell will “see”
primarily, though certainly also the original properties of the
underlying NPs determine interactions with the cells [97]. In
general, adsorbed proteins "smear out" differences in the
surface chemistry between different NPs. Thus, typically two
different types of NPs show more pronounced differences in
their interaction with cells in case exposure is done in serum-
free media (i.e., without proteins) rather than in serum-
containing media [97]. The effect of ligands immobilized on the
surface of NPs designated for ligand–receptor-mediated uptake
is diminished by the protein corona, which partly overcoats the
ligands [134]. However, due to the fact that specific targeting
still is possible [84], enough ligands still are biologically active.
For highly defined NPs, such as nearly monodisperse NPs over-
coated with a shell of an amphiphilic polymer [135], the corona
formed by special model proteins can be surprisingly well orga-
nized. By using fluorescence correlation spectroscopy (FCS),
Röcker et al. investigated the adsorption of human serum
albumin onto FePt NPs and found clear evidence that the
proteins formed a monolayer on the surface of the NP [136].
Additional FCS studies by using other important serum proteins
invariably confirmed the formation of monolayer. The thick-
ness of the monolayer could be related to the molecular dimen-
sions of the adsorbed protein determined by X-ray diffraction.
All proteins studied were found to adsorb in a specific orienta-
tion determined by local charge distributions on the protein
surface [20,137,138]. However, adsorption of proteins to the
surface of NPs is not only driven by the basic physicochemical
properties of the NP such as size, shape, surface charge, but also
by other parameters such as the incubation temperature [139].
While model systems involving only one type of NPs and one
type of protein help to analytically quantify protein adsorption,
such as by determining binding constants [30,136], the bio-
logical reality is more complex. Serum-containing cell culture
media comprise hundreds of different proteins. To make it
worse to analyze, protein adsorption is also a dynamic process.
Thus, proteins which are initially bound to the NP surface can
later be replaced by others [140,141], which also is referred to
as the Vroman effect [142]. It has been shown, for example, that
surfactant lipids bound on multiwall carbon nanotubes are
replaced with blood plasma proteins after a subsequent incuba-
tion [143]. Mass spectrometry is an invaluable tool for quanti-
fying the amounts of different adsorbed protein species
[140,141]. The dynamic exchange of proteins, induced by their
different adsorption kinetics and affinities to the NP surface is
reflected in the discrimination between "soft" and "hard" corona
[144,145]. The initial, soft corona is formed by the most abun-
dant proteins, which are then replaced by the high-affinity
proteins to yield the hard corona. It has been suggested that
differences for different protein species can be characterized by
their dissociation constants [30]. In a simple model the dissocia-
tion constant tells which protein concentration is required to
saturate half of the NP surface with proteins under equilibrium
conditions [30]. With simple treatments such as the Hill Model
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[146] one may characterize the protein corona around NPs with
only a few parameters, which would be a great help in
comparing results obtained with different systems, thus
allowing for a more comprehensive understanding. While the
protein corona around NPs has been heavily investigated these
data ultimately are only relevant for the first interaction of NPs
with cells. After spontaneous endocytosis NPs are inside intra-
cellular vesicles. This imposes a completely different environ-
ment than that of the extracellular medium, in particular low
pH, presence of endo-/lysosomal enzymes, and different
reducing agents [147]. Thus, after NP uptake the protein corona
around NPs may change significantly. The original proteins can
be displaced by other intracellular proteins, and even more
severe, part of the original protein corona may be digested
enzymatically [44,45,148,149]. Changes of the protein corona
in turn may also alter the physicochemical properties (such as
colloidal stability) of the NPs [96]. In this manner, for a full
understanding of NP interaction with cells along the pathway of
NP uptake the physicochemical characterization of NPs should
also be done intracellularly, which, however, is complicated.
This opens up a window for future research efforts.
Toxic effects of NPs
NPs clearly can trigger toxic effects in cells such as cytotoxi-
city, oxidative stress, (pro-)inflammation, and genotoxicity
[150-152]. While again the detailed mechanisms are very com-
plex and by far not understood in a comprehensive way, yet
again there are certain characteristic features [153]. Toxic
effects can result from the NPs themselves (e.g., by their
catalytic surface or by their organic coating, such as in the case
of cetyltrimethylammonium bromide (CTAB), a surfactant
commonly used to synthesize gold nanorods) or by ions
released from the NPs [154,155]. Ion release from certain ma-
terials such as Ag, ZnO, or CdSe is in particular triggered by the
highly acidic pH in endo-/lysosomal compartments [156]. In
both cases adverse biological effects are typically correlated
with the production of reactive oxygen species (ROS)
[157,158]. Also membrane damage plays a decisive role. In
case of dissolvable NPs, the extent to which toxicity originates
from the NPs themselves and to which extent from released ions
is still subject to an intense scientific debate. Unfortunately, it is
experimentally complicated to separate both effects. Even if
before exposure all free ions were removed from the NP solu-
tion, inside cells new ions would be released. Thus, it is virtu-
ally impossible to have cells exposed exclusively to NPs
without free ions [87]. One may argue that on the other hand
cells could be exposed just to the free ions. While this is true,
exposure to free ions will result in different intracellular ion
distributions than the one obtained by ions which have been
released from the NPs intracellularly, which again complicates
direct comparison. Physicochemical properties can be, in some
way, correlated with NP toxicity. In other words, reporting toxi-
city without accompanying in-depth NP characterization is not
very useful concerning a detailed understanding of the mecha-
nism. Surface coatings and impurities in the NPs can play an
important role. Thus, also the coatings alone, as well as poten-
tial impurities need to be investigated towards potential toxic
effect in control experiments. If only the physicochemical prop-
erties of “pure” NPs are considered, NPs with low colloidal
stability have bigger effective sizes, thus are internalized to a
larger extent, and thus typically have a greater adverse bio-
logical impact [154]. In order to account for concentration
effects, it is advisable to correlate toxicity with particle internal-
ization by using adequate methods. Enhanced uptake is one
major reason (amongst others) why positively charged NPs
(which are incorporated to a higher extent) elicit an increased
adverse cellular effect compared to negatively charged ones
[97,117,118]. This opens a dilemma. While in general, positive
charge is better for enhanced uptake, too much positive charge
becomes so toxic that it outweighs the added benefit of
enhanced uptake. Thus, for delivery applications an optimum
between both effects has to be found. This opens up another
important point about the biological impact of NPs that merits
discussion. There is a big difference between the use of NPs for
cellular labeling or biosensing studies in research, as opposed to
any therapeutic (in vivo) utility, and the two should never be
thought of together or directly compared. It was, for example,
recently shown that semiconductor quantum dot NPs (QDs)
were unable to elicit a more negative biological effect when
used for cellular labeling than a panel of dyes commonly used
for the same intrinsic purposes [159]. Along with this, often
transformed and immortalized cell lines are used in biological
research, meaning that they are essentially cancerous. Thus,
what appears to be adverse biological impact in these experi-
ments has to be qualified with this context in mind. For cellular
labeling, perhaps, there is the need for a particular experiment
that should drive the issue of toxicity. If the use is specifically
for in vitro labeling, tracking or sensing, there are multiple
studies that have shown that over the time course required to
perform such studies, the impact on cellular viability/prolifera-
tion at appropriate NP concentrations is minimal and is often
comparable to or even less impactful than the use of traditional
materials designed for the same purpose [159]. In this case
“chronic toxicity” does not play a role, as the experiment is
terminated before such an effect may occur. In contrast, for in
vivo delivery one has to consider that NPs will remain in the
organism over extended periods of time [160], and thus, bene-
fits of treatment have to be weighted with long-term toxic
effects [161]. Consequently, toxicity of NPs always has to be
seen in the context of the applications the NPs are used for, but
furthermore, the potential accidental exposure beyond the appli-
cation has to be considered and its risk has to be assessed. In the
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context of this review we have focused on in vitro studies. The
advantage of such studies is the easy screening capability and
the possibility to monitor in detail biomolecular pathways and
changes in gene expression as a measure of a possible bio-
logically adverse response. In case NP toxicity is investigated in
a comprehensive study, however, involvement of in vivo exper-
iments is crucial.
Conclusion
Due to their interesting functional properties, numerous applica-
tions of NPs exist, e.g., plasmonic NPs [2,75], magnetic NPs
[162,163] or fluorescent NPs [164]. For optimizing NP prop-
erties for biological applications, an understanding of their
interaction with mammalian cells needs to be gained. However,
the interaction of NPs with cells is complex due to the many
different types of NPs, cells, and exposure scenarios being used
within the field. Still, one may make an attempt to reduce
details to very general statements, in order to highlight some
essential elements, which was the motivation for this review.
Endocytosis is the common route of NP uptake. NPs which
strongly interact with the cell plasma membrane are also inter-
nalized more efficiently. Hereby differences in uptake are not
digital (i.e., "yes" or "no"), but rather are based on different
concentration-dependent kinetics. After internalization NPs
inside intracellular vesicles are in an environment (acidic pH,
enzymes) completely different from that in the cytosol and the
extracellular space, which can modify their properties. The
translocation of the NPs from these vesicles to the cytosol is a
current challenge, which is referred to as endosomal escape
dilemma. Uptake studies best should involve a quantitative
distribution analysis. While endocytotic uptake of NPs has been
extensively investigated, the eventual loss of internalized NPs
as a result of mitotic division, NP exocytosis, or NP transcy-
tosis on the other hand has not been comprehensively studied
yet. Cellular uptake studies of NPs require as much characteri-
zation of the NP material as currently possible. However, many
physicochemical properties of NPs such as size, shape, charge,
and colloidal stability are highly entangled, which complicates
analysis. Analysis of physicochemical properties should be
always performed in the incubation medium in which the
uptake of NPs by cells is studied. The incubation medium can
for example modify the colloidal stability of the NPs. Colloidal
stability does not only interfere with size but also with other
parameters such as shape. In general, small, elongated, and
positively charged NPs are incorporated preferentially to big,
flat, and uncharged NPs.
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Abstract In this review, an overview of the current state-of-the-art of gold-based
nanomaterials (Au NPs) in medical applications is given. The unique properties of
Au NPs, such as their tunable size, shape, and surface characteristics, optical
properties, biocompatibility, low cytotoxicity, high stability, and multifunctionality
potential, among others, make them highly attractive in many aspects of medicine.
First, the preparation methods for various Au NPs including functionalization
strategies for selective targeting are summarized. Second, recent progresses on
their applications, ranging from the diagnostics to therapeutics are highlighted.
Finally, the rapidly growing and promising field of gold-based theranostic nano-
platforms is discussed. Considering the great body of existing information and the
high speed of its renewal, we chose in this review to generalize the data that have
been accumulated during the past few years for the most promising directions in the
use of Au NPs in current medical research.
S. Ashraf (*), B. Pelaz, M.G. Soliman, Q. Zhang, and C. Carrillo-Carrion (*)
Fachbereich Physik, Philipps Universita¨t Marburg, 35037 Marburg, Germany
e-mail: ashraf@staff.uni-marburg.de; carolina.carrillocarrion@physik.uni-marburg.de
P. del Pino
CIC biomaGUNE, San Sebastian, Spain
M. Carril
CIC biomaGUNE, San Sebastian, Spain
Ikerbasque, Basque Foundation for Science, 48011 Bilbao, Spain
A. Escudero
Fachbereich Physik, Philipps Universita¨t Marburg, 35037 Marburg, Germany
Instituto de Ciencia de Materiales de Sevilla, CSIC-University of Seville, 41092 Seville, Spain
W.J. Parak
Fachbereich Physik, Philipps Universita¨t Marburg, 35037 Marburg, Germany
CIC biomaGUNE, San Sebastian, Spain
Keywords Diagnostics • Gold nanoparticles • Nanomedicine • Theranostics •
Therapeutics
Contents
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
2 Synthesis and Functionalization of Au NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
2.1 Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
2.2 Functionalization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
3 Use of Au NPs Towards Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
3.1 Detection and Sensing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
3.2 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
4 Use of Au NPs in Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
4.1 Au NPs as Passive Carriers in Delivery Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
4.2 Au NPs as Active Therapeutic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
5 Use of Au NPs Towards Theranostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
6 Applications of Au NPs in Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
7 Concluding Remarks and Future Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
1 Introduction
In recent years, there has been an unprecedented expansion in the field of
nanomedicine, which involves the development of novel nanoparticles (NPs)
envisaged for the diagnosis and treatment of several diseases, especially cancer.
NPs possess extraordinary capabilities to detect, image, and potentially treat dis-
eases at the cellular and molecular levels [1–7]. Although micelle-based NPs (such
as formulations loaded with doxorubicin, paclitaxel, or cisplatin) [8] are most
advanced towards use in clinical practice, inorganic NPs also offer great potential.
Among various inorganic NPs, Au NPs are important examples in the field of
nanomedicine, thanks to their chemical, physical, and optical properties
[9–13]. Their unique physical and chemical properties, such as inertia, biocompat-
ibility, low cytotoxicity, stability against oxidation and degradation in vivo, and
ease of conjugation to biomolecules, provide significant benefits in comparison
with other NPs from a medico-biological point of view. The optical properties of
Au NPs are determined by the so-called localized surface plasmon resonance band
(LSPR) [14], which is associated with a collective excitation of conduction elec-
trons. Depending on the size, shape, structure, and the NPs environment, the LSPR
can be localized in a wide region from the visible to the infrared. Implementation of
different surface chemistries enables them to have high stability, high carrier
capacity, ability to incorporate both hydrophilic and hydrophobic substances, and
compatibility with different administration routes. Because of the nano-size, Au
NPs have good tumor retention capabilities as they can penetrate the leaky tumor
vasculature. These properties make Au NPs interesting materials for sensing,
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detection, imaging, targeted delivery of drugs and genes, photo-induced therapies,
enhanced radiotherapy, and so on. Furthermore, the multifunctionality potential of
Au NPs provides an ideal platform for developing the theranostic modalities
combining therapeutic, targeting, and imaging functions, demonstrating synergistic
effects of multi-therapies. Figure 1 shows a simplified scheme of different areas of
research where Au NPs are involved in the development towards nanomedicine.
The evolution of research has progressed from the synthesis and functionalization
towards applications. The evolution started with simple and unimodal applications
towards more complex multimodal applications (e.g., multimodal imaging, dual-
mode therapies, etc.). The latest development is focused on theranostics
nanoplatforms, which can diagnose, deliver targeted therapy, and monitor response
to therapy. Although the natural evolution is from the bottom to the top (as drawn in
the scheme), in parallel (i.e., in transversal mode), studies of toxicity and
bio-distribution are key aspects to guarantee the success of their applications.
These studies and results of the application performances have a direct feedback
in synthesis and functionalization for improvements. These inputs are the reason
why new strategies of synthesis are an area of continuous active research.
The following sections describe some recent advances in the different areas of
research using Au NPs, mainly focusing on their potential for medical applications
and the hurdles to be overcome to translate them into clinical trials. Bio-distribution
Fig. 1 Scheme showing different areas of research of Au NPs, involved in the development of
their applications in nanomedicine
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and toxicity have been extensively reviewed and discussed in a number of recent
publications [15–18], and thus we discuss it in the conclusions section. As the topic
of this review involves huge amounts of information with a high speed of renewal,
we focus on major ideas and some of the most recent and promising studies
performed during the past few years.
2 Synthesis and Functionalization of Au NPs
2.1 Synthesis
Before the advent of nanoscience, Au NPs were already attracting interest because of
their optical properties. There are many historical examples in which Au NPs were
applied even without knowing it (e.g., the Lycurgus Cup or stained-glass windows).
In the last few decades, the control in the synthesis of Au NPs has evolved greatly.
Nowadays it is possible to produce Au NPs with different sizes and shapes in a highly
controlled manner. Many reviews and book chapters have already been published
about the state- of‐ the- art of Au NPs synthesis [13, 19–22]. Thus, here we aim to
provide an overview of some of the most recent achievements in the synthesis of Au
NPs using wet- chemistry (though also other routes such as laser ablation exist [23]).
Most wet-chemistry-based Au NPs are synthesized in aqueous media, but there
are some important examples to produce hydrophobically-capped Au NPs (e.g., the
Brust–Schriffin method) [24]. These NPs are typically spherical with a size less
than 10 nm. It is well known that most of the applications of Au NPs in
nanomedicine are based on their optical properties, i.e., LSPR [25]. The desire
for tuning of the LSPR has been a driving force to develop synthesis strategies
allowing for Au NPs of different sizes and shapes. Although controlled synthesis of
Au NPs has been known since the days of Michael Faraday, most synthetic
strategies to produce water soluble spherical Au NPs are based on the Turkevich
method [26]. This method has been continuously improved to produce better
samples (e.g., with narrow size distribution and more homogeneous NPs). This
optimized methodology also allows the growing of Au NPs of sizes up to 200 nm
[27]. Yet arguably the most interesting Au NPs for bio-applications are anisotropic
Au NPs that exhibit their LSPR in the biological window. This biological window
comprises the spectral region of 700–1100 nm, in which the body tissue compo-
nents absorb less light. This range is therefore the desired region to locate the LSPR
of Au NPs intended to be used for bio-applications (e.g., photothermal therapy
(PTT) [28, 29] or optoacoustic imaging (OAI) [30]). Recent controls over shape
during the synthesis of Au NPs make it possible to tune the position of the LSPR by
changing parameters such as the shape (rods, prisms, etc.) [28, 31] or the structure
of the NPs (e.g., hollow vs homogeneous) [32]. To induce the growth of anisotropic
NPs it is necessary to provoke either a kinetically controlled growth of the NPs or to
induce the blocking of some growing facets [33]. The sphere is the most stable
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shape in terms of energy. If the NPs synthesis is performed under thermodynam-
ically controlled conditions, the NPs obtained are spherical. In general, to obtain
non-spherical NPs the synthetic conditions have to be tuned to induce kinetically
controlled NPs growth. This can be performed using surfactants that block some
growing facets (e.g., cetyltrimethylammonium bromide (CTAB) or polymers) [34],
using halides (e.g., Br!, I!) [35] or weak and mild reductants (e.g., Na2S2O3) [28].
To date, Au nanorods remain the most broadly used anisotropic NPs. These
rod-shaped NPs were described almost at the same time by the groups of El-Sayed
[36, 37] and Murphy [28]. Since then, the synthesis of these NPs has been deeply
explored. In general, the synthesis of Au nanorods is performed by using the growth
seeding process. First, small spherical Au NPs are synthesized and then added to the
growing solution rich in CTAB to induce rod-shaped growth. Because of the
cytotoxicity of CTAB [38], Murray et al. have recently developed a modified Au
nanorods synthesis method in which the required CTAB concentration is reduced
by half (from 0.1 M from El-Sayed and Murphy to 0.05 M) [31, 39]. This synthesis
is based on the use of aromatic additives.
Another important type of anisotropic NPs is the Au nanoshells developed by
Halas et al. [40]. These structures are built using a silica core in which gold is
grown. Their LSPR can be modulated by controlling the relationship between the
core size and the thickness of the gold shell. By changing the shape of the core,
other similar structures have also been described such as “nanorice” [41]. Halas
et al. also described a synthesis for “nanomatryushkas,” which are multilayered
spheres. The simplest “nanomatryushka” contains a core of a gold sphere of
ca. 40 nm coated with a SiO2 shell and a second shell of Au [42]. Several bilayers
of SiO2 and Au can be deposited to obtain more complex “nanomatryushkas.”
Au nanoprisms also have been described. The synthesis of triangular nanoprisms
can often only be achieved with a low yield [43] and by using toxic surfactants (e.g.,
CTAB or CTAC (cetyltrimethylammonium chloride)) [44]. A synthesis route
eliminating the use of toxic surfactants has recently been reported, which allows
for tuning the LSPR position by controlling the amount of reductant. This synthesis
is based on the reduction of a gold salt by thiosulfate (Fig. 2a) [28].
Au nanostars also exhibit their LSPR in the biological window. Many different
synthetic procedures to produce Au nanostars have been reported. For generating
Au nanostars, typically the seed-growing method is used. For instance, Liz-Marza´n
et al. published a method in which gold salt was reduced to metallic gold on top of
the 15-nm Au NPs stabilized with poly(vinylpyrrolidone) (PVP) in the presence of
dimethylformamide and PVP [45].
Finally, Au nanocages, originally developed by the group of Y. Xia, have been
applied extensively with different purposes in nanomedicine [46, 47]. These cages
are prepared by using a sacrificial silver nanocube, which then is oxidized to promote
the reduction of gold through a galvanic replacement process. Similar approaches
have been described using silver nanospheres [48] and silver nanoprisms [49].
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Aiming to use green chemistry and less toxic reagents, the production of Au NPs
using natural extracts from microorganisms (e.g., micro alga [50] or fungi [51]) or
plants has been also explored [50, 52]. Nevertheless, the yield and quality of these
Au NPs is still far below the quality of the previously described approaches.
Au-based hybrid materials have been developed too, trying to combine the great
optical properties of gold with the properties of another material. Several examples
of core-shell structures of Au containing iron oxide [53–55] or semiconductors
cores [54] or Au cores coated with silver (bimetallic NPs [56]) can be found in the
literature. More recently, Au has been combined with more novel materials such as
nanodiamonds [57] or graphene [58, 59].
2.2 Functionalization
After synthesis and before their use in bio-applications, NPs must be provided with
stable coatings which should warrant high colloidal stability. Thus, robust organic
coatings ensure that the NPs’ properties remain intact in biological media
[60]. Indeed, the NPs surface determine their biological fate [61]. In addition, any
kind of by-product related to the synthesis, including excess of reagents or cyto-
toxic surfactants, should ideally be washed off to remove potential toxic effects
caused by these impurities. To achieve coatings qualifying for these requirements,
the NPs’ surfaces need to be engineered. One of the biggest advantages of the use of
Au is its high reactivity with thiol groups [62]. This reactivity permits stabilizing
the NPs with ligands containing a thiol reactive group. Ligand exchange by which
original surfactants are replaced by new ones is the most common stabilizing
procedure for Au NPs. Ligand exchange can be used to water transfer
hydrophobically-capped NPs (e.g., NPs capped with alkanethiol chains) [63] and
to replace toxic surfactants (e.g., CTAB) used to produce anisotropic NPs such as
Au nanorods [64, 65].
Fig. 2 Schemes for the synthesis and functionalization of Au NPs. (a) Synthesis of Au
nanoprisms, PEGylation, and linkage of glucose (Glc) and tetramethylrhodamine (TAMRA)
using carbodiimide (EDC) chemistry [28]. (b) Strategy of phase transfer to coat Au nanorods
(GNRs) with amphiphilic polymers [75]
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Typically, polyethylene glycol (PEG) chains which provide the NPs with a
colloidal high stability in biological media and long in vivo retention times
[19, 66] are the most widely used stabilizers for Au NPs. Nowadays, there are
many companies which offer an endless number of hetero-functional PEG chains.
Using bi-functional PEG allows for future chemical modifications for the attach-
ment of molecules (e.g., dyes, carbohydrates, antibodies, peptides, etc.) and/or to
provide charge to the NPs (Fig. 2a) [28, 67, 68]. Not only PEG is used to stabilize
Au NPs – other ligands, such as dihydrolipoic acid [69], proteins (e.g., bovine
serum albumin) [70], or polymers are used regularly to enhance the NPs’ stability in
complexes media. Polymers used for this purpose include, for example, polyelec-
trolytes [71], PVP [72], or amphiphilic polymers [73].
The use of amphiphilic polymers to stabilize NPs and to promote their transfer
from organic solvents to aqueous solutions is based on polymer coating of the NPs.
This approach can be used for virtually any kind of NPs containing aliphatic chains
on the surface (e.g., oleic acid, oleylamine, etc.) [73, 74]. The advantages of this
technique are many: (1) coated NPs exhibit a high colloidal stability against media
with high salt concentrations and/or proteins; (2) NPs coated with the same polymer
have the same surface chemistry; (3) these polymers can be made with reactive
groups in their hydrophilic domain (e.g., carboxylic acids), which then can be
further modified with biologically relevant molecules. The main limitation of this
technique is that it can be only used with NPs soluble in organic solvents. Yet most
of the anisotropic Au NPs are synthesized in water. An extension of this method
based on phase transfer of the water-soluble Au NPs to organic solvents has
recently been reported. This method has been demonstrated for spherical Au NPs
(with size up to 15 nm) and Au nanorods (Fig. 2b) [75].
Once Au NPs are sufficiently colloidally stable in biological media, as a function
of their surface chemistry, different chemical modifications can be performed.
Bioconjugate chemistry protocols developed for modifying proteins, peptides,
and/or surfaces can be adapted to NPs [76, 77]. Concerning bio-conjugation, we
refer to some recent reviews [11, 78–80]. In summary, currently the synthesis and
functionalization of Au NPs has become very versatile. This allows scientists to
develop the best customized systems for each application.
3 Use of Au NPs Towards Diagnostics
3.1 Detection and Sensing
Different analytical assays involving Au NPs are widely used as sensors, ranging
from the detection of ions and elements to more complex molecules, including
those of biomedical interest, such as oligonucleotides, proteins, antibodies, and
even bacteria and other microorganisms. The methods of designing sensing bio-
markers that could be associated with the early stage diagnosis of different diseases
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are nowadays attracting special interest. The current challenges consist of designing
sensing devices that are able to recognize more specifically different types of
analytes, discriminating molecules with similar characteristics, including the use
of sensor arrays, which often combine several analytical approaches. Advances in
enhancing the sensitivity and reducing the time of analysis are also currently
required. The physical and analytical basis of sensing with Au NPs can be summa-
rized in different main areas [81]. They include measurements based on colorimetry
and plasmon resonance, fluorescence, electrochemistry, and more recently, surface
enhanced Raman spectroscopy (SERS) [82].
Colorimetric assays are based on a visible change of color of functionalized Au
NPs suspensions when interacting with the appropriate analyte [83–86]. Colorimet-
ric analyses are normally fast and can often be evaluated with the naked eye. As
explained before, Au NPs exhibit plasmonic properties. The position and intensity
of this LSPR band depend not only on the metal type, NPs size, shape, structure,
composition, and dielectric constant of the surrounding medium [87], but also on
the aggregation of the NPs [88]. Colorimetric assays are based on this effect,
because analytes that produce a change in the aggregation state of Au NPs give
rise to a change in the LSPR absorption band of the NPs dispersion [89]. Such an
effect is not only used to sense cations and anions [89–92], but has also been applied
to sense molecules of biomedical interest. For example, DNA has been detected by
Au NPs wrapped with long genomic single- and double-stranded DNA (ssDNA and
dsDNA) molecules [93]. Proteins such as melamine and human carbonic anhydrase
II have also been sensed by cyanuric acid derivative grafted Au NPs [94] and
polypeptide-functionalized Au NPs [95], respectively. More complex molecules
such as folate receptors (FRs), consisting of cysteine-rich cell-surface glycoproteins
that can bind folate (FA), can be sensed by FA-modified ssDNA functionalized Au
NPs. In the presence of FRs, ssDNA terminally tethered to FA is protected from
degradation by exonucleases, and an aggregation of the Au NPs takes place through
the formation of cross-linked NPs networks, resulting in a color change of the
solution from red to blue [96]. Polyethyleneimine (PEI)-stabilized Au NPs have
been used for highly selective and sensitive colorimetric sensing of heparin
[97]. Abnormal concentration values of human chorionic gonadotropin (hCG) can
be associated with ectopic pregnancy. The concentration of this biomarker can be
determined using Au NPs in the presence of positively charged hCG-specific
peptides. In this case, hCG inhibits the peptide-induced aggregation of the Au
NPs, giving rise to a simple, rapid, and sensitive colorimetric assay [98]. A rapid
and low-cost colorimetric analysis of bacteria in drinking water has been designed
by using β-galactosidase conjugated Au NPs with a colorimetric substrate
(chlorophenol red-β-D-galactopyranoside (CPRG)) deposited on a paper-based
test strip [99]. The aggregations of antibody-conjugated oval-shaped Au NPs that
selectively target specific sites on the surface of pathogens have been used to sense
Salmonella [100]. Although colorimetric assays based on Au NPs involve the large
shift of the LSPR band depending on NPs aggregation, a small LSPR peak shift can
also be produced when an appropriate analyte binds to the surface-bound receptors
of plasmonic NPs, because of a change in the refractive index [101]. In contrast to
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agglomeration-based protocols, this shift in the LSPR frequency is not enough to be
detected by the naked eye, but can be observed by absorption measurements. Au
NPs deposited on several substrates have been used to detect analytes such as DNA
[102], human IgG (Immunoglobulin G) [103], and insulin [104] in this way. Recent
advances in the detection of microRNAs (miRNAs) by Au nanoprisms without the
need for labels [105] and in the sensing of trace oligonucleotides biomarkers [106]
have also been reported. Au NPs deposited on the metal sensing surface increase the
sensitivity of planar surface plasmon resonance sensors, provided by the high
dielectric constants of Au NPs and the electromagnetic coupling with the metal
film [107]. This approach has been used for the sensing of different proteins [108]
and oligonucleotides [108, 109].
Fluorescence assessments involving Au NPs are widely centered on fluorescence
quenching-based methods. Au NPs show an important quenching effect on
fluorophores close to their surface caused by their extraordinary high molar extinc-
tion coefficients and broad energy bandwidths [83, 110]. Specific interactions with
the sensing molecules have been used to detect many different molecules of
biomedical interest. Some assays are based on the appearance of fluorescence
when the target molecules interact with the Au NP-based-sensors. For example,
the quenching of a fluorophore attached to an Au NP through an oligonucleotide
chain disappears in the presence of DNA [111], when the fluorophore gets detached
from the NPs because of displacement by the DNA strand. Similar strategies have
been used to sense proteins [112] and bacteria [113] using Au NPs conjugated with
fluorescent polymers. Au NPs functionalized with enzymes have also been used to
sense proteins, with an enhanced sensitivity through enzymatic catalysis [114].
Fluorescence quenching assays involving Au NPs are not only restricted to the
detection of single analytes. More complicated sensing techniques, focused on the
study of the interaction of different analytes, have also been reported. For example,
dsDNA-conjugated Au NPs (dsDNA-Au NPs) and water-soluble conjugated poly-
electrolytes are used as complementary sensing elements to construct hybrid
sensors for detecting protein–DNA interactions [115]. The use of sets of sensors
showing different patterns of responses in an array can provide fingerprints that
allow for classification and identification of different target molecules [116]. Such
an approach is used with DNA–Au NPs conjugates, in which a combination of
colorimetric and fluorescence assessments enables better selectivity to distinguish
different proteins [117]. Similar combination of colorimetric and fluorometric
approaches has been reported for a sensor array consisting of two types of novel
blue-emitting collagen-protected Au nanoclusters and macerozyme R-10-protected
Au nanoclusters with lower synthetic demands, which has been recently used to
sense eight different proteins [118].
The modulation of quenching of fluorescent semiconductor quantum dots (QDs)
close to Au NPs in the presence of molecules which inhibit the interaction between
QDs- and Au NPs-conjugated biomolecules has been used to sense molecules of
biomedical interest such as avidin [119]. Normal, cancerous, and metastatic human
breast cells have been distinguished by comparing the fluorescence of different
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cationic Au NPs functionalized with poly( p-phenyleneethynylene) (PPE), which
show different affinities for normal and tumor cells [120].
The conductivity, roughening of the conductive sensing interface, and the
catalytic properties of Au NPs have been harnessed for the huge amount of
analytical assays based on electrochemical measurements that involve Au and
other metal-based NPs [121]. Different immunosensors based on Au NPs have
recently been reported to detect cancer biomarkers [122, 123]. Au NPs deposited on
electrode surfaces are known to enhance the electrochemical detection of different
analytes because of their ability to decrease the overpotentials of many electroan-
alytical reactions, maintaining the reversibility of redox reactions [124, 125]. This
approach has been used to detect several drugs such as isoniazid [126] and hCG
[127]. Au nanorods have also been used as sensing interface in pencil graphite
electrodes for the electrochemical sensing of deferiprone, an anti-HIV drug,
resulting in an amplification of the electrochemical sensing signal [128].
Antibody-functionalized Au NPs, showing target specificity and affinity towards
different biomarkers [129], have been used to sense Salmonella by differential
pulse voltammetry (DPV) [130]. Cancer circulating cells have been sensed by
combining the specific labeling through antibody-modified Au NPs and the sensi-
tivity of the Au NPs-electro-catalyzed hydrogen evolution reaction (HER) detec-
tion technique [131]. The reaction of cell surface proteins with specific antibodies
conjugated to Au NPs and the catalytic properties of the Au NPs on hydrogen
formation from hydrogen ions can be used to quantify the NPs internalized by
cancer cells [132, 133].
Raman scattering permits the detection and analysis of many molecules, by
giving a unique spectroscopic signature which potentially identifies the species
[134]. The Raman scattering signal can be substantially enhanced by the presence
of plasmonic NPs, resulting in SERS [135, 136]. This effect is highly influenced by
the size, shape, orientation, and aggregation of the NPs [108]. In fact, Au NPs with
different morphologies have been used for SERS-based detection [137–
139]. Label-free and Raman-dye labeled assays are two different existing SERS-
based detection methods. Label-free assays follow vibrational information about
the analytes themselves, whereas the dye-labeled methods detect analytes indirectly
by monitoring the SERS signal of a Raman label attached to the metallic SERS
substrate [140]. Different SERS assays for sensing DNA [141, 142] and proteins
[143, 144] using Au NPs can be found in the literature. An extended bi-dimensional
array of Au concave nanocubes supported on a polydimethylsiloxane (PDMS) film
has recently been proposed for the SERS sensing of proteins that show low intensity
Raman signals [145]. The assembly of spherical Au NPs on a highly anisotropic
silica-coated substrate has recently been reported for the detection of prostate
specific antigen by SERS [146] and the selectively quenching of the SERS signals
from the dye molecules adsorbed onto star-shaped Au NPs not internalized by cells
has been used to identify intracellular distributions of Au NPs [147].
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3.2 Imaging
For the treatment of many diseases and non-invasive evaluation/detection of intra-
cellular and/or intra-subcellular compartments, molecular imaging based on func-
tional nanomaterials is of paramount importance [148, 149]. For molecular imag-
ing, different types of NPs are currently in use. Examples include polymer-based
NPs [150–152], dendrimer-based NPs [153, 154], lipid-based NPs [155, 156],
magnetic NPs [157–160], QDs [161–163], carbon nanotubes (CNTs) [164, 165],
silica NPs [166–168], and Au NPs [169–172]. Among all the above-mentioned
NPs, Au NPs possess extraordinary potential for imaging at the cellular and even
molecular level. Various Au NPs are currently in use in molecular imaging, based
on their different size, shape, and physical properties. Examples include spherical
Au NPs [171, 172], nanorods [173–175], nanobipyramids [19], nanoshells [176],
nanocages [177–179], core/shell NPs [171, 180], nanostars [181–183], and
nanocubes [149], etc.
Au NPs have unique characteristics which enable their use as contrast agents in
bio-medical imaging [184, 185]. In this field, they are being used as probes in dark
field confocal imaging (DFCI), one- and two- photon fluorescence imaging
(OTPFI), optoacoustic imaging (OI), computed tomography (CT), photothermal
optical coherence tomography (POCT), positron emission tomography (PET), and
imaging based on surface enhanced Raman scattering (SERS) [175, 184]. Different
imaging modalities of the Au NPs can be combined, which can provide comple-
mentary information. In the following, a description of using Au NPs as contrast
agents for the different imaging techniques is given.
DFCI provides contrast enhancement in unstained biological samples, but its
main limitation is that it provides low light levels in images. Thus, for better
visualization the biological samples should be strongly illuminated, which can,
however, damage the samples. The imaging contrast of dark field microscopy can
be enhanced by utilizing the high scattering properties of Au NPs [186]. For cellular
detection, mostly the light scattering properties of Au NPs are utilized for straight-
forward image analysis. Light scattered from Au NPs is detected by using high
resolution objective lenses of dark field confocal (DFC) microscopes in the form of
bright spots, though the size of Au NPs is generally smaller than the diffraction
limit of DFC. Using Au nanoshells it was recently possible to observe the binding
and antibody mediated specific targeting of cancer cells in in vitro experiments
using the dark field scattering properties of the NPs [187]. Similarly, for cancer
cells localization, targeting, and real time tracking of Au nanorods-induced DNA
damage in cancer cells was visualized using DFCI [188]. Scattering properties of
Au NPs are also being utilized for better imaging of breast cancer cells [189]. How-
ever, despite the high scattering cross sections of Au NPs for enhancing the contrast
in DFCI, their use is limited to in vitro experiments [184].
Photoluminescent properties of sub-nanometer Au nanoclusters made them
attractive candidates in OTPFI based on their brightness, non-blinking behavior
and stable emission [190, 191]. The luminescence of Au nanoclusters in the near
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infrared (NIR) window is used for fluorescence imaging and they have greater
photostability than QDs [191]. Not only nanoclusters but also other Au NPs, such as
nanoshells and nanostars, can be used in one photon fluorescence imaging (OPFI),
after conjugation of the Au NPs with NIR active fluorophores such as indocyanine
green or Cy5 [192]. After conjugation with these fluorophores, these structures help
in emission enhancement of these dyes for better fluorescence imaging. Presence of
a metal surface close to fluorophores does not always quench fluorescence, but can
also provide fluorescence enhancement, in particular for very close distances. In
OPFI, Au NPs functionalized with fluorophores, offer a suitable platform for
in vitro and in vivo cancer imaging and diagnostics [193, 194]. When Au NPs are
excited with femtosecond pulsed lasers whose resonance frequency matches with
the LSPR band of the Au NPs, two photon absorption occurs which results in two
photon luminescence from the Au NPs [182, 193, 195]. For monitoring in vivo
biological events, two photon luminescence imaging (TPLI) provides sufficient
penetration depth and high three-dimensional (3D) spatial resolution. The signal
intensity of TPL (two photon luminescence) can be enhanced three times in
magnitude by utilizing the high luminescent properties of Au nanorods and
nanocages without the photo-bleaching or blinking that is observed in many
fluorophores used in this technique [196]. The contrast of Au nanostars conjugated
with wheat germ agglutinin in TPL-based imaging can be utilized for imaging their
uptake [182]. Similarly, other Au NP structures, such as nanorods, nanocages, and
nanoshells, are also being used as contrast agents in TPL with a resolution at the
single NP level inside blood vessels. In this way, in vivo tracking of Au NPs and
fluorescence lifetime imaging for visualizing dynamical processes in cell media is
possible [197, 198]. After one and two photon luminescence-based imaging, Au
nanocages are now also being utilized in three photon luminescence imaging, based
on their strong multi-photon absorption capabilities, leading to in vivo detection
with diminished background signals and reduced photothermal toxicity [199]. Fur-
ther studies are still required for using Au NPs in multi-photon luminescence for a
better understanding of their role in this imaging technique.
The penetration depth of OI-based imaging, which is typically carried out with
NIR pulsed sources, is similar to ultrasound-based imaging, i.e., several centimeters
in biological tissues (typically less than 5 cm). This is better compared to simple
optical imaging, in which depth resolution is only on the millimeter scale. The
photothermal properties of Au NPs provide high contrast in OI [30]. Upon photo-
excitation, the non-radiative decay of Au NPs converts light energy into heat, which
causes a sharp rise of temperature in the local environment of the NPs, resulting in
thermal and acoustic response enhancement in those tissues which contain the
photoexcited NPs. The increased thermal response of Au NPs enhances the pressure
waves propagating through the surrounding tissues and results in improving the
temporal and spatial resolution of tomographic images [200].
In clinical detection of several diseases, CT has received increasing attention
because of the high spatial and density resolution. For imaging biological systems
using CT, contrast agents are usually required (which can enhance the density of the
imaging area) for improving the accuracy in diagnosis. Iodine-based small
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molecules such as “Omnipaque” are normally used in clinics, but are associated
with certain drawbacks such as short imaging time, non-specificity, and renal
toxicity. For overcoming these drawbacks nowadays, Au NP-based suitable con-
trast agents are being developed. In CT, because of the high atomic number of Au,
Au NPs are providing higher spatial and density resolution compared to iodine-
based contrast agents. In CT-based imaging, Au NPs attenuate X-rays much more
efficiently compared to “Omnipaque,” resulting in contrast enhancement by several
orders of magnitude [201, 202]. Moreover, by suitable tuning the size and
functionalization of the Au NPs, besides improving CT imaging it is also possible
to achieve target specificity, long circulation time, and reduced renal toxicity [203].
Optical coherence tomography (OCT) can image cellular and sub-cellular struc-
tures 100 times better than CT and magnetic resonance imaging (MRI) and provides
10–25 times better spatial resolution compared to ultrasound-based images
[204]. OCT is a non-invasive technique, resembling ultrasound-based imaging
but, in this technique, instead of sound, reflections of NIR light are used for
imaging. NIR active contrast agents, e.g., Au nanorods, can significantly improve
OCT-based imaging because of their large differences in absorption-scattering
profiles. Au nanoshells and nanocages, because of their strong scattering properties,
can also provide enhanced optical contrast and brightness in OCT for improving the
imaging of cancerous cells [205]. In this technique, tissues are illuminated with low
coherent light and matching the coherence between incident and reflected beams of
light helps in the detection of back-reflected light. This backscattered light thus
helps in imaging. Because OCT is much more sensitive towards detection of
scattering from the tissues than absorption, the scattered light helps in studying
the morphology of tissues [205]. In OCT, Au NPs are being used as exogenous
contrast agents based on their ability to produce distinctive backscattered light
which is detectable in highly scattering tissues, thereby helping in studying the
morphology of tissues [206]. Though OCT is a powerful 3D diagnostic tool in real
time imaging, its resolution is low because of intense scattering from some optically
dense tissues under investigation. To overcome this limitation nowadays, POCT
(photothermal-OCT) imaging techniques using the photothermal properties of Au
NPs are being developed [207]. In POCT, when light resonant with the plasmon
energy of Au NPs strikes, Au NPs are excited and light is converted into heat and
the surface temperature of the tissues is enhanced. The increase in surface temper-
ature results in changes in the local refractive index of the medium which is then
optically detected by POCT. Because of active detection of photothermal heating,
POCT can identify and separate absorbing targets from scattering background,
thereby helping in high resolution imaging compared to OCT [208].
In early stage diagnosis of cancer, PET – with its highly sensitive nuclear
imaging modality – is extensively utilized in clinical studies using small doses of
radioactive materials. However, these radioactive materials, especially small radio-
active molecules, usually have short circulatory life- times in in vivo studies. After
radiolabeling, Au NPs (e.g., nanocages, nanoshells, and spherical NPs) can remain
inside the bloodstream for longer periods of time. Hence they facilitate long-term
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bio-imaging [209]. In PET, radioisotopes undergo positron emission decay or
positive beta decay and positrons are emitted. These emitted positrons traverse a
short distance inside tissues, lose kinetic energy, and interact with electrons. This
union with electrons results in their annihilation and production of gamma photons
in the form of light which is used for making images [209]. Sometimes PET is
coupled with Cerenkov luminescence (CL)-based imaging for better visualization
and cross-checking the imaging results. CL-based imaging is a molecular imaging
technique based on Cerenkov radiation, which can originate from the decay of
alpha-, beta-, or positron-emitting radionuclides [179]. Recently, a radiolabeled
precursor of a gold salt (H198AuCl4) was used for the synthesis of radioactive Au
nanocages which gave CL. The CL originating from the decay of radionuclides
helps in real-time CL-based imaging and monitoring of tumors over extended
periods of time. CL of radionuclides can be increased by using high refractive
index materials such as gold in conjugation with higher energy radionuclides. Thus
CL imaging based on Au NPs can effectively bridge the gap between nuclear and
optical imaging [179]. CL-based imaging can use radionuclides for diagnosis of
diseases, which are routinely used for PET based imaging. CL based imaging
improves PET-based imaging in terms of resolution. CL imaging signal can be
modulated by using smart imaging agents such as NPs, and hence better insight in
tumor biology can be obtained [210]. Over the last decade there have been numer-
ous studies for enhancing the efficacy of SERS-based molecular imaging using Au
NPs conjugated with Raman active moieties. Au NPs enhance the Raman scattering
of vicinal molecules by means of chemical and electromagnetic enhancements. Au
NPs enable identification of single molecules spectroscopically at room tempera-
ture by amplifying (ca. 1015-fold) the Raman scattering signals of adsorbed species.
The LSPR of Au NPs enhances Raman signals in SERS-based imaging, which
helps in better detection of tumor margins during the surgical removal of tumors
[211]. The use of Au NPs provides photostability, improved contrast, and higher
spectral specificity in SERS-based imaging [184].
Among all enlisted imaging techniques, no single modality can be considered as
ideal and sufficient for getting all requisite information for a particular question.
Nowadays, multimodal imaging probes based on Au NPs are being designed which
possess integrated or complementary functions. For example, SERS-based imaging
is highly sensitive and multiplexed imaging is possible with this technique, but it
has poor penetration depth. On the other hand, OI has better penetration depth and
high spatial resolution, but its sensitivity is limited. For multiplexed imaging, Au
nanorod-based SERS/OI can be used for early stage detection of cancer. Similarly,
Au NPs having triple modality are being used for MRI/SERS/OI-based imaging
[212]. For disease (particularly cancer) intervention, Au NP-based multifunctional/
multimodal imaging platforms have enough potential for the development of future
contrast agents useful for nanomedicine. One can envision the potential applica-
tions of Au NPs for multiplexed detection and imaging of cancer and other such
types of diseases by proper tailoring of their functionalization, size, shape, compo-
sition, and hybridization with other materials [184].
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4 Use of Au NPs in Therapeutics
The properties of Au NPs can be exploited in therapy in two ways – as passive
carriers for delivery, in which the therapeutic effect arise from active molecules
bound to the carrier, or as active therapeutic agents, where the therapeutic effect
directly originates from the Au NPs. The first use of Au NPs for therapeutic
applications was as delivery vehicles for drugs and genes, because NPs in the
size range 2–100 nm can interact with biological systems at the molecular level,
and can allow for targeted delivery and passage through biological barriers. Later
on, also investigations showing that Au NPs can be intrinsically therapeutic became
available. This is because Au NPs can actively mediate molecular processes to
regulate cell functions. In this section we summarize the potential of Au NPs in
therapy, providing examples of currently investigated strategies.
4.1 Au NPs as Passive Carriers in Delivery Systems
Au NPs are widespread in the field of delivery of different kinds of therapeutic
molecules. They are very attractive as nanocarriers because of their colloidal
stability, ease of preparation, and their on-demand tunable size and surface modi-
fication possibilities. In addition, they are essentially bio-inert, non-toxic and lack
immunogenicity. All these features in combination with their ability to enter cells
by endocytic pathways naturally make them good vehicles for a plethora of bio-
molecules and drugs to be delivered inside cells [13, 213]. Normally, the cargoes
are loaded onto the Au NPs’ surface either by non-covalent binding (via ionic or
hydrophobic interactions) or by direct binding on the Au surface by thiolated
linkers. Once inside the cells, the cargo may slowly detach from the surface of
the Au NPs or its release may be triggered by internal stimuli such as pH [214] or
cytosolic glutathione [215], which is able to reduce disulfide bonds, releasing
molecules linked to the NPs surface via that kind of linkage. Furthermore, Au
NPs are well known for their optical properties which are not only useful in the field
of imaging and biosensing, but also serve to detach molecules selectively from the
NPs surface when irradiated with light. Upon irradiation of plasmonic Au NPs at
their LSPR frequency with a continuous wave laser, they absorb energy and reduce
the attraction between the Au surface and non-covalently linked molecules, which
eventually produces desorption of the cargo. In contrast, high energy pulse irradi-
ation provokes the reshaping of the nanocarriers and the rupture of Au–S bonds,
releasing more strongly linked cargoes. Interestingly, light irradiation of plasmonic
nanomaterials allows for spatio-temporal controlled release of drugs and biomole-
cules because the delivery only takes place during irradiation of the NPs and stops
when the laser is off [216–218]. The most commonly used Au NPs for delivery
applications are nanospheres, and nanorods.
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Au NPs have been used for decades for the purpose of gene delivery, traditionally
developed for the transfection of plants using gene guns [219]. Nowadays, Au NPs
are also used in gene therapy as non-viral carriers for delivering nucleic acids inside
the cells [220]. Gene therapy may include the delivery of DNA inside cells to induce
certain protein expression, or the introduction of miRNA able to interfere with the
correct translation of messenger RNA inside the cells, avoiding protein production
and silencing a particular gene responsible for a cellular malfunction. Gene therapy is
increasingly important, particularly in the field of cancer treatment. However, deliv-
ery of naked nucleic acids is hampered by their fast degradability inside the body and
their polyanionic nature that inhibits the cellular uptake. There are many reports in
the literature that have demonstrated that adsorption of nucleic acids onto positively
charged Au NPs drastically reduced their degradability and helps their internalization
into cells. This could be achieved, for example, by coating Au NPs with positively
charged lysine amino acids [221] or with positively charged polymers [222–
225]. However, to ensure that the genetic material reaches the nucleus, more sophis-
ticated constructions may be required. Such constructions may involve the use of PEI,
a poly-cationic polymer able to escape endosomes because of the “proton sponge”
effect causing membrane disruption [226], although it has been shown to be cytotoxic
after a certain dose threshold. Hence, several authors have coated Au NPs with PEI to
trap DNA or RNA, taking advantage of the endosomal escaping capacity of PEI,
and substantially reducing its cytotoxicity [227–232]. Chen et al. have recently
described a smart three-layered nanocarrier, based on the layer-by-layer (LBL)
deposition of PEI/chitosan-aconitic anhydride (CS-Aco)/PEI/ shRNA (short/small
hairpin RNA) onto Au NPs. CS-Aco was introduced as a pH-triggered charge-
reversible compound which hydrolyzed into positively charged CS once inside the
lysosomes, causing the disassembly of the nanocarrier layers. The as-released
Au-PEI NPs facilitated lysosomal membrane disruption and hence the successful
delivery of shRNA-PEI into the cytoplasm [214]. Although PEI is particularly
attractive for nucleic acids delivery, similar results have been achieved by other
poly-cationic polymers adsorbed onto Au NPs [220, 233]. For instance, Lee and
co-workers fabricated siRNA-loaded Au NPs using the LBL approach with alternat-
ing positively charged poly-L-lysine (PLL) and negatively charged siRNA. They
successfully coated the Au NPs with four layers of PLL and three layers of siRNA,
which were slowly released inside the cells by protease degradation of PLL and
displayed gene silencing capability [234]. As already pointed out, another way of
delivering DNA or RNA avoiding normal cell internalization pathways is adsorption
onto naked Au NPs or projectiles and direct bombardment inside the cells using gene
guns. This strategy is frequently used in plants, but nowadays it has also been
explored for mammalian tissues [235, 236].
Drug delivery is also an important field in which Au NPs are utilized. This field
is of particular interest in the case of cancer treatment to avoid systemic toxicity
during chemotherapy and to facilitate the delivery of hydrophobic drugs
[237]. Indeed, the group of Rotello showed how to entrap two different hydropho-
bic drugs (tamoxifen and β-lapachone) in hydrophobic pockets created within
alkanethiol monolayers surrounding Au NPs and their effective delivery
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[238]. Some other strategies involve the chemical modifications of drugs to link
them covalently onto NPs, which could, in some cases, compromise the drug
performance. Gibson et al. covalently functionalized Au NPs with approximately
70 molecules of anticancer drug paclitaxel per NP, but they did not report about the
delivery and biological activity of the drug [239]. Nonetheless, most studies are
based on systems to deliver doxorubicin (DOX) [240, 241], which is known for its
properties for treating cancer, but also for its toxicity and side effects. The group of
Li has recently reported high loading of PEGylated hollow Au nanospheres with
DOX (up to 63% in weight) and their delivery after NIR light irradiation
[242]. Apart from drugs, Au NPs have also been used as carriers for vaccines by
decorating their surfaces with appropriate ligands (selected antigens and T-helper
peptides) which were able to elicit an immunogenic response [243].
Interestingly, Au NPs have been used not only as carriers but also as smart
container openers. Plasmonic Au NPs were embedded in between polyelectrolyte
layers in LBL constructed capsules carrying a therapeutic cargo within the capsule
cavity. In a similar fashion, as explained before, irradiation of light onto those NPs
led to the spatio-temporal controlled disassembly of the polymeric capsules pro-
ducing the immediate cargo release [244–248].
Nowadays, all these delivery systems are evolving into more sophisticated
constructions, which take advantage of the optical properties of Au NPs for
combined drug therapy with photothermal ablation (PTA) and imaging [249] and
in combination with other materials such as carbon [250, 251]. For instance, some
recent reports along this dimension describe the wrapping of Au NPs or nanorods
with hydrophilic graphene oxide nanosheets as carriers for gene therapy and
improved PTA therapy [252–254].
4.2 Au NPs as Active Therapeutic Agents
When Au NPs act as therapeutic agents per se, several therapies can be distin-
guished depending on the NPs properties exploited. In the following we illustrate
the wide range of potential therapies using Au NPs with some selected recent
examples.
One of the most promising groups of therapeutic strategies using Au NPs are
light-based therapies. These utilize the application of light to irradiate
photosensible materials, whereby this light-activation is directly responsible for
the desired therapeutic effects (i.e., destroying tumor cells). This group of light-
based therapies includes photothermal therapy (PTT), photodynamic therapy
(PDT), and photoimmunotherapy (PIT) [255, 256]. Although PDT and PIT use a
photosensitizer (i.e., light-activated drugs) for the release of reactive oxygen spe-
cies (ROS) and the activation of immune responses, PTT is based on the use of
photosensible materials (e.g., Au NPs) to generate local heat after being irradiated
with electromagnetic radiation. The main difference between PIT and PDT is that in
PIT monoclonal antibodies are associated with photosensitizers to improve the
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selective binding to the target tissues [255]. PTT has lately received more interest
because it does not require oxygen to interact with the target cells or tissues and is
able to use longer wavelength light, which is less energetic and therefore less
harmful to other cells and tissues. PTT using Au NPs, also called plasmonic
photothermal therapy (PPTT), exploits the unique LSPR properties of Au NPs.
When an energy source such as electromagnetic radiation is applied, conversion to
heat energy efficiently occurs in Au NPs because of electron excitation and
subsequent non-radiative relaxation through electron–phonon and phonon–phonon
coupling. This generated thermal energy can induce temperature increases of more
than 20 !C (i.e., hyperthermia), which can thereby induce tumor tissue ablation
[255, 256].
There are several advantages of using Au NPs for PTT: (1) Au NPs have high
absorption cross sections, and thus only minimal irradiation energy is required,
(2) the conversion of light into heat is very fast (about 1 ps), (3) Au NPs are
biocompatible, and (4) the ability of tuning the LSPR absorption (changing the size
and shape of Au NPs) to absorb light in the visible up to the NIR region. Although
visible light is successful in destroying cells labeled with spherical Au NPs, the NIR
region is especially crucial to penetrate deep into tissues, with minimal attenuation
by water and hemoglobin. The light can penetrate up to 10 cm in soft tissues in the
“biological window” (650–900 nm), a region ideal for the LSPR absorption of Au
nanoshells, nanorods, nanoprisms, and nanocages [28, 257]. When comparing the
different NPs structures in terms of their applications in PTT, Au nanorods exhibit
the best efficient NIR photothermal heat conversion. Although nanoshells have a
larger absorption cross-section because of their larger size, and as a result they
produce more heat, the nanorod shape has been shown to be twice as efficient in
converting light radiation into thermal energy (photothermal efficiency)
[258]. El-Sayed et al. determined the most effective Au nanorods size for PTT
heat generation [259]. In this context, 28" 8 nm Au nanorods were found to be the
most effective, both in theoretical calculations and in in vitro experiments with
human oral squamous cell carcinoma. Au nanorods in this dimension were the best
compromise between the total light absorbed and the fraction that is converted into
heat. Additionally, nanorods in this size led to an intense electromagnetic field that
extends far enough from the NPs surface to allow for field coupling between NPs
aggregates, resulting in enhanced experimental photothermal heating in solution.
For example, Lin et al. [260] synthesized PEG-coated Au nanorods that showed
enhanced PTT when used in the soft tissues of a genetically engineered mouse
model (GEMM) of sarcoma. This model recapitulates the human disease more
accurately in terms of structure and biology than subcutaneous xenograft models.
This study represented a nice demonstration of a therapeutic, NPs-mediated thermal
ablation protocol in a GEMM. Untargeted PEG-Au nanorods accumulated in the
sarcomas at levels comparable to those in subcutaneous xenografts, providing
evidence that passive targeting is indeed sufficient for PEG-Au nanorods to accu-
mulate in a physiologic tumor microenvironment. Significant delays in tumor
growth with no progression in some instances demonstrated the success of this
method. A similar approach was used by Chen et al. [261], where PEG- Au
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nanocages could be passively delivered and accumulated into animal tumors,
causing irreversible damage to tumor cells after exposure to NIR laser. Interest-
ingly, PEG-Au nanocages were found not only on the surface but also in the core of
the tumor.
There are increasing efforts to enhance therapeutic treatments by combining
therapy methods that show synergistic effects, as in the case of PTT and PDT. For
example, Choi et al. have reported a method which combines both phototherapies
using Au nanorods-photosensitizer complexes and two different light sources to
excite the photosensitizers and photothermal NPs separately because of their
absorption mismatch [262]. In this work, the negatively charged photosensitizer
Al(III) phthalocyanine chloride tetrasulfonic acid (AlPcS4) was attached onto the
positively charged surface of Au nanorods by electrostatic interaction, and the
photodynamic effect of the AlPcS4 photosensitizer was temporarily suppressed
after complex formation with Au nanorods. In the intracellular environment the
photosensitizer was released and it could finally be optically activated for
phototherapeutic effect. Two different light sources were used to excite Au
nanorods (810 nm laser) and AlPcS4 photosensitizer (675 nm laser) separately.
Tumor growth was suppressed by 95% with PTT/PDT dual therapy, whereas the
suppression was only 79% with PDT alone.
These examples successfully demonstrate the potential of NIR-active Au NPs
for use in light-based therapies. The current challenge in these phototherapies is to
increase the level of selectivity to act on tumor tissues with minimum damage to the
surrounding healthy tissue. Furthermore, better control over bio-distribution and
clearance are critical issues to be addressed.
Au NPs are also used for enhanced X-ray radiotherapy. A challenge of X-ray
radiation therapy in general is that high-dose X-rays under therapeutic conditions
damage normal cells. Au NPs, upon X-ray irradiation, can act as dose enhancers
and/or generate radicals that damage cancer cells and induce cell apoptosis. There
are two main features of Au NPs which make them very good candidates for acting
as X-ray radiosensitizers. First, Au has high number of protons (Z¼ 79) and
neutrons, compared with the previous elements evaluated for dose enhancing
such as iodine (Z¼ 53) and gadolinium (Z¼ 64). This translates into an increased
photoelectric cross-section. Second, the size of Au NPs is critical for escaping the
tumor vasculature using the enhanced permeability and retention (EPR) phenom-
ena. Thus, Au NPs have been proposed as potential radiosensitizers for X-rays
mediated cancer therapy, allowing for a reduction in X-ray dose with improved
therapeutic results [263–266]. Yang et al. have recently demonstrated the potential
effects of radiation-induced killing of melanoma cells as mediated by amphiphilic
Au NPs embedded within the walls of lipid nanocapsules. Interestingly, the
membrane-penetrating properties of these amphiphilic Au NPs allowed for signif-
icant enhancement of the radiotherapy efficiency, which opens a path for improving
the efficacy of frontline radiotherapy treatments [264]. An additional way to
improve the radiotherapeutic enhancement effects has been reported by using Au
NPs with glucose (Glc) and PEG as ligands (PEG-Glc-Au NPs) [265]. The enor-
mous reduction in tumor size after 47 days of treatment was also because of the role
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of PEG and Glc in improving uptake and bio-distribution, which led to a concen-
tration of PEG-Glc-Au NPs in tumor tissue 20 times higher than in healthy cells
48 h after injection. Alternatively, the potential of Au NPs to aggregate within
tumors can be exploited in this direction [266]. In addition, 15 nm Au NPs have
been designed to aggregate and remain largely in the tumor, after direct intra-
tumoral infusion, thus changing from NIR-transparent to NIR-absorbent, enabling
tumor-specific heating upon NIR illumination. Aggregation within tumors seems to
be induced by the lower pH of the tumor milieu and endosomes/lysosomes or other
mechanisms, such as by labile ligand bonds and lysosomal enzymes. This aggre-
gation effect, and subsequent heating by NIR followed by X-ray treatment, was able
to reduce the X-ray dose needed for tumor control by a factor >3. Because of the
limited penetration of NIR, certain superficial or accessible tumors (e.g., a subset of
head, neck, and melanoma) would be immediate candidates to evaluate the poten-
tial of this strategy. These examples illustrate the huge potential of Au NPs to
enhance radiotherapy treatments, providing useful insights for further clinical
studies.
It is important to note that the mechanism by which Au NPs can lead to dose
enhancements in radiation therapy differs when comparing photon and proton
radiations for NPs excitation. The dose enhancement using protons can be up to
14% and is independent of proton energy, in contrast to photon excitation where the
dose enhancement is highly dependent on the photon energy used. A theoretical
Monte Carlo simulation study [267] concluded that the potential of Au NPs to
enhance radiation therapy depends on the type of radiation source, and proton
therapy can be enhanced significantly only if the Au NPs are in close proximity
to target tissues.
Radioactive Au NPs are being used to make radiation therapy more effective.
The radioactive properties of 198Au (βmax¼ 0.96 MeV; half-life 2.7 days) make it
an ideal candidate for use in radiotherapeutic applications [268]. A major challenge
in cancer therapy has been delivery and retention, as it is necessary to increase the
therapeutic payload to get an effective tumor treatment. In this regard, NPs
containing radioactive isotopes can concentrate within the tumor and provide an
opportunity to tune the radioactive therapeutic dose delivered to tumor cells.
Furthermore, 198Au NPs have extraordinary tumor retention capabilities because
of their natural affinity to leaky tumor vasculature. In this area, relevant advances
have been achieved [268–270]. Khan et al. developed a method for the encapsula-
tion of radioactive Au within a dendrimeric composite and demonstrated that
radioactive Au NPs could deliver therapeutic doses to tumors [269]. More recently,
gum arabic glycoprotein (GA)-functionalized Au NPs, consisting of beta-emitting
198Au, were used for reducing the sizes of inoperable prostate tumors
[268, 270]. Interestingly, the optimum hydrophobicity of the GA matrix allowed
for effective penetration across tumor membranes. The therapeutic efficacy of
GA-198Au NPs was demonstrated in prostate tumor-bearing severely compromised
immunodeficient (SCID) mice models, reaching an unprecedented 82%, 3 weeks
after single-dose intratumoral administration of GA-198Au NPs (408 μCi).
The findings of significant therapeutic efficacy, good in vivo tolerance, and
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non-toxic features make these NPs potentially ideal candidates for future human
applications.
Radiofrequency (RF) fields can be used to induce Au NP-mediated thermal
ablation in a similar manner to that of photothermal and radio-sensitization thera-
pies. The efficiency of RF-based therapy is significantly enhanced by using Au NPs,
which are accumulated in the tumor area and then absorb main RF radiation power
to heat cancer cells and thus cause their selective destruction. In particular, an
intense source of RF radiation with frequency of 13.6 MHz and the power of 600 W
induced the heating of suspensions of Au NPs with a heating rate of ~20 K/s, which
resulted in considerable cell necrosis [271]. The NPs heating mechanism in an RF
field is a very complex phenomenon. Glazer et al. have demonstrated that Au NPs
heat primarily via Joule heating [271, 272]. Briefly, the Au NPs are hypothesized to
function as tiny resistors, where free electrons on the surface have restricted
movements. Therefore the friction created at the individual NP level releases heat
into the surrounding aqueous solution [273].
The potential use of Au NPs coupled to RF waves was evaluated for the
treatment of human hepatocellular and pancreatic cancer cells [274]. Direct injec-
tion of citrate-Au NPs into the tumor allowed focusing of the RF waves (13.56 MHz
RF field) for selective heating of cancer cells. The resulting induced heat was lethal
to these cancer cells bearing Au NPs in vitro. It was also demonstrated that the Au
NPs had no intrinsic cytotoxicity or antiproliferative effects in the two human
cancer cell lines studied. In another example, Curley et al. designed a method
using Au NPs functionalized with the epidermal growth factor receptor (EGFR)
inhibitor cetuximab in Panc-1 (pancreatic adenocarcinoma) and Difi (colorectal
adenocarcinoma) cells which express high levels of EGFR [275]. This method
proved to be cytotoxic to nearly 100% of the pancreatic and colorectal cells, but
hardly any of the cells from the control group were damaged. The advantages of this
therapy are that shortwave (megahertz range) RF energy is non-ionizing, penetrates
deeply into biological tissues with no adverse side effects, and heats Au NPs
efficiently. Thus, this technique may represent an effective treatment for numerous
human malignant diseases using non-invasive RF hyperthermia.
The finding that Au NPs are able to inhibit angiogenesis (i.e., the formation of
new vessels in organs or tissues) has also opened a new path to control the growth
and spread of cancerous tissues via angiogenesis therapy. One method to inhibit
angiogenesis in vivo is to block the function of pro-angiogenic heparin-binding
growth factors (HB-GFs) such as vascular endothelial growth factor
165 (VEGF165) and basic fibroblast growth factor (bFGF). Mukherjee et al. dem-
onstrated that Au NPs inhibit VEGF165-induced proliferation of endothelial cells
in a dose-dependent manner [276]. This inhibition effect was tested in vivo using a
nude mouse ear model, showing that after a week of daily intraperitoneal injections,
the ascites volume had reduced in the NPs treated mice compared to the non-treated
tumor-bearing mice. More recently, detailed studies of the antiangiogenic proper-
ties of Au NPs concluded that Au NPs not only inhibit VEGF165-induced HUVEC
(Human Umbilical Vein Endothelial Cells) proliferation but also repress endothe-
lial cell migration and tube formation [277]. Using Au NPs of different sizes and
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surface charges, it was demonstrated that a naked Au NPs surface is required and
that the core size plays an important role to inhibit the function of heparin-binding
growth factors (HB-GFs) and subsequent intracellular signaling events. Further-
more, the inhibitory effect of Au NPs was produced by the change in HB-GFs
conformation/configuration (denaturation) by the NPs, whereas the conformations
of non-HB-GFs remained unaffected [278]. The antiangiogenic properties of Au
NPs have also been exploited for the treatment of chronic inflammatory diseases
such as rheumatoid arthritis. Intra-articular delivery of Au NPs has been demon-
strated to be an effective treatment strategy for collagen-induced arthritis [279].
5 Use of Au NPs Towards Theranostics
Recent research has paved the way for multimodal ‘theranostic’ (i.e., a combination
of therapy and diagnosis) nanocarriers designed for carrying out simultaneous
detection/diagnosis and treatment of the disease following administration
[184, 280–282]. Au NPs are suitable for developing theranostic NPs thanks to
their unique characteristics that enable their use as contrast agents, as therapeutic
entities, and as scaffolds to adhere functional molecules, therapeutic cargoes (e.g.,
drugs/genes), and targeting ligands [184, 281]. Several examples of Au-based
theranostic NPs are illustrated in Fig. 3, which are explained below.
Au-based theranostic NPs that utilize light-based techniques for monitoring and
treating diseases are of special interest as they allow for spatially and temporally
controllable drug release, localized therapy, and minimally invasive treatment
modalities that reduce patients discomfort [282]. An interesting photo-triggered
theranostic system has been developed by Khlebtsov et al. [283], consisting of a
silver/gold (Ag/Au) nanocage core surrounded by a silica shell containing the NIR
photosensitizer Yb–2,4-dimethoxyhematoporphyrin (Yb–HP) for monitoring
tumors and simultaneous dual therapy, i.e., PTT/PDT (Fig. 3a). A significant higher
death rate of HeLa cervical cancer cells was observed in vitro when they were
incubated with the composite NPs and irradiated by 630-nm light because of PTT
by the Ag/Au NPs as well as PDT using the presence of Yb-HP. Furthermore, the IR
luminescence of Yb-HP (900–1060 nm, originating from Yb3þ ions, and located in
the tissue transparency window) could be used for diagnostic purposes and for
controlling the accumulation and bio-distribution of the composite NPs in tumors.
Another example of theranostic NPs for simultaneous X-rays/ CT dual-imaging and
dual-mode enhanced radiation therapy (RT) and PTT was reported by Huan et al.
[284]. Folic acid-conjugated and silica-modified Au nanorods were synthesized and
showed highly selective targeting, excellent X-ray/CT imaging ability, and
enhanced RT and PTT effects (Fig. 3b). These multifunctional NPs could specif-
ically bind to folate receptors on the surface of MGC803 gastric cancer cells and
were imaged in vivo using both X-ray and CT imaging followed by treatment via
RT or PTT. Alternatively, activatable theranostic NPs were developed by using
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Au@Ag/Au NPs assembled with activatable aptamer probes, which provided high-
contrast image-guided site-specific PTT therapy [287]. The Au@Ag/Au NPs simul-
taneously serve as an optical heater and a fluorescence quencher. The activatable
aptamer probes comprised a thiolated aptamer and a fluorophore-labeled comple-
mentary DNA. Thus, the activatable theranostic NPs with quenched fluorescence in
the free state could undergo signal activation through target binding-induced
conformational change of the activatable aptamer probes in specific tumor tissues,
and then achieve on-demand treatment under image-guided irradiation. By using S6
aptamer as a model, in vitro and in vivo studies of A549 lung cancer cells verified
Fig. 3 Simplified examples of diverse Au-based theranostic NPs. (a) Silver/gold (Ag/Au)
nanocages surrounded by a silica shell containing the NIR photosensitizer Yb–2,4-dimethoxyhe-
matoporphyrin (Yb–HP) for monitoring tumors via IR luminescence and simultaneous dual-
therapy PTT/PDT [283]. (b) Au nanorods conjugated with folic acid for selective targeting, cancer
cells X-ray/CT dual-imaging and treatment via enhanced-RT or PTT [284]. (c) Au NPs
functionalized with a fluorophore labeled hairpin-DNA for simultaneous gene specific silencing
and intracellular tracking of the silencing events [285]. (d) Use of Au NPs, either alone or with
linked cargo molecules, for generating plasmonic nano-bubbles (PNBs) which allow tumor
detection via light scattering, cargo delivery via creation of transient holes on the cell membrane
and finally cell destruction via mechanical impact [286]
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that these NPs greatly improved imaging contrast and specific destruction. This
strategy might be explored as a versatile platform for simultaneous detection and
treatment of multiple kinds of cancer cells with the use of specific aptamers for
varying cancer targets.
Conde et al. [285] recently developed an interesting Au-based theranostic
system capable of intersecting all RNA pathways: from gene specific
downregulation to silencing the silencers, i.e., siRNA and miRNA pathways
(Fig. 3c). The system consists of Au NPs functionalized with a fluorophore labeled
hairpin-DNA, which allows one to downregulate a specific gene directly and also to
silence single gene expression, exogenous siRNA, and endogenous miRNAs,
simultaneously tracking cell internalization and identifying the cells where silence
is occurring (i.e., the fluorescence signal is directly proportional to the level of
silencing). The usefulness of this approach was demonstrated for silencing an
endogenous miRNA (miR-21) commonly upregulated in cancer, such as in colo-
rectal carcinoma cells (HCT-116). The photothermal properties of Au NPs can also
be used to generate transient vapor nano-bubbles to produce a tunable nanoscale
theranostic agent, described as PNBs [286]. These PNBs are generated when Au
NPs are locally overheated with short laser pulses because of the evaporation of a
very thin volume of the surrounding medium, which in turn creates a vapor nano-
bubble that expands and collapses within nanoseconds. The bubble scatters the
light, thus acting as an optical probe which allows for tumor detection, and the fast
expansion of the PNB produces a localized mechanical impact which damages cell
membranes, resulting in cell death, and therefore acting as a therapeutic agent. This
novel theranostic system has been successfully applied as an in vivo tunable
theranostic cellular agent in zebrafish hosting prostate cancer xenografts, presenting
higher therapeutic selectivity when compared with Au NPs alone [288]. Au NPs
conjugated with anti-EGFR antibody C225 could actively target EGFR-positive
A549 lung carcinoma cells. Following cellular uptake, single human prostate
cancer cells could be detected and ablated under optical guidance in vivo by tunable
PNBs in a single theranostic procedure. By varying the energy of the laser pulse, the
PNBs size could be dynamically tuned in a theranostic sequence of two PNBs: an
initial small PNB detected a cancer cell through optical scattering, followed by a
second bigger PNB, which mechanically ablated this cell without damaging the
surrounding tissues, and its optical scattering confirmed the destruction of the cells.
This innovative and promising theranostic strategy concept of a ‘cell theranostics’
approach that unites diagnosis, therapy, and confirmation (guidance) of the results
of therapy in a single process at cellular level principally can help to improve both
the rapidity and the precision of treatment [288]. Recently, the same group has used
this concept for both, localized delivery of molecular cargo as well as mechanical
destruction of cells by generation of a transient PNB around the Au NPs with a
single incident laser pulse. Small PNBs can create a transient hole on the cell
membrane to ‘inject’ molecular cargo without damage to the cells. Large PNBs, on
the other hand, can cause mechanical destruction of the cells of interest [289]
(Fig. 3d).
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Based on these examples, it is apparent that theranostic Au NPs have opened the
door to novel and advanced treatment strategies that combine therapeutics with
diagnostics, aiming to monitor the response to treatment and increase drug efficacy
and safety, which would be a key part of personalized medicine.
6 Applications of Au NPs in Clinical Trials
Some of the above-mentioned medical applications using Au NPs are already in the
stage of pre-clinical or clinical trials.
The diagnostics company “Nanosphere” has developed the so-called Nanosphere’s
Verigene® System, which utilizes advanced automation and Au NPs to enable rapid
direct detection of nucleic acids and high-sensitivity protein detection on the same
platform. This technology has already received food and drug administration (FDA)
approval in the United States. It is based on Au NPs of 13–20 nm diameter
functionalized with either a defined number of oligonucleotides (i.e., short pieces of
DNA or RNA) or a defined number of antibodies specific to a particular protein of
interest.
One therapy using Au NPs which has reached clinical trials is CYT-6091, 27 nm
citrate-coated Au NPs conjugated with thiolated-PEG and tumor necrosis factor-α
(TNF-α) (Aurimmune; CytImmune Sciences). The NPs have the dual effect of
increasing tumor targeting and tumor toxicity in comparison with the use of TNF-α
alone [290]. In this trial the side effects and best dose of CYT-6091 in treating
patients with advanced solid tumors by intravenous administration have been
studied [291]. Future clinical studies should focus on combining CYT-6091 with
approved chemotherapies for the systemic treatment of non-resectable cancers.
Using the same CYT-6091 NPs, another clinical trial has been carried out to
evaluate the tissue distribution and the selective tumor trafficking of CYT-6091 in
patients with primary and metastatic cancers [292]. Patients, stratified according to
cancer type, received CYT-6091 and then underwent standard-care surgery. Tumor
and normal tissues were removed during surgery for analysis of antitumor effects
and tissue distribution of CYT-6091 by electron microscopy.
Au nanoshells (AuroShells®, Nanospectra Biosciences), which consist of a silica
core of 120 nm diameter with a 15-nm gold shell, were used in clinical trials to treat
head and neck cancers using PPTT. This therapy, called AuroLase® Therapy,
consisted of an injection of Au nanoshell NPs into the patient’s bloodstream.
After 12–24 h (enough time for the NPs to accumulate inside the tumor), an
808 nm IR laser was used to heat the NPs and destroy tumor cells [293]. These
NPs are currently under clinical trials in patients with primary and/or metastatic
lung cancer where there is airway obstruction. In this study, patients are given a
systemic infusion of NPs and a subsequently escalating dose of laser radiation
delivered by an optical fiber via bronchoscopy.
In the treatment of atherosclerotic lesions, two delivery techniques for NPs and
PPTT are under clinical trials (NANOM FIM) [294]. Patients underwent nano-
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intervention either with the delivery of silica-Au NPs in a mini-surgery implanted
bioengineered on-artery patch, or with the delivery of silica-Au iron-bearing NPs
with targeted micro-bubbles or stem cells by means of magnetic navigation system
vs stent implantation. The primary results showed a similar degree of regression of
total atheroma volume after 12 months for both approaches of delivery.
Another technique being tested in pre-clinical trials works is on validating poly-
valent Au NPs functionalized with RNAi (RNA interference) as anti-glioma thera-
peutics [295]. This nano-RNAi platform can be used to target signature lesions of
glioblastoma, which play an important role in driving glioma pathogenesis, mediating
therapeutic resistance, and instigating neurologically debilitating necrogenesis.
RNAi-Au NPs are being validated onmultiple levels, using glioma stem cell cultures,
derived xenografts, and genetically engineered glioma mouse models.
Despite these examples, the full clinical impact of Au NP-based therapies is not
yet known. There is clearly a need to translate already developed applications to
clinical trials in a timely but safe manner.
7 Concluding Remarks and Future Outlook
We have discussed novel strategies for the synthesis and functionalization of Au
NPs to evaluate their potential use in nanomedicine. In addition, their detection and
sensing properties have been explored for diagnosing some diseases. Au NPs either
alone or in hybrid form can also improve the performance of practically used
imaging techniques. Moreover, Au NP-based therapies are generally superior in
terms of specificity, selectivity, efficiency, and cytotoxicity compared to the same
methods without Au NPs. Additionally, Au composite NPs have recently been
evaluated for their theranostic potential both in vitro and in vivo. Nowadays, the
main focus is the transition of Au NPs from laboratories to the clinics. Though the
initial theranostic efficacy of Au NPs shows promising results, there are still many
challenges which need to be addressed before their use in clinical practice. The first
challenge involves the long-term retention, cytotoxicity, and ultimate renal clear-
ance of the NPs. Though the biodistribution and toxicity of Au NPs have been
extensively studied, reliable predictions based on these results are rare. Therefore,
more studies need to be performed to ensure their safety before use in humans. The
biodistribution of Au NPs is dependent on their size, geometry and surface chem-
istry. Dissimilarities of reported results dealing with Au NPs of the same size and
shape have been attributed to the type of coating or stabilizing agents used. In order
to overcome this problem, strategies to improve comparability and standardization
of nanotoxicological studies are needed. Moreover, there should be a shift of the
focus of toxicological experiments from ‘live–dead’ assays to the assessment of cell
function, allowing observation of bioresponses at lower doses, which are more
relevant for in vivo scenarios. Second, detection and sensing of analytes in complex
biological fluids (such as urine, blood, etc.) are still complicated to achieve. Third,
non-invasive clinical trials at the molecular level need to be better explored. Fourth,
194 S. Ashraf et al.
the development of personalized medicines for the treatment of individual patients
according to their genetic profiles is so far merely a vision described in scientific
papers. Last, but not least, vaccinations based on Au NPs for humans and/or
animals against biologically active factors or diseases still remain a dream to be
fulfilled. Addressing these and other such types of challenges may help in the future
to shift Au NP-based nanomedicines further into clinics.
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Particle-based fluorescence sensors for the quantification of
specific ions can be made by coupling ion-sensitive
fluorophores to carrier particles, or by using intrinsically
fluorescent particles whose fluorescence properties depend on
the concentration of the ions. Despite the advantages of such
particle-based sensors for the quantitative detection of ions,
such as the possibility to tune the surface chemistry and thus
entry portal of the sensor particles to cells, they have also some
associated problems. Problems involve for example crosstalk
of the ion-sensitive fluorescence read-out with pH, or spectral
overlap of the emission spectra of different fluorescent
particles in multiplexing formats. Here the benefits of using
particle-based fluorescence sensors, their limitations and
strategies to overcome these limitations will be described and
exemplified with selected examples.
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Introduction
Ions play an important role in cells, such as Na+, K+, Cl!,
and Ca2+ for electric signaling. Irregularities in ion distri-
butions can be associated with medical diseases, such as
reduction of Cl!-channels in the case of cystic fibrosis
[1,2]. Observation of ion concentrations in cells thus can
be relevant in medical diagnosis. Besides in vivo diagnosis
also cellular in vitro models are of interest. Here response
in ion concentrations upon pharmacological treatment
may help to screen different pharmaceutical agents con-
cerning their biological activity [3""]. For such in vitro
models particle-based ion sensors with fluorescence-read-
out are a helpful tool.
Potential of particles-based ion-sensitive
fluorescence sensors
Particle-based fluorescence sensing of specific ions is an
interesting methodology as it offers important technical
features [4–7,8",9,10]: firstly, fluorescence-based detec-
tion is a very convenient method in the field of sensing in
life science applications because of its high sensitivity,
simplicity, and diversity of fluorescent materials available.
In contrast to electronic detection fluorescence can also
be recorded conveniently from the interior of cells, mak-
ing this technique suitable in particular for in vitro sen-
sing. Secondly, besides acting as mere carrier for ion-
sensitive organic fluorophores, there is an increasing
number of intrinsically fluorescent particles, such as
quantum dots, carbon dots, lanthanide nanoparticles, or
metal nanoclusters. These particles can exhibit different
fluorescence properties than classical organic fluoro-
phores (i.e. (depending on the particle material) continu-
ous absorption spectra, longer fluorescence lifetimes,
reduced photobleaching, etc.), and are thus complemen-
tary to organic fluorescence dyes [11]. The size of the
particles hereby can reach from the nanometer to the
micrometer range. Thirdly, particle-based sensors always
involve the particle as carrier, which allows for addition of
other compounds, such as other fluorophores (e.g. for
fluorescence resonance energy transfer, FRET) [12],
ligands for colloidal stability or for targeting, or thera-
peutic compounds [13,14], and thus permits an excep-
tional tailoring in the design of these systems. In case
magnetic nanoparticles are used as carriers the same
system could act magnetically guided as drug delivery
carrier, which simultaneously monitors the delivered drug
[15]. Also polyelectrolyte capsules are a very universal
system toward the integration of many different func-
tional units into one particle [16], in addition to the actual
ion-sensitive fluorophores [17]. Fourthly, working with a
particle-based system offers the possibility of having a
universal interaction with cells, as the interaction of
particles with the cell environment is predominantly
governed by the physico-chemical properties of the
particle surface, and thus can be made similar for particles
responsive to different ions [18]. Cellular uptake and
intracellular distribution is thus predominantly deter-
mined by the particle carrier. Different ion-sensitive
fluorophores on the other hand typically have very differ-
ent chemical structure and thus may interact in a differ-
ent way (i.e. being cell-permeable, incorporated by
endocytotic pathways, no cellular entry). Finally, it is
important to point out that particle-based sensors detect
Available online at www.sciencedirect.com
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ion concentrations at their surface, which can be quite
different from bulk concentrations [19]. This however
can be turned into an advantage as presence of the
particle surface helps tuning the working-point by
adjusting the surface chemistry [20]. While these points
illustrate the huge potential of such sensors, unfortu-
nately there are also problems associated with particle-
based fluorescence sensing, which will be highlighted in
the following sections, together with some potential
solutions to address them.
Crosstalk with pH
The crosstalk of ion-sensitive fluorophores with pH is a
major problem, that is fluorescence readout does not only
response to changes in concentrations of the ion species
which are to be quantified, but also to changes in pH. This
is very critical and difficult to solve in the case of intra-
cellular sensing applications, in case particle sensors are
administered via cellular internalization. Spontaneous
internalization of particles predominantly is via endocy-
totic pathways, and thus involves massive changes in pH,
in which the particles are translocated from neutral to
slightly alkaline extracellular medium to highly acidic
intracellular vesicles [3!!,21]. Thus, in case of a particu-
late ion-sensitive fluorophore, which does not only
respond to its target ion, but also to pH, it is not straight-
forward to interpret changes in fluorescence readout, as
they may reflect changes in target ion concentration or in
pH. An illustration of this problem is shown in Figure 1,
where quantum dots (QDs) bar-coded polyelectrolyte
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QDs barcoded polyelectrolyte capsules with ion-sensitive fluorophores embedded in their cavity were used for multiplexed measurements of several
ions simultaneously. (a) Different sensor fluorophores such as FITC (fluorescein 5(6)-isothiocyanate; sensitive toward pH), SBFI (sodium-binding
benzofuran isophthalate in the form of tetra-ammonium salt; sensitive toward Na+), and PBFI (potassium binding bezofuran isophthalate in the form of
tetra-ammonium salt; sensitive toward K+) and a reference fluorophore Dy647 (Dy647 as N-hydroxysuccinimidyl-ester; Dy647 is not sensitive to the
cellular environment) conjugated with dextran were loaded inside the cavities of these porous capsules. To distinguish the different capsule species
barcodes made by mixtures of QDs with different color were embedded inside the outer shell of these capsules. (b) Fluorescence microscopic images
of a mixture of all the capsules at low and high concentrations of sodium, potassium and protons are shown from left to right. Changes in fluorescence
could be observed upon changes in ion concentrations. (c–e) The pH sensitive capsules were able to sense low and high pH even in the presence of
other ions. On the other hand, the Na+ and K+ sensors were not able to sense their respective ions at all pH values. Due to crosstalk with pH it was not
possible to determine Na+ and K+ concentrations at low pH, and in this way these capsules would not have been able to distinguish Na+ and K+ in
highly acidic lysosomes.Adapted from Ref [8!].
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capsules with different ion-sensitive fluorophores
embedded in their cavity were used for multiplexed
measurements of several ions [8!]. While this system
has been demonstrated being able to detect Na+ and
K+ ions simultaneously, this was only possible at con-
trolled pH. In this way this sensor system could not be
used for reporting local Na+ and K+ concentrations upon
the internalization pathway of the particles, upon which
severe changes in pH are involved. This problem could
be resolved by integrating a pH sensor, which then would
be based on a calibration curve to deconvolute pH effects.
Uncertainty in fluorescence intensity-based
detection
According to the signal-output mode, particle-based fluor-
escent probes can work in different sensing mechanisms, in
which upon presence of the target ions intensity, wave-
length, lifetime, and polarization of fluorescence is changed.
To date, most of the proposed particle-based fluorescent
sensors are based on fluorescence-intensity changes. Unfor-
tunately they suffer from uncertainties in the calibration of
the responses, particularly when these systems are applied
as intracellular probes (i.e. fluctuations in intracellular
particle densities), which can produce misleading readouts.
One solution to partially overcome this problem is by means
of ratiometric approaches [6,22–25], which only require
relative determination of fluorescence intensities to a refer-
ence, instead of absolute intensity measurements. As men-
tioned, particles allow for easy incorporation of reference
fluorophores [20]. Alternatively fluorescence wavelength-
shift and lifetime detection are recently used approaches to
overcome this limitation. However, there are relatively few
ion-sensitive fluorophores involving wavelength-shift
modes available. One demonstrated example involves an
alteration in the band-gap energy of QDs upon the presence
of target ions, causing shift of the emission wavelength
[26]. Fluorescence lifetime-based sensing approaches
are more universal. The combination of time-resolved
fluorescence with QDs is of particular interest due to
the longer fluorescence lifetime of QDs (typically five
to hundreds of nanoseconds) as compared to that of
most organic fluorophores and cell autofluorescence.
The potential of these systems for quantifying ions,
such as Cl" or H+ in bulk solutions mimicking the
intracellular environment has recently been demon-
strated [27,28,29!!]. A novel step in this direction is
the use of fluorescence lifetime imaging microscopy
(FLIM) for sensing purposes, which is based on using
the fluorescence lifetime of QD probes collected from
FLIM images as analytical signal for determining the
concentration of the target ions. The example illustrated
in Figure 2 clearly shows the great potential of FLIM for
intracellular imaging and sensing [29!!].
Spectral overlap in multiplexing formats
Nowadays there is an increasing demand for multi-
parameter chemical and biological sensing. However,
unfortunately the emission spectra of many ion-sensitive
fluorophores show overlap, and thus the number of fluor-
ophores that can be spectrally resolved and indepen-
dently detected in parallel is limited [30,31]. To solve
this major problem of spectral crosstalk the use of
particle-based fluorescence systems plays an important
role. There are several ways of discrimination between
different fluorescence signals: spectral resolution (i.e.
fluorescence signals of different wavelength), spatial
resolution (i.e. fluorescence originating from different
locations), and temporal resolution (i.e. fluorescence with
different lifetimes) [30]. In this direction, two very prom-
ising strategies of realizing multiplexing without spectral
overlap problems are the use of temporal resolution
(distinguishing the emission of different fluorophores
with time-dependent fluorescence spectroscopy), the
interaction of different fluorophores in FRET, or the
combination of both strategies. While organic fluoro-
phores have similar lifetimes of a few ns, QDs have much
longer fluorescence lifetimes, reaching even ms by dop-
ing. By using QDs as donor and several (ion-sensitive)
fluorophores as acceptors, successful FRET systems
based on lifetime measurements have been developed
[32–34,35!]. The combination of QDs (as donors and/or
acceptors) with organic dyes (as acceptors) and lanthanide
complexes (as donors) allows for the use of different
FRET pathways and spectral candidates for the design
of time-resolved fluorescence multiplexing formats due
to their long photoluminescence lifetimes (ms) [36,37!].
This advantage has been used for time-resolved immu-
noassays based on FRET from luminescent terbium
complexes (LTC) to different quantum dots or five
different organic fluorophores [38,39], allowing the sim-
ultaneous determination of several tumor markers from
a single sample. These examples show how the problem
of spectral overlap, which has blocked the advance in
multiplexing platforms during years, can be solved via
FRET and fluorescence lifetime based spectrotemporal
approaches.
Intracellular delivery
Delivery of particle sensors to specific intracellular
locations is not trivial, and in fact one of the biggest
challenges nowadays. Endocytosis is the classical natural
entry of particles into cells [21], consequently leading to a
localization of the particles inside acidic intracellular
vesicles (endosomes and lysosomes) [40]. Delivery routes
to different cellular regions such as the cytosol, mito-
chondria, and the nucleus can be divided in two main
groups, physical and biochemical strategies. Physical
strategies include microinjection, electroporation, and
photothermal heating [41], which allow (optionally in
the context with receptor-specific ligands on their sur-
face) for the delivery of the particles to intracellular
targets. In contrast, biochemical strategies involve
specific surface ligands of the particles. In this way
particles are released from the intracellular vesicles after
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endocytosis to the cytolsol (‘endosomal escape’) [42,43].
Several functionalizations of the particle surface with
specific ligands are used in this direction, such as cell
penetrating peptides (CCPs) [44], transferrin [45],
nuclear-localization sequence (NLS) peptides [46], endo-
plasmic reticulum (ER) signal peptides [47], triphenylpho-
sphonium derivates (TPP) [48], and polyethyleneimine
(PEI) [49]. It even has been suggested that under certain
conditions very small particles can directly traverse the
cell membrane (i.e. by transient poration) [50] and thus
bypass the endocytotic uptake. However, the details of
such mechanisms are still under scientific discussion and
controversial results can be found in the literature. In
spite of all the studies carried out in this topic, there are
not yet reliable general methods for delivering particles
into the cytosol, and even less for sub-cellular organelles
[51]. Thus, successful delivery strategies still must be
determined for each particle-based system on a case-by-
case basis.
Calibration
The performance of most of the reported sensing systems
for intracellular applications are based on the interp-
olation of the intracellular readouts using corresponding
extracellular calibration plots [27,28]. It is well-known
that the intracellular environment can alter the behavior
of the response of the sensor, as consequence for example
of the fact of ‘protein corona’ formation [52]. Even work-
ing with solutions mimicking the intracellular environ-
ment, one never can be sure that the scenario is exactly
the same as inside the cells. Therefore a proper way to
face this problem may be by carrying out a calibration
inside cells, in order to introduce all the factors of uncer-
tainty in the calibration model. In addition one has to take
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Example for the use of FLIM in combination with pH-sensitive CdSe/ZnS QDs for sensing of intracellular pH. (a) FLIM images of QDs suspended in
solutions mimicking the intracellular environment at different pH values. The scale bars (white lines) represent 10 mm. (b) Fluorescence lifetime
histograms collected from the images in (a). (c) FLIM images of MC3T3-E1 cells before (i) and after incubation with QDs (ii and iii). Image (i) shows the
autofluorescence of the cells. MC3T3-E1 cells were incubated with nigericin and buffers mimicking the extracellular medium at pH 4.87 (ii) and 8.14 (iii).
The scale bars (white lines) represent 10 mm. (d) Fluorescence lifetime histograms collected from the images in (c).
Adapted from Ref [29!!].
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into account that particles can be also partially disinteg-
rated inside cells (e.g. by proteolytic enzymes), which
obviously may impact fluorescence readout [53].
Outlook
Particle-based ion-sensitive fluorescence sensing is an
interesting methodology, in particular for the develop-
ment of in vitro assays. Due to the particular nature these
sensors (in case they are big enough) can be easily
localized and could be introduced as artificial ‘cellular
organelles’, allowing for spatially resolved online monitor-
ing of intracellular ion concentrations. In particular the
possibility of measuring the changes in intracellular ion
concentration upon exposure of cells to specific pharma-
ceutical agents would offer a convenient way to measure
dose-response curve and pharmacokinetics on the level of
individual cells [54]. Thus, these platforms could provide
significant advances in drug screening, also in the direc-
tion of ‘personalized medicine’, in which cellular
response to treatment can be detected.
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